Entertainment Gaming Asia DEF 14A Definitive proxy

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )

Filed by the Registrantþ

Filed by a Party other than the Registranto

Check the appropriate box:

o Preliminary Proxy Statement

o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

þ Definitive Proxy Statement

o Definitive Additional Materials

o Soliciting Material Pursuant to §240.14a-12

VendingData Corporation

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

þ No fee required.


o	Fee computed on table below per Exchange ActRules 14a-6(i)(1) and 0-11.


	1)	Title of each class of securities to which transaction applies:


	2)	Aggregate number of securities to which transaction applies:


	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange ActRule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):


	4)	Proposed maximum aggregate value of transaction:


	5)	Total fee paid:

o Fee paid previously with preliminary materials.


o	Check box, if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


	1)	Amount Previously Paid:


	2)	Form, Schedule or Registration Statement No.:


	3)	Filing Party:


	4)	Date Filed:

VendingData Corporation
1120 Town Center Drive, Suite 260
Las Vegas, Nevada 89144

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON SEPTEMBER 10, 2007

To our Stockholders:

A Special Meeting (the “Special Meeting”) of Stockholders of VendingData Corporation, a Nevada corporation, will be held on Monday, September 10, 2007 at 10:00 a.m., at 1120 Town Center Drive, Suite 260, Las Vegas, Nevada 89144, to:

1. Authorize and approve a Securities Purchase and Product Participation Agreement between us and Elixir Group Limited, a Hong Kong company (“Elixir”), and to authorize and approve the issuance of shares of our common stock and warrants to Elixir pursuant thereto;

2. Authorize and approve the grant of options to purchase up to 5,000,000 shares of our common stock to certain officers, directors and employees of Elixir and its affiliates;

3. Authorize and approve an amendment to our Amended and Restated 1999 Stock Option Plan to increase the number of shares of common stock reserved under the plan;

4. Authorize and approve an amendment to our articles of incorporation to increase our authorized common stock;

5. Re-elect five directors and elect three new directors, each to serve until our 2008 annual meeting of stockholders;

6. Vote on the adjournment or postponement of the Special Meeting to another time and date if such action is necessary for the board of directors to solicit additional proxies in favor of proposals 1, 2, 3, 4 or 5; and

7. Consider any other business that properly comes before the meeting.

Only stockholders of record at the close of business on August 16, 2007 will be entitled to notice of, and to vote at, the meeting and any adjournments of the meeting.It is important that your shares be represented at the meeting. Please mark, sign, date, and mail the enclosed proxy card in the postage-paid envelope provided, regardless of whether you plan to attend in person.

Sincerely,

Mark R. Newburg
President and Chief Executive Officer

August 17, 2007

Las Vegas, Nevada

PROXY STATEMENT

TABLE OF CONTENTS


Questions and Answers about the Meeting			2
Voting of Shares			4
Proxy Solicitation			5
Proposal One — Authorize and Approve the Securities Purchase and Product Participation Agreement with Elixir and the Issuance of our Common Stock and Warrants Pursuant Thereto			5
The Participation Agreement			16
Proposal Two — Approve the Grant of Options to Acquire 5,000,000 Shares of our Common Stock to the Elixir Parties			23
Proposal Three — Authorize and Approve an Amendment to our Amended and Restated 1999 Stock Option Plan to Increase the Number of Shares of Common Stock Reserved Under the Plan			24
Proposal Four — Approve an Amendment to our Articles of Incorporation to Increase our Authorized Common Stock			24
Proposal Five — Re-Election of Five Directors and Election of Three New Directors			25
Proposal Six — Authorization to Adjourn or Postpone the Meeting to Solicit Additional Votes for Approval			29
Security Ownership of Certain Beneficial Owners and Management			30
Equity Compensation Plan Information			31
Executive Compensation			32
Certain Relationships and Related Transactions with the Company			36
Section 16(a) Beneficial Ownership Reporting Compliance			36
Other Business			37
Householding of Special Meeting Materials			37
Proposals for the Next Annual Meeting			37
Annex A — Securities Purchase and Product Participation Agreement, with Exhibits			A-1
Annex B — Opinion of Capstone Valuation Services, LLC			B-1
Annex C — Proposed Amendment to our Articles of Incorporation			C-1

VendingData Corporation

PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS
To Be Held September 10, 2007

The accompanying proxy is solicited on behalf of the board of directors of VendingData Corporation in connection with a Special Meeting in Lieu of our 2007 Annual Meeting of Stockholders (the “Special Meeting”) to be held on Monday, September 10, 2007 at 10:00 a.m., at 1120 Town Center Drive, Suite 260, Las Vegas, Nevada 89144, for the purposes set forth in the accompanying notice of meeting.

Please mark and sign the enclosed proxy card and return it in the accompanying envelope. No postage is required if your returned proxy card is mailed within the United States. We will bear the cost of soliciting proxies, including the preparation, assembly and mailing of the proxies and soliciting material, as well as the cost of forwarding the materials to the beneficial owners of our common stock. Our directors, officers and regular employees may, without compensation other than their regular compensation, solicit proxies by telephone, electronic mail, personal conversation or other means of communication. We may reimburse brokerage firms and others for expenses in forwarding proxy material to the beneficial owners of our common stock.

Any proxy given pursuant to this solicitation and received in time for the Special Meeting will be voted according to the instructions given in the proxy. Any stockholder giving a proxy may revoke it any time prior to its use at the Special Meeting by giving a written revocation notice to our secretary, by filing a revoking instrument or a duly executed proxy bearing a later date with our secretary or by attending the Special Meeting and voting in person.

We expect that this proxy statement, the proxy and notice of meeting will first be mailed to our stockholders on or about August 20, 2007.

QUESTIONS AND ANSWERS ABOUT THE MEETING


Q:		Why am I receiving this proxy statement?


A:		We are calling this Special Meeting of Stockholders to conduct ordinary business, such as the election of members of our board of directors, as well as to obtain the approval of our stockholders on certain other agreements and undertakings by us, as follows:


		• As more fully described in Proposal One, we entered into a Securities Purchase and Product Participation Agreement (the “Participation Agreement”) with Elixir Group Limited, a Hong Kong company (“Elixir”), pursuant to which we will issue to Elixir up to 55,000,000 shares of our common stock and warrants to purchase up to 88,000,000 shares of our common stock in consideration for Elixir’s sourcing and identification of gaming operators in the general Asia market, on our behalf, for the purpose of our entering into lease agreements with such gaming operators for the placement of electronic gaming machines. In Proposal One, we are asking our stockholders to approve the Participation Agreement and the issuance of our common shares and warrants to purchase common shares in connection therewith.

		• As more fully described in Proposal Two, we have granted to certain officers, directors and employees of Elixir and its affiliates non-plan options to purchase up to 5,000,000 shares of our common stock. The exercise of such options is subject to the close of the transactions contemplated by Proposal One and the approval of VendingData shareholders. In Proposal Two, we are asking our stockholders to approve our grant of the options, and the issuance of our common shares upon exercise of the options.

		• As more fully described in Proposal Three, we wish to amend our 1999 stock option plan to increase the number of shares of common stock reserved for issuance under the plan. In Proposal Three, we are asking our stockholders to approve an amendment to our 1999 stock option plan for the purpose of increasing the number of shares of our authorized common stock issuable pursuant to the plan.

		• In order to issue the shares of common stock under proposals One, Two and Three, we will need to increase our authorized shares of common stock. The increase in our authorized shares of common stock can only be effected by way of amendment to our articles of incorporation, and we must obtain the approval of our stockholders to amend our articles. In Proposal Four, we are asking our stockholders to approve an amendment to our articles of incorporation for the purpose of increasing the number of shares of our authorized common stock.

Q:		What is the maximum number of shares we will issue in connection with Proposals One, Two and Three?

A:		If Proposals One, Two and Three are approved, we will be authorized to issue an aggregate of up to 157,000,000 additional Shares of our common stock, comprised of the following: (i) 55,000,000 shares issuable upon the successful completion by Elixir of certain milestones more fully described in the Participation Agreement; (ii) 88,000,000 shares issuable upon the exercise of warrants to purchase our common stock granted to Elixir, which shall vest and first become exercisable subject to the successful completion of certain milestones more fully described in the Participation Agreement; (iii) 5,000,000 shares issuable upon the exercise of options granted to certain officers, directors and employees of Elixir and its affiliates; and (iv) 9,000,000 shares issuable upon exercise of the additional 9,000,000 options authorized under the 1999 stock plan.

Q:		What do I need to do now?

A:		We urge you to carefully read and consider the information contained in this proxy statement. If applicable, you should then vote as soon as possible in accordance with the instructions provided in this proxy statement and on the enclosed proxy card or submit your voting instructions by internet or by telephone if that option is available to you.

Q:		How do I vote?

A:		If you are a VendingData stockholder of record, you may vote in person at the Special Meeting or by submitting a proxy for the meeting. You can submit your proxy by completing, signing, dating and returning the enclosed proxy card in the accompanying pre-addressed postage paid envelope. If you hold your shares in “street name,” which means your shares are held of record by a broker, bank or nominee, you must


		provide the record holder of your shares with instructions on how to vote your shares. Please refer to your proxy card or the voting instruction card used by your broker, bank or nominee to see if you may submit voting instructions using the internet or telephone.

Q:		What happens if I do not vote?

A:		If you do not submit a proxy card or vote at the Special Meeting, your proxy will not be counted as present for the purpose of determining the presence of a quorum, and your shares will not be voted at the meeting. If you submit a proxy card and affirmatively elect to abstain from voting, your proxy will be counted as present for the purpose of determining the presence of a quorum but will not be voted at the Special Meeting. Broker non-votes will also have the same effect as shares not voted at the meeting.

Q:		If my VendingData shares are held in “street name,” will my broker, bank or nominee vote my shares for me on all proposals?

A:		No. Your broker, bank or nominee cannot vote your shares on matters other than the election of directors unless you provide instructions on how to vote in accordance with the information and procedures provided to you by your broker, bank or nominee.

Q:		Can I change my vote after I have mailed my signed proxy or direction form?

A:		Yes. If you are a record holder, you can change your vote at any time before your proxy is voted at your stockholder meeting by:

		• delivering to the corporate secretary of VendingData a signed notice of revocation;

		• granting a new, later-dated proxy, which must be signed and delivered to the corporate secretary of VendingData; or

		• attending the Special Meeting and voting in person; however, your attendance alone will not revoke your proxy.

		If your shares are held in street name and you have instructed your broker or nominee to vote your shares, you must follow your broker or nominee’s directions in order to change your vote or revoke your proxy.

Q:		What should I do if I receive more than one set of voting materials?

A:		You may receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive.

Q:		What if I object to the proposed transactions? Do I have dissenter’s rights?

A:		No. Dissenter’s rights are not available for the types of transactions discussed in this proxy statement.

Q:		Whom should I call with questions?

A:		If you have any questions about the transaction or if you need additional copies of this proxy statement or the enclosed proxy card, you should contact:


Georgeson Inc.		VendingData Corporation
17 State St. 10th Floor	or	1120 Town Center Drive, Suite 260
New York, New York 10004		Las Vegas, Nevada 89144
Telephone:(212) 440-9800		Telephone: (702) 733-7195
Toll-free:(866) 647-8876		Attn: Arnaldo F. Galassi
		Chief Financial Officer

VOTING OF SHARES

Our board of directors has fixed the close of business on August 16, 2007 as the record date for determining the stockholders entitled to notice of, and to vote at, the Special Meeting. On August 16, 2007, 36,526,593 shares of our common stock, $0.001 par value, were outstanding and held by 266 recordholders. Each share outstanding on that date entitles its holder to one vote in person or by proxy on each matter to be voted on at the Special Meeting.

Quorum

The presence at the Special Meeting, in person or by proxy, of the holders of a majority of the outstanding shares of common stock entitled to vote at the meeting is required for a quorum for the transaction of business. In general, shares of common stock represented by a properly signed and returned proxy card will be counted as shares present and entitled to vote at the meeting for purposes of determining a quorum.

Vote Required for Approval

Pursuant to Section 78.330 of the Nevada General Corporation Law, a plurality of the shares voting at the Special Meeting is required to elect directors. This means that if there are more nominees than the eight positions to be filled, the eight nominees who receive the most votes will be elected. In counting votes on the election of directors, abstentions, broker non-votes (i.e. shares held of record by a broker which are not voted because the broker has not received voting instructions from the beneficial owner of the shares and either lacks or declines to exercise authority to vote the shares in its discretion) and other shares not voted will be counted as not voted. These shares will be deducted from the total shares of which a plurality is required.

The approval of holders of a majority of our outstanding common stock is required to approve the proposed Participation Agreement and the transactions thereunder and the proposed amendment to our articles of incorporation for the purpose of increasing our authorized common stock.

All other proposals presented in this proxy statement will be approved if a majority of the shares present or represented at the meeting and entitled to vote on the proposal are voted in favor of such matter. In counting votes on each such matter, broker non-votes will be counted as not voted on the matter. Shares that are not present or represented at the meeting will be deducted from the total number of shares of which a majority is required.

Voting of Proxies

Shares of common stock represented by properly executed proxy cards will be voted according to the choices specified. Proxies that are signed by stockholders but that lack any voting instructions will be votedFOR the election of all of the nominees for director listed in this proxy statement, andFOR all other proposals set forth in this proxy statement. If any other business properly comes before the Special Meeting, shares represented by proxy will be voted according to the best judgment of the proxy holders named on the proxy card.

PROXY SOLICITATION

We are soliciting proxies from our stockholders for our Special Meeting of Stockholders. We will pay the cost of solicitation of proxies from our stockholders, including preparation, assembly, printing and mailing of this proxy statement and the proxy cards. Copies of solicitation materials will be furnished to banks, brokerage houses, fiduciaries and custodians holding in their names shares of our common stock beneficially owned by others to forward to such beneficial owners. We may reimburse persons representing beneficial owners of our common stock for their costs of forwarding solicitation materials to such beneficial owners. In addition to solicitation by use of the mails, proxies may be solicited by our board of directors, officers and employees, and Georgeson Shareholder Communications, in person or by telephone, electronic mail, or other means of communication. No additional compensation for soliciting proxies will be paid to our board of directors, officers or regular employees for such services, but Georgeson Shareholder Communications will be paid its customary fee, excluding expenses, of approximately $8,500 for soliciting proxies on our behalf.

PROPOSAL ONE — AUTHORIZE AND APPROVE THE SECURITIES PURCHASE AND PRODUCT PARTICIPATION AGREEMENT WITH ELIXIR AND THE ISSUANCE OF OUR COMMON STOCK AND WARRANTS PURSUANT THERETO

On June 12, 2007, we entered into a Securities Purchase and Product Participation Agreement (the “Participation Agreement”) with Elixir Group Limited, a Hong Kong company (“Elixir”). Pursuant to the Participation Agreement, we will issue to Elixir our common shares and warrants, subject to Elixir’s sourcing and identification of gaming operators located in the general Asia region on our behalf. We will place electronic gaming machines with gaming operators pursuant to lease agreements between us and the operators on a revenue sharing basis. Elixir will also sell to us the electronic gaming machines to be placed under the lease agreements.

The Participation Agreement and the related transactions are subject to certain conditions, including the approval of our stockholders. The Participation Agreement contemplates a possible change of control of our company, with Elixir having the opportunity to earn in excess of 50% of our issued and outstanding shares upon the completion of certain milestones. We believe that the Nevada General Corporation Law requires that the Participation Agreement and related transactions receive the approval of the holders of a majority of our common shares outstanding as of the record date. In addition, pursuant to Rule 713(b) of the American Stock Exchange (“AMEX”) Company Guide, the affirmative vote of our stockholders is required to approve the issuance or potential issuance of shares resulting in a change of control of our company.

Elixir is an indirect wholly-owned subsidiary of Melco International Development Limited (“Melco”). Elixir is engaged in the business of developing and distributing gaming technology solutions in Asia. Elixir’s executive offices are located at 19/F., Zhu Kuan Building, Avenida Xian Xing Hai, Macau; telephone (853) 2961 888.

Terms of the Transaction

This section highlights selected information concerning the Participation Agreement. To better understand the transaction and the Participation Agreement, you should read this entire document carefully, including the section “Participation Agreement” beginning on page 16 and the Participation Agreement attached as Annex A and incorporated by reference into this document.

According to the terms of the Participation Agreement, Elixir will have the right to “earn-in” an equity interest in VendingData based on the achievement of various performance milestones in terms of (a) the cumulative number of the electronic gaming machines that are contracted to be placed and leased pursuant to lease agreements entered into between VendingData and the gaming operators sourced and identified by Elixir (the “gaming machines under contract”) and (b) the cumulative number of electronic gaming machines physically placed by VendingData and in operation in the gaming premises of gaming operators pursuant to the lease agreements (the “gaming machines in operation”). The close of the transaction is subject to the placement of at least 1,000 gaming machines in operation. At the close, VendingData will issue to Elixir

25,000,000 common shares and warrants, with an exercise price of $2.65 per share, to purchase up to 88,000,000 additional common shares of VendingData. The warrants will vest and first become exercisable based on the achievement of certain milestones with respect to the number of gaming machines under contract and in operation. Elixir will be entitled to earn a total of 55,000,000 VendingData common shares (inclusive of the 25,000,000 shares issued at closing) and the warrants will vest and become exercisable subject to achieving the following milestones with respect to the cumulative number of gaming machines under contract and in operation as follows:


	Cumulative		Cumulative
	Gaming Machines		Gaming Machines		Shares Earned		Vesting of Warrants
	Under Contract		in Operation		By Elixir		Earned By Elixir

		1,000		1,000		25,000,000		0
		2,000		1,000		15,000,000		22,000,000
		3,000		2,000		10,000,000		22,000,000
		4,000		3,000		5,000,000		22,000,000
		5,000		4,000		0		22,000,000

Total		5,000		4,000		55,000,000		88,000,000

In addition to the above, upon VendingData’s initial placement of 1,000 gaming machines in operation with gaming operators identified by Elixir, VendingData will reduce by $1.00 the exercise price of all warrants (other than 6,000,000 common share warrants priced at $2.65) sold to Elixir pursuant to a securities purchase agreement entered into in October 2006 (the “2006 Warrants”). When the cumulative number of gaming machines under contract reaches 2,000 units and the cumulative number of gaming machines in operation reaches 1,000 units, VendingData will further reduce by $1.00 the exercise prices of the 2006 Warrants. When the cumulative number of machines under contract reaches 3,000 units and the cumulative number of machines in operation reaches 2,000 units, VendingData will further reduce by $1.00 the exercise prices of the 2006 Warrants.

At such time that at least 2,000 gaming machines are under contract and 1,000 gaming machines are in operation, Elixir will likely have earned shares representing in excess of 50% of our outstanding common shares, resulting in a change of voting control of VendingData. Pursuant to the Participation Agreement, VendingData has also agreed to expand its board of directors to no more than eight and nominate to its board three persons appointed by Elixir, who shall be elected to the VendingData board effective as of the close of the transactions under the Participation Agreement.

The Participation Agreement includes customary representations, warranties and covenants by Elixir and VendingData. The transactions contemplated by the agreement are conditioned upon completion by Elixir of a satisfactory due diligence investigation of VendingData and the approval of the agreement and related transactions by VendingData’s stockholders, including the election of the Elixir nominees and an amendment to VendingData’s articles of incorporation to increase its authorized capital. The above transactions are expected to close, subject to VendingData shareholder approval and the other conditions to closing, immediately following the Special Meeting.

Pursuant to the Participation Agreement, James Crabbe and Mark Newburg, VendingData’s chairman of the board and chief executive officer, respectively, have agreed to vote all of the shares of the company’s common stock under their control in favor of the transactions contemplated by the Participation Agreement for the purpose of obtaining the shareholder approval required thereunder.

the VWAP; however, no adjustment will be made for shares issued in connection with the exercise of outstanding stock options and warrants.

In connection with the closing of the transactions contemplated by the Participation Agreement, VendingData will enter into a registration rights agreement with Elixir. The registration rights agreement requires VendingData to file a selling shareholder registration statement with the SEC, within 30 days following the closing of the transactions under the Participation Agreement, for purposes of registering the resale of the shares of VendingData’s common stock issued to Elixir pursuant to the transaction, including all shares that are issued, or may be issued, upon exercise of the warrants. Pursuant to the registration rights agreement, the holders of the securities are also entitled to certain demand and piggyback registration rights.

Background of the Transaction

In first quarter of 2005, we decided to strengthen our management team and in March 2005 we appointed Mark Newburg to our board of directors. Mr. Newburg assumed the role of executive director of the VendingData board in March 2005, and in April 2005 Mr. Newburg was appointed treasurer of our company. We also brought on board Arnaldo Galassi as a financial management consultant in March 2005. In October 2005, we appointed Mr. Newburg to serve as our president and chief executive officer and Mr. Galassi to serve as our chief financial officer.

After coming on board, Mr. Newburg and Mr. Galassi commenced an analysis of VendingData’s strategic plans and options, which would continue throughout the remainder of the year and 2006. As part of the process, we retained two NASD member investment banking firms, Roth Capital Partners in September 2005 and Jefferies & Co., Inc. in March 2006, to assist us in analyzing our various options for maximizing shareholder value, including strategic acquisitions, joint ventures and a sale of the company.

Along with conducting the strategic analysis of VendingData’s options, our management team focused on strengthening our product line, including the decision to discontinue our SecureDrop product, the continued roll-out of our chip washer and our next generation shuffler products, and our strategic acquisition of the high frequency RFID casino chip technology.

In December 2005, Mr. Newburg, Mr. Crabbe and Peter Zee, our vice president of engineering and manufacturing, held preliminary discussions with members of Elixir management concerning various business opportunities, ranging from licensing arrangements to potential business combinations. Mr. Zee was familiar with Elixir management due to his extensive business experience in Hong Kong. Our management considered that Elixir was the dominant distributor of gaming device products and solutions to the Asian and South Pacific gaming markets. Our management considered that Elixir could provide us with an opportunity to access and expand into the lucrative Asian gaming device market. Over the next several weeks we continued our discussions with Elixir concerning a number of different business opportunities. Our discussions eventually settled on a distribution arrangement which would serve as a basic business relationship and allow the parties to further assess the desirability of a more comprehensive commercial relationship.

On January 5, 2006, we entered into a sales representative agreement with Elixir pursuant to which we provided Elixir with exclusive distribution rights for our high frequency RFID casino chip for certain Southeast Asia casino properties and non-exclusive distribution rights elsewhere in Asia. The sales representative agreement had an initial three year term with rollover provisions. At the time, we agreed with Elixir to pursue further talks concerning an expanded commercial relationship and a possible business combination. In April 2006, we executed and returned Elixir’s mutual confidentiality and non-disclosure agreement, after which VendingData and Elixir each began its due diligence investigation of the other, including the other party’s business, finances, products and employees.

During this period, our management made inquiries to other potential acquirers and partners concerning alternative strategic acquisitions, joint ventures and business combinations. Between April 2005 and January 2007, our management, with the input of our investment bankers, identified those companies that might be interested in a business combination or the like with VendingData. Those companies consisted mostly of established companies in the gaming device business who might have an interest in our product line. Based on

our modest level of revenue and history of unprofitability, and the input of our investment bankers, our management ruled out private equity firms and other non-gaming industry parties as potential acquirers. There were numerous meetings held with the referenced companies to explore distribution arrangements, patent and product line purchase opportunities as well as business combinations. None of those discussions resulted in any meaningful progress towards a material business opportunity.

Commencing in April 2006, VendingData and Elixir began serious discussions concerning a potential business combination. Elixir expressed to us their interest in our product line, including our then recently acquired high frequency RFID casino chip technology, our Chinese manufacturing capabilities and our Chinese research and development center.

In August 2006, VendingData and Elixir decided to suspend discussions concerning the proposed business combination of the two companies due to the possible need to include another potential partner in the discussions. The parties continued discussions concerning an expanded commercial relationship and an equity investment by Elixir.

On October 11, 2006, we entered into an alliance agreement, an amended and restated sales representative agreement and a securities purchase agreement with Elixir. Pursuant to the alliance agreement, we agreed with Elixir to enter into negotiations to establish a manufacturing alliance pursuant to which (i) Elixir would integrate its research and development operations in Macau with our engineering operations in Zuhai, China, (ii) after a satisfactory testing period, we would manufacture all products required by Elixir at our China manufacturing facilities, and (iii) Elixir would make an equity investment in a special purpose entity to be formed by us to hold our manufacturing facilities in China.

Pursuant to the amended and restated sales representative agreement, we appointed Elixir as our exclusive distributor throughout Asia, and to those casinos controlled by certain designated customers, regardless of location, for our chips, plaques, chip washers, and all new products developed or sold by us that do not directly compete with any product distributed by Elixir. The initial period of exclusivity is five years, and may be extended for an additional 15 year period provided that Elixir achieves an aggregate sales target of $20,000,000 during the initial five year period.

Pursuant to the securities purchase agreement, Elixir agreed to purchase, for the aggregate price of $2.65 million, 1,000,000 shares of our common stock and warrants to purchase 16,000,000 shares of our common stock at exercise prices ranging from $2.65 to $5.50 per share for a period of 36 months beginning on December 31, 2007. The foregoing is not a complete summary of the material terms and conditions of the alliance agreement, amended and restated sales representative agreement, or securities purchase agreement. Please refer to our reports and proxy statement on file with the SEC, including our current report onForm 8-K dated October 11, 2006, for a complete description of the terms and conditions, including copies of the agreements. The transactions under the securities purchase agreement were approved by our stockholders at our annual meeting of stockholders held on December 28, 2006 and we closed on the purchase and sale of the common shares and warrants under the securities purchase agreement on January 18, 2007.

Following the close of the securities purchase agreement, our management and Elixir continued discussions concerning a proposed business combination. On March 16, 2007, we signed a non-binding memorandum of understanding with Elixir concerning our acquisition of all of the capital shares of Elixir in exchange for our issuance of a controlling block of our common shares to Melco. The parties resumed their due diligence inquiries of the other, and in March 2007 our counsel prepared an initial draft of a securities purchase agreement and plan of reorganization to be entered into between us and Melco. We delivered the initial draft to Melco on April 1, 2007.

In late April 2007, we agreed with Melco and Elixir to consider an alternative to a business combination. Commencing in late April, we commenced discussions with Elixir concerning a structure whereby Elixir could “earn-in” equity in VendingData by assisting in the placement of electronic gaming machines with gaming operators in the general Asia market. During these discussions, it became clear that our business focus post-closing was going to be the gaming device markets in Asia. We held extensive discussions with Elixir concerning the status and future of our U.S. business. We considered that VendingData has historically

struggled to compete in the U.S. gaming device markets, and that our competitors have significantly greater financial and management resources. We determined that we should surrender our U.S. gaming licenses following the close in order to allow us to devote our resources to an Asia-based business model. We believe this decision will result in significant cost savings to us and allow us to focus our time and capital on developing our Asian business. Upon the successful execution of our Asia-based business model, we may consider returning to the U.S. gaming device market.

From late April 2007 and through June 11, 2007, VendingData, Elixir and their respective legal advisors engaged in extensive negotiations regarding the terms of the definitive Participation Agreement and the ancillary agreements and exchanged numerous drafts of these agreements as a result. These discussions included a series of conversations between VendingData’s senior management, Elixir’s senior management, and representatives of Greenberg Traurig, LLP, outside counsel to VendingData, and Latham & Watkins LLP, outside counsel to Elixir, relating to, among other things, the terms of which Elixir would earn equity in VendingData based on VendingData’s placement of electronic gaming machines and Elixir’s representation on the board of directors of VendingData. During early June, we concluded our financial due diligence and the definitive documents were finalized. During the period late April 2007 through June 11, 2007, the VendingData board of directors held several board meetings and informal telephonic board calls in order to update members of the board on negotiations and provide instruction to management.

In expectation of a change in control transaction with Elixir, we engaged Capstone Valuation Services, LLC (“Capstone”) in May 2007 to render an opinion to the board of directors of VendingData as to the fairness of any such transaction from a financial point of view to the holders of capital stock of VendingData.

On June 9, 2007, Capstone made an oral presentation to the board of directors of VendingData at which Capstone provided a detailed financial analysis of Elixir, VendingData and the proposed transaction contemplated by the Participation Agreement. At that meeting, Capstone provided a comprehensive summary of the documents and financial information concerning VendingData and Elixir reviewed by Capstone in conducting its analysis, including historical and projected financial information for both companies and the historical trading in VendingData’s common stock. Capstone also provided an analysis of the range of present values of VendingData, using the income approach/discounted cash flow and guideline company method analyses, based on VendingData’s projected results of operations under four scenarios, including (i) the closing of the initial transactions under the Participation Agreement and the projected operations based on Elixir’s satisfaction of all milestones under the Participation Agreement, (ii) the closing of the initial transactions under the Participation Agreement and the projected operations based on Elixir’s failure to achieve any of the milestones under the Participation Agreement, (iii) the abandonment of the transactions under the Participation Agreement and VendingData’s continued commercial relationship with Elixir on a reduced scale, and (iv) the abandonment of the transactions under the Participation Agreement and the termination of all commercial relationships between VendingData and Elixir.

On June 10, 2007, Capstone presented to the VendingData board of directors its written opinion that, as of such date, and based upon and subject to certain matters stated in its opinion, the consideration to be received by VendingData under the Participation Agreement was fair from a financial point of view to the stockholders of VendingData (other than Elixir). On June 11, 2007, the VendingData board unanimously approved the Participation Agreement. On June 12, 2007, VendingData and Elixir executed the definitive Participation Agreement and related documents. The transaction was announced in a joint press release on the following business day, June 13, 2007.

VendingData Board of Directors’ Reasons for the Transaction

The VendingData board of directors has unanimously approved the Participation Agreement, has unanimously determined that the transactions thereunder, including the issuance of the common stock and warrants to Elixir as contemplated by the Participation Agreement, is advisable, fair to and in the best interests of VendingData and its shareholders and unanimously recommends a vote FOR the proposal to approve the transactions contemplated by the Participation Agreement.

In concluding to approve the Participation Agreement, the board of directors of VendingData considered the following:


	•	Although VendingData has developed a suite of gaming devices and solutions, it has historically been unable to substantially develop a market for its products. The gaming device industry is dominated by a small number of gaming device manufacturers and distributors, and all of them have far greater financial and management resources. The VendingData board believed that even if VendingData had the capital and human resources required to compete with these gaming device manufactures, VendingData would face intense competition from others who had stronger market positions and competitive advantages, in addition to having far greater financial and human resources.

	•	VendingData’s ability to develop and ultimately market its products and solutions has been constrained throughout by a lack of capital and access to sales channels. As of March 31, 2007, VendingData had working capital of $1,141,582. Meanwhile, VendingData continued to experience losses from operations, including negative net cash flows from operations of $2,334,449 for the three months ended March 31, 2007. In the second quarter of 2007, the VendingData board was advised that the company required over time a minimum of $10 million in order to fund its continued operations in the absence of the transactions contemplated by the Participation Agreement. VendingData management conducted informal discussions with sources of investment capital, including parties who had recently provided or arranged for the provision of investment capital, and did not receive any indication of interest in their provision of additional capital, except in the context of a material transaction with Elixir. The VendingData board was concerned that any equity financing round would be dilutive to the current shareholders and at a per share price below the market price per share for common stock at that time. The VendingData board was also concerned that the pursuit of an equity financing round would substantially dilute the current shareholders of VendingData, while not providing sufficient assurances that the financing would in time lead to an increase in share price.

	•	The VendingData board of directors believes that Elixir will be able to drive sales to VendingData in amounts that will allow VendingData to achieve a profitable level of operations and income per share that VendingData could not reasonably expect to achieve in the absence of the Participation Agreement.

The VendingData board of directors consulted with VendingData’s management and its financial and legal advisors and considered the advice of consultants that it had retained in the past to provide advice for the formulation strategies and options for maximizing shareholder value. In addition to considering the strategic factors outlined above, the VendingData board of directors considered the following additional factors in reaching its conclusion to approve the Participation Agreement and recommend that the VendingData stockholders approve the Participation Agreement:


	•	general market conditions for VendingData’s products and services;

	•	opportunities and competitive factors within the gaming industry;

	•	the potential benefits to VendingData’s stockholders as a result of growth opportunities following the close of the Participation Agreement; and

	•	the opinion of Capstone Valuation Services, LLC rendered in writing on June 10, 2007 to the VendingData board of directors that, as of such date, and based upon and subject to certain matters stated in its opinion, the consideration to be received by VendingData under the Participation Agreement was fair from a financial point of view to the stockholders of VendingData (other than Elixir).

The above discussion of the material factors is not intended to be exhaustive, but does set forth the principal factors considered by the VendingData board of directors. After due consideration, the VendingData board of directors unanimously determined that the Participation Agreement, including the issuance of VendingData common stock and warrants to Elixir as contemplated by the Participation Agreement, is advisable, fair to and in the best interests of VendingData and its shareholders.

In view of the wide variety of factors considered by the VendingData board of directors in connection with the evaluation of the Participation Agreement and the complexity of these matters, the board did not consider it practical to quantify, rank or otherwise assign relative weights to the foregoing factors, and it did not attempt to do so. Rather, the board made its recommendation based on the totality of the information presented to it, and the investigation conducted by it. The VendingData board of directors considered all these factors and determined that these factors, as a whole, supported the conclusions and recommendations described above.

Recommendation of the VendingData Board of Directors

The VendingData board of directors recommends that VendingData stockholders voteFOR the authorization and approval of the Participation Agreement with Elixir, and the authorization and approval of the issuance of common stock and warrants pursuant thereto.

Opinion of VendingData’s Financial Advisor

In May 2007, VendingData engaged Capstone Valuation Services, LLC (“Capstone”) to render an opinion to the board of directors of VendingData as to the fairness from a financial point of view to the holders of capital stock of VendingData of the consideration to be received by VendingData under the Participation Agreement. VendingData selected Capstone because of its reputation and experience in the areas of valuation and financial advisory services. Capstone is regularly engaged in the valuation of businesses and their securities in connection with a variety of business combination transactions, as well as for estate, tax, corporate, litigation and other purposes. Capstone’s staff includes chartered financial analysts, certified public accountants and accredited senior appraisers of the American Society of Appraisers.

Pursuant to a letter agreement, dated May 29, 2007, VendingData agreed to pay Capstone a fee aggregating $165,000, the final portion of which ($40,000) is payable 60 days after delivery of its written opinion. In addition, VendingData reimbursed Capstone for all of its out-of-pocket expenses (including the fees and expenses of outside counsel) reasonably incurred by it in connection with the engagement, and VendingData has agreed to indemnify Capstone, its managing directors, personnel and affiliates against potential liability relating to its services. Capstone had not provided any services to VendingData or any affiliate of VendingData during the two years preceding the present engagement.

At a meeting of the board of directors of VendingData on June 9, 2007, Capstone presented to the board a comprehensive summary of its analysis of the value to be received by VendingData under the Participation Agreement, including the different methodologies applied to the underlying data. Capstone also provided an analysis of the range of present values of VendingData, using the income approach/discounted cash flow and guideline company method analyses, based on VendingData’s projected results of operations under four scenarios, including (i) the closing of the initial transactions under the Participation Agreement and the projected operations based on Elixir’s satisfaction of all milestones under the Participation Agreement, (ii) the closing of the initial transactions under the Participation Agreement and the projected operations based on Elixir’s failure to achieve any of the milestones under the Participation Agreement, (iii) the abandonment of the transactions under the Participation Agreement and VendingData’s continued commercial relationship with Elixir on a reduced scale, and (iv) the abandonment of the transactions under the Participation Agreement and the termination of all commercial relationships between VendingData and Elixir.

On June 10, 2007, Capstone delivered its written opinion to the board of directors of VendingData that, as of such date and based upon and subject to the assumptions, qualifications and limitations set forth therein, the consideration to be received by VendingData under the Participation Agreement was fair from a financial point of view to the stockholders of VendingData (other than Elixir).

The following is a brief summary of the Capstone opinion and all material information and the methodologies that Capstone employed in arriving at its opinion. The full text of Capstone’s written opinion, dated June 10, 2007, which sets forth, among other things, the assumptions made, matters considered and qualification and limitations of the review undertaken by Capstone in rendering its opinion, is attached as Annex B to this proxy statement and is incorporated by reference. VendingData stockholders are urged to read

this opinion carefully and in its entirety. Capstone’s advisory services and opinion were provided for the information and assistance of the VendingData board of directors in connection with its consideration of the Participation Agreement. Capstone’s opinion is not intended to be and does not constitute a recommendation to any stockholder of VendingData as to how such stockholder should vote with respect to the proposed transaction and should not be relied upon by any stockholder as such. Capstone was not requested to opine as to, and the Capstone opinion does not in any manner address, VendingData’s underlying business decision to proceed with or effect the transaction, or any aspect of the transactions under the Participation Agreement other than the fairness from a financial point of view to the stockholders of VendingData (other than Elixir) of the consideration to be received by VendingData.

In arriving at its opinion, Capstone, among other things:


	•	considered a draft dated June 9, 2007 of the Participation Agreement;

	•	considered certain financial and other information relating to VendingData, Elixir and Melco that was publicly available or furnished to Capstone by VendingData, including financial forecasts;

	•	met with or interviewed members of VendingData’s and Elixir’s management to discuss the business, operations, historical financial results and future prospects of VendingData upon the close of the Participation Agreement;

	•	considered certain financial and securities data of VendingData and Elixir and compared that data with similar data for other publicly-held companies in businesses similar to those of VendingData and Elixir;

	•	considered the financial terms of certain recent acquisitions of companies in businesses similar to those of VendingData;

	•	performed a discounted cash flow analysis and a guideline company method analysis; and

	•	considered such other information, financial studies, analyses and investigations and financial, economic and market criteria as Capstone deemed relevant and appropriate for purposes of its opinion.

According to VendingData’s management, VendingData had net operating loss carryforwards of approximately $90 million as of March 31, 2007. For purposes of its opinion, Capstone assumed the net operating loss carryforwards would have no value after giving effect to the equity issuances contemplated by Participation Agreement; however, as discussed further below a significant portion of the carryforwards will survive the closing of the transaction under the Participation Agreement and may be available for application to taxable income reported by VendingData in future years. Capstone relied upon and assumed, without independent verification, the accuracy and completeness of all financial and other information that was publicly available or furnished to it by VendingData or Elixir. Capstone did not make an independent evaluation or appraisal of the assets of VendingData nor was Capstone furnished with any such appraisals. Capstone did not solicit third party indications of interest, and its opinion does not address whether the consideration to be received by VendingData represents the highest price obtainable. Also, Capstone performed no procedures to determine the solvency of VendingData or Elixir, and its opinion does not constitute a solvency opinion.

Capstone’s opinion was necessarily based on economic, market and other conditions as in effect on, and the information provided to Capstone, as of, the date of its opinion. It should be understood that subsequent developments may affect the opinion and that Capstone does not have any obligation to update, revise, or reaffirm its opinion.

Tax Consequences

The transactions under the Participation Agreement should not have any tax consequences to VendingData’s stockholders. However, the transactions under the Participation Agreement will impact the application of VendingData’s net operating loss carry forwards to income earned in future years. At March 31, 2007, VendingData had net operating loss carryforwards for U.S. federal income tax purposes of approximately $89,558,043 that may be available to offset against future taxable income. These operating loss carryforwards

expire in the years 2010 through 2025. Section 382 of the Internal Revenue Code of 1986, as amended, limits VendingData’s ability to fully utilize these net operating loss carryforwards and realize any benefit therefrom in the event that a VendingData shareholder increases their percentage ownership in the outstanding common shares of VendingData to more than 50% within a three year period (an “ownership change”). In the event of an ownership change, the amount of income that VendingData may offset each year by its pre-ownership change net operating loss carryforwards is generally limited to an amount determined by multiplying the total fair market value of outstanding VendingData stock at the time of the ownership change by the Federal long term tax exempt rate (such rate is 4.32% as of July 2007) in effect on the date of the ownership change.

For example, assuming that (i) an ownership change occurs in December 2007 by virtue of Elixir acquiring additional common shares resulting in its ownership of more than 50% of the outstanding common shares of VendingData, (ii) on the date of the ownership change the price per share of Vending Data stock is $3.00, and (iii) there are 60 million shares outstanding on the date of the ownership change, then the fair market value of the outstanding VendingData stock would be $180,000,000. Under this example, VendingData would be allowed to use $7,776,000 of its pre-ownership change net operating loss carryforwards ($89,558,043 as of March 31, 2007) each subsequent tax year until all of the pre-ownership change net operating loss carryforwards expire or are exhausted.

Except for the aforementioned impact on VendingData’s net operating loss carryforwards, the transactions under the Participation Agreement should not have any tax consequences to VendingData.

Regulatory Matters

Hart-Scott-Rodino Act and Antitrust

Under theHart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules promulgated thereunder by the Federal Trade Commission (the “FTC”), the transactions under the Participation Agreement may require, prior to their consummation, that notifications be given and certain information furnished to the FTC and the Antitrust Division of the Department of Justice (the “Antitrust Division”) and specified waiting period requirements have been satisfied.

Gaming

During the course of the negotiations and development of the Participation Agreement, it became clear that the business focus of VendingData following the close was going to be the gaming device markets in Asia. Consequently, it was decided that VendingData should channel its energies and resources into the Asian markets. In order to most efficiently accomplish our goals and objectives with respect to Asia, it was decided that VendingData should surrender its gaming licenses in the U.S. following the close of the transactions under the Participation Agreement. Pursuant to the Participation Agreement, VendingData has agreed that promptly after closing of the transactions under the Participation Agreement it shall commence the process of surrendering its gaming licenses in the United States and shall use its best efforts to surrender all such gaming licenses, and in doing so modify its business operations to eliminate the requirement for such licenses under the gaming laws of the U.S., so as to no longer be subject to any gaming laws or the jurisdiction of any gaming authority in the U.S. Based on the expected surrender of VendingData’s gaming licenses in the U.S. following the close, there should be no gaming regulatory approvals are necessary in order to consummate the transactions under the Participation Agreement.

Accounting Treatment

Our issuance of common shares and warrants to Elixir under the Participation Agreement will be accounted for under EITFNo. 96-18,Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services, which addresses the accounting for, among other things, the issuance of equity in exchange for services rendered. As electronic gaming machines are placed with gaming operators identified by Elixir in satisfaction of the milestones set forth in the

Participation Agreement, and Elixir earns equity thereby, we will debit deferred costs and credit accrued unit placement cost liability, in the dollar amount of common shares earned using the value of the shares earned based on market prices as of the date of placement. As revenue is earned, the deferred costs will be amortized over the life of the lease agreement relating to the applicable electronic gaming machines.

Investment Considerations

In addition to the other information included in this proxy statement, you should carefully consider the following before deciding whether to vote for approval and adoption of the Participation Agreement and the transactions contemplated thereby.

Our shareholders will undergo significant equity dilution pursuant to the transactions contemplated by the Participation Agreement. There can be no assurance that we will be able to satisfy the conditions to Elixir’s obligation to consummate the transactions under the Participation Agreement or that the transactions under the Participation Agreement will otherwise be consummated. However, if we are successful in consummating the transactions under the Participation Agreement, our shareholders will experience significant equity dilution due to the number of shares we will need to issue under the agreement. At the closing of the transactions under the Participation Agreement, Elixir will hold at least 26,000,000 shares of our common stock, which includes the 1,000,000 common shares it purchased from us in January 2007. Assuming that we issue no further common shares between now and the closing, Elixir’s 26,000,000 common shares will represent approximately 43% of our issued and outstanding common shares. If Elixir earns all 55,000,000 common shares under the Participation Agreement, and all 88,000,000 warrants issued to Elixir thereunder vest and become exercisable, Elixir will own approximately 61% of our issued and outstanding common shares (assuming we issue no further common shares between now and then) and approximately 70% of our issued and outstanding common shares on a fully diluted basis (assuming we issue no further common shares or options, warrants or the like to purchase our common shares between now and then).

The transactions contemplated by the Participation Agreement will lead to a change in the control of VendingData. At the closing of the transactions under the Participation Agreement with Elixir, Elixir will have the power to significantly influence all matters requiring approval by our stockholders, including the election of directors and approval of mergers and other significant corporate transactions. Based on its ability to earn-in additional common shares or exercise its warrants, Elixir will have the ability to acquire in excess of 51% of our outstanding common shares and thereby control all matters requiring approval by our stockholders, including the ability to elect our entire board of directors. Pursuant to the Participation Agreement, Elixir has agreed to vote its shares in support of the election of two of our present directors for a period of two years following the closing. However, our stockholders should assume that following the closing, Elixir will have the ability to elect at least a majority of directors and thereby control our management and all stockholder actions. This concentration of ownership will make it difficult for other stockholders to effect substantial changes in our company, and also will have the effect of delaying, preventing or expediting, as the case may be, a further change in control of our company.

The accounting treatment of the transactions under the Participation Agreement will negatively impact our reportable net profit (loss) over the life of the gaming machine lease agreements that relate to the equity earned by Elixir. Our issuance of common shares and warrants to Elixir under the Participation Agreement will be accounted for under EITFNo. 96-18,Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services, which addresses the accounting for, among other things, the issuance of equity in exchange for services rendered. As electronic gaming machines are placed with gaming operators in satisfaction of the milestones set forth in the Participation Agreement, and Elixir earns equity thereby, we will debit deferred costs and credit accrued unit placement cost liability, in the dollar amount of shares earned using the value of the shares earned based on market price as of the date of placement. As revenue is earned, the deferred costs will be amortized over the life of the lease agreement relating to the applicable electronic gaming machines. Assuming a VendingData share price of $3.00 throughout the period Elixir earns all 55,000,000 common shares under the Participation Agreement, VendingData would realize a cumulative total of approximately $165,000,000 in non-cash charges to its income statement over the life of the gaming machine lease agreements that relate to the common shares

earned by Elixir. Although this amount is a non-cash charge and would not negatively impact cash flow from operations or EBITDA, the charges are likely to materially negatively impact VendingData’s reportable net profit (loss) from operations.

The transactions under the Participation Agreement represent a material change in our business model, and that business model has not been proven by us. Our decision to pursue the transactions under the Participation Agreement, and specifically our decision to issue the significant equity to Elixir based upon the resulting placement of electronic gaming machines, was based in large part on certain pro forma financial projections and underlying forecasts and assumptions concerning future events and circumstances, including, but not limited to, Elixir’s ability to source and identify gaming operators in the general Asia market with which we might place electronic gaming machines and the commercial success of those machines, which our management believed to be significant to our future operations under the Participation Agreement. Some assumptions will invariably not materialize and some unanticipated events and circumstances occurring subsequently may affect other assumptions. Therefore, the actual results achieved may vary from the pro forma projections considered by our management, and the variations may be material. No assurance can be given that our future results of operations under the Participation Agreement will meet with consumer acceptance or market success.

Cautionary statement regarding forward-looking statements. This proxy statement contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our business and the expected impact of the proposed transactions under the Participation Agreement. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this proxy statement that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (“Securities Act”). These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in this proxy statement and the risks detailed from time to time in our SEC reports. Many of the important factors that will determine these results are beyond our ability to control or predict. VendingData’s stockholders are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of the proxy statement. Except as otherwise required by law, VendingData does not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this proxy statement or to reflect the occurrence of unanticipated events.

THE PARTICIPATION AGREEMENT

This section of the proxy statement describes the material aspects of Participation Agreement. While we believe that the description covers the material terms of the transaction and Participation Agreement, this summary does not cover all of the terms of the Participation Agreement and may not contain all of the information that is important to you. You should read carefully this entire document and the other documents to which we refer, including the Participation Agreement that is attached as Annex A, for a more complete understanding of the transaction and the Participation Agreement.

Structure of the Transaction

According to the terms of the Participation Agreement, Elixir will “earn-in” an equity interest in VendingData based on the achievement of various performance milestones in terms of (a) the cumulative number of the electronic gaming machines that are contracted to be placed and leased pursuant to lease agreements entered into between VendingData and the gaming operators sourced and identified by Elixir (the “gaming machines under contract”) and (b) the cumulative number of electronic gaming machines physically placed by VendingData and in operation in the gaming premises of gaming operators pursuant to the lease agreements (the “gaming machines in operation”). Pursuant to the Participation Agreement, an electronic gaming machine will be deemed to have been placed upon VendingData’s execution of a written lease agreement with a licensed gaming operator in the Asia market, pursuant to which VendingData leases the machine to the operator, for a minimum period of three years, and the operator agrees to pay to VendingData at least 20% of the net win from the operation of the machine. Net win is defined as all amounts played in or wagered on the electronic gaming machine during the relevant period minus the amount of money paid out of the machine to players, after deduction of applicable gaming taxes.

The close of the transaction is subject to the placement of at least 1,000 gaming machines in operation. At the close, VendingData will issue to Elixir 25,000,000 common shares and warrants, with an exercise price of $2.65 per share, to purchase up to 88,000,000 additional common shares of VendingData. The warrants will vest and first become exercisable based on the achievement of certain milestones with respect to the number of gaming machines under contract and in operation. Elixir will be entitled to earn a total of 55,000,000 VendingData common shares (inclusive of the 25,000,000 shares issued at closing) and the warrants will vest and become exercisable subject to achieving the following milestones with respect to the cumulative number of gaming machines under contract and in operation as follows:


	Cumulative		Cumulative
	Gaming Machines		Gaming Machines		Shares Earned		Vesting of Warrants
	Under Contract		in Operation		by Elixir		Earned by Elixir

		1,000		1,000		25,000,000		0
		2,000		1,000		15,000,000		22,000,000
		3,000		2,000		10,000,000		22,000,000
		4,000		3,000		5,000,000		22,000,000
		5,000		4,000		0		22,000,000

Total		5,000		4,000		55,000,000		88,000,000

The exercise price of the warrants to be issued to Elixir and the number of shares issuable pursuant to the warrants are subject to adjustment for stock splits, dividends, rights offerings and other dilutive events. In addition, the number of shares of common stock for which the warrants may be exercised is subject to adjustment if VendingData issues shares of its common stock, or securities convertible into or exchangeable for shares of its common stock at a price less than the volume-weighted average price (“VWAP”) on the record date. Such an adjustment will be made every time VendingData issues common stock at a price below the VWAP; however, no adjustment will be made for shares issued in connection with the exercise of outstanding stock options and warrants. The Elixir warrants also contain net issuance provisions. A copy of the form of warrant to be issued to Elixir is attached as Exhibit A to the Participation Agreement which is attached to this proxy statement as Annex A.

Placement of Electronic Gaming Machines

According to the terms of the Participation Agreement, VendingData shall grant Elixir the exclusive right to source and identify on behalf of VendingData gaming operators in the Asia market for the placement of electronic gaming machines by VendingData. Elixir has agreed to use its reasonable best efforts to source and identify gaming operators in the Asia market with the goal of achieving the milestones for the placement of electronic gaming machines contemplated by the Participation Agreement.

Unless otherwise agreed to in writing, each party shall bear its own costs and expenses and provide all staff and labor in connection with the placement of electronic gaming machines under the Participation Agreement; provided, however, VendingData shall reimburse Elixir for all direct costs incurred in setting up at the location where the electronic gaming machines are installed including, without limitation, costs associated with casino management systems, computers, and signage.

Pursuant to the Participation Agreement, Elixir has agreed to sell to VendingData electronic gaming machines from time to time at Elixir’s cost. In the event of Elixir’s purchase of the electronic gaming machines for resale to VendingData from a party not affiliated with Elixir, Elixir’s cost shall be the purchase price paid by Elixir plus 15%. In the event of the manufacture of the electronic gaming machine by Elixir or Elixir’s purchase of the electronic gaming machine for resale to VendingData from an affiliate of Elixir, Elixir will sell such electronic gaming machine to VendingData at the same price as it would sell such electronic gaming machine in an arm’s length transaction with an unrelated third party.

VendingData has agreed to use its commercially reasonable best efforts to raise additional capital as soon as practicable after the closing date in order to repay all amounts owing to Elixir for electronic gaming machines sold to VendingData by Elixir. Elixir shall use reasonable commercial efforts to assist VendingData in raising such capital. In the event such capital raising does not occur or is not sufficient to purchase electronic gaming machines or pay the amounts owing to Elixir for the past purchase of electronic gaming machines, Elixir shall provide trade credit to VendingData, with all amounts owing to Elixir bearing interest, commencing January 1, 2008, at an annual rate of 8%.

Closing of the Transaction

The closing of the transactions under the Participation Agreement is subject to the placement of at least 1,000 electronic gaming machines in operation, along with the satisfaction of all other conditions set forth in Sections 2.3 and 2.4 of the Participation Agreement and summarized below. As used in this proxy statement and the Participation Agreement, the term “closing” refers to transactions principally consisting of the resulting placement of at least 1,000 electronic gaming machines in operation and VendingData’s issuance of 25,000,000 common shares and the 88,000,000 warrants. From time to time following the closing, VendingData shall issue to Elixir, subject to Elixir’s satisfaction of the appropriate milestones, one or more certificates evidencing the VendingData common shares attributable to the resulting placement of additional electronic gaming machines with gaming operators identified by Elixir under the Participation Agreement.

Either party may terminate the Participation Agreement if the closing has not occurred by 4:30 p.m., Las Vegas time on October 31, 2007 or such later date as may be agreed by the parties in writing; provided, that the right to terminate the Participation Agreement on such grounds shall not be available to any party whose

failure to comply with its obligations under the Participation Agreement has been the cause of or resulted in the failure of the closing to occur on or before such time.

Conduct of Business Prior to Closing

VendingData has agreed that it will conduct its business in the ordinary course, in accordance with past practices and in compliance with all applicable laws, rules and regulations. VendingData has also agreed to promptly advise Elixir in writing of any material change in its business or financial condition and periodically report to Elixir the status of its business, operations and finances. VendingData has also agreed that it will refrain from doing any of the following prior to the closing of the transaction without the prior written consent of Elixir:


	•	amend or propose any amendments to its certificate of incorporation, bylaws or other comparable organizational documents;

	•	acquire or agree to acquire any business or division thereof;

	•	sell, lease, license, mortgage or otherwise subject to any lien or dispose of any of its properties or assets that are material to VendingData;

	•	incur any indebtedness, enter into any financing arrangements, modify the terms of any existing indebtedness or prepay any interest on any indebtedness;

	•	enter into, modify, amend or terminate any material contract;

	•	make any change to its accounting methods, principles or practices;

	•	fail to use commercially reasonable efforts to maintain the material assets of VendingData in their current physical condition, except for ordinary wear and tear and damage;

	•	merge or consolidate with or into any other legal entity or dissolve or liquidate;

	•	adopt, amend or terminate any employee benefit plan or employment or consulting agreements with any officer, director or employee, or materially increase the compensation or benefits payable to any officer, director or employee;

	•	issue, sell or grant options or rights to purchase any of the shares of VendingData, other than for limited exceptions set forth in the Participation Agreement;

	•	acquire or redeem, directly or indirectly, or amend the terms of any shares of common stock;

	•	split, combine or reclassify its capital stock or declare, set aside, make or pay any dividend or distribution on any shares of its capital stock;

	•	make any tax election;

	•	settle or agree to settle any suit, action, claim, proceeding or investigation; or

	•	agree to take any of the foregoing actions or take any action which would make any representation or warranty in the Participation Agreement untrue or incorrect.

Meeting of Stockholders

VendingData is obligated under the Participation Agreement to hold and convene a meeting of its stockholders for the purposes of considering the approval and adoption of the Participation Agreement, the amendment to VendingData’s articles of incorporation to increase its authorized capital and the election of Elixir’s nominees to the VendingData board of directors. VendingData has agreed that the proxy statement delivered to its stockholders shall include a statement that the VendingData board of directors recommends that the shareholders of the company approve and adopt the Participation Agreement, the amendment to VendingData’s articles of incorporation and the election of Elixir’s nominees to the VendingData board of directors; provided, however, that the VendingData board may, at any time prior to the time of the

VendingData stockholder meeting, withdraw, modify or change any such recommendation to the extent that the VendingData board determines in good faith, after receiving written advice from outside legal counsel, that such recommendation would not be consistent with its fiduciary duties to the VendingData stockholders.

Pursuant to the Participation Agreement, James Crabbe and Mark Newburg, VendingData’s chairman of the board and chief executive officer, respectively, have agreed to vote all of the shares of VendingData common stock under their control in favor of the transactions contemplated by the Participation Agreement.

Board Representation

Pursuant to the Participation Agreement, at the closing the authorized number of members of the VendingData board of directors shall be no more than eight and Elixir will be entitled to appoint to the VendingData board no less than three as of the closing. At least one Elixir nominee shall be entitled to serve on each committee of the VendingData board, provided, in the case of the audit committee, such Elixir nominee satisfies the applicable independence requirements.

Pursuant to the Participation Agreement, Elixir has agreed that until the second anniversary of the closing, the pre-closing shareholders of VendingData will be entitled to the benefit of the continued representation on the VendingData board of directors of two of its existing directors (referred to herein as the “VendingData Nominees”). In the event of the resignation, termination or death of either VendingData Nominee, the remaining VendingData Nominee shall be entitled to name a replacement. At least one VendingData Nominee shall qualify as an independent director under AMEX Rule 121A(2) and meet the criteria for independence as set forth inRule 10A-3(b)(1) under the Exchange Act. At least one of the VendingData Nominees shall be entitled to serve on each committee of the board of directors of the Company, provided, in the case of the audit committee, such VendingData nominee satisfies the independence requirements of the audit committee charter.

Conflicts Committee

Pursuant to the Participation Agreement, the VendingData board of directors shall create and maintain a committee of the VendingData board, to be known as the conflicts committee, made up exclusively of at least three members of the VendingData board who satisfy the independence requirements of AMEX Rule 121A(2) and meet the criteria for independence as set forth inRule 10A-3(b)(1) under the Exchange Act, and who are not then, and during two years prior to their appointment or election have not been, an officer, director, employee of or consultant or advisor to Elixir and or any affiliate of Elixir. Elixir may appoint at least one representative to the conflicts committee if that person satisfies the foregoing criteria. The conflicts committee shall operate under a charter in the form of the conflicts committee charter attached as Exhibit C to the Participation Agreement attached to this proxy statement as Annex A. Pursuant to its charter, the conflicts committee shall have the power to veto any agreement or transaction between VendingData and Elixir or any of its affiliates involving an aggregate amount in excess of $200,000 and that has been approved by the VendingData board of directors.

The conflicts committee charter shall not be amended or modified unless (i) such amendment or modification has been approved and recommended by a majority of the members of the conflicts committee and (ii) at least five business days preceding the effective date of such amendment or modification VendingData has filed with the SEC a current report onForm 8-K that accurately and fully discloses the proposed amendment or modification and the basis for the conflicts committee’s recommendation.

Gaming Licenses

Pursuant to the Participation Agreement, VendingData has agreed that promptly after closing of the transactions under the Participation Agreement it shall the commence the process of surrendering its gaming licenses in the United States and shall use its best efforts to surrender all such gaming licenses, and in doing so modify its business operations to eliminate the requirement for such licenses under the gaming laws of the United States, so as to no longer be subject to any gaming laws or the jurisdiction of any gaming authority in the United States.

Conditions to the Closing of the Transaction

The obligations of VendingData and Elixir to effect the close of the transactions under the Participation Agreement are subject to the satisfaction or waiver of various conditions, which include the following:


	•	VendingData’s receipt of shareholder approval and, if necessary, the approval by the shareholders of Melco of the terms of the Participation Agreement and the transactions contemplated thereunder;

	•	If applicable, the waiting period applicable to the consummation of the transaction contemplated by the Participation Agreement under applicable antitrust laws shall have expired or been terminated, and there shall not be in effect any voluntary agreement between VendingData, Melco or Elixir and the FTC or the Department of Justice pursuant to which VendingData, Melco or Elixir has agreed not to consummate the transactions contemplated by the Participation Agreement for any period of time;

	•	VendingData’s receipt of approval by the AMEX of an application for the listing of the VendingData common shares issuable to Elixir under Participation Agreement;

	•	the filing of an amendment to VendingData’s articles of incorporation with the Nevada Secretary of State for purposes of increasing VendingData’s authorized common stock to an amount sufficient to provide for VendingData’s issuance of all of the common shares issuable to Elixir under Participation Agreement; and

	•	on the closing date, (A) no legal action, suit or proceeding shall be pending or threatened which seeks to restrain or prohibit the transactions contemplated by the Participation Agreement and (B) there shall exist no actual or potential regulatory impediment to the legal and beneficial ownership of VendingData’s common shares by Elixir.

Each of the closing conditions can, to the extent legally permissible, be waived by written mutual consent of VendingData and Elixir.

In addition, the obligations of VendingData to effect the close of the transactions under the Participation Agreement are subject to the fulfillment or waiver, prior to the closing date, of each of the following conditions:


	•	the representations and warranties of Elixir contained in the Participation Agreement shall be true and correct in all material respects; and

	•	all obligations, covenants and agreements of Elixir required to be performed at or prior to the closing shall have been performed, including, but not limited to, the placement of at least 1,000 electronic gaming machines in operation.

These closing conditions are waivable, to the extent legally permissible, in writing, by VendingData.

Finally, the obligations of Elixir to effect the close of the transactions under the Participation Agreement are subject to fulfillment or waiver, prior to the closing date, of each of the following conditions:


	•	the representations and warranties of VendingData contained in the Participation Agreement shall be true and correct in all material respects;

	•	all obligations, covenants and agreements of VendingData required to be performed at or prior to the closing shall have been performed;

	•	a legal opinion of Elixir’s Nevada counsel, in form and substance reasonably satisfactory to Elixir;

	•	Elixir’s three nominees shall have been elected to the VendingData board of directors effective as of the closing date;

	•	the completion by Elixir and its advisors of legal, financial and business due diligence to Elixir’s reasonable satisfaction; and

	•	execution of a waiver by Bricoleur Capital Management LLC to the effect that the transactions contemplated under the Participation Agreement do not constitute a change in control of VendingData and will not accelerate the maturity of amounts payable under a note agreement between Bricoleur and VendingData.

These closing conditions are waivable, to the extent legally permissible, in writing, by Elixir.

Indemnification of Officers and Directors

Pursuant to the Participation Agreement, all rights to indemnification by VendingData existing in favor of each individual who is an officer or director of VendingData as of the date of the Participation Agreement for their acts and omissions as a director or officer of VendingData occurring prior to the closing, as provided in VendingData’s bylaws (as in effect as of the date of the Participation Agreement) and as provided in any indemnification agreement between VendingData and such person (as in effect as of the date of the Participation Agreement), shall survive the closing and shall continue in full force and effect pursuant to the terms thereof.

Pursuant to the Participation Agreement, from the closing of the transactions under the Participation Agreement until the fourth anniversary thereof, VendingData shall maintain in effect the existing policies (primary and excess) of directors’ and officers’ liability insurance maintained by VendingData as of the date of the Participation Agreement for the benefit of each officer or director of VendingData as of the date of the Participation Agreement with respect to their acts and omissions as directors and officers of VendingData occurring prior to the closing; provided, however, that VendingData may substitute for the existing policies a policy or policies of comparable coverage.

Termination of the Participation Agreement

Unless terminated earlier pursuant to any of the provisions below, the Participation Agreement shall continue for a period of six years from the closing date. According to the terms of the Participation Agreement, it may be terminated:


	•	by written agreement of VendingData and Elixir;

	•	by either VendingData or Elixir upon written notice to the other, if the closing shall not have taken place by 4:30 p.m., Las Vegas time on October 31, 2007 or such later date as may be agreed by the parties in writing, although the right to terminate on such grounds shall not be available to any party whose failure to comply with its obligations under the Participation Agreement has been the cause of or resulted in the failure of the closing to occur on or before such time;

	•	by either VendingData or Elixir if any legal requirements permanently restraining, enjoining or otherwise prohibiting consummation of the transactions contemplated by the Participation Agreement shall become final and non-appealable (whether before or after the shareholder approval has been obtained);

	•	by Elixir if the VendingData board of directors (i) fails to include in the proxy statement delivered to the stockholders of VendingData its recommendation without modification or qualification that shareholders approve and adopt the Participation Agreement and the transactions contemplated thereby, including the election to the VendingData board of the Elixir director nominees, (ii) withdraws or modifies in an adverse manner such recommendation or its approval of the Participation Agreement and the transactions contemplated thereby or (iii) fails to reaffirm such approval or recommendation upon Elixir’s request within five business days of such request;

	•	by either VendingData or Elixir if the Special Meeting is held and the VendingData stockholders have not approved the Participation Agreement and the transactions contemplated thereby, including the election to the VendingData board of the Elixir director nominees, or, if applicable, Melco fails to obtain from its stockholders their approval of the Participation Agreement and the transactions contemplated thereby;

	•	by Elixir in the event of a triggering event (as defined below); or

	•	by either VendingData or Elixir if the other party has breached any of its representations, warranties, covenants or obligations set forth in the Participation Agreement such that not all of the terminating party’s conditions to closing can be satisfied, and the breach is not cured within the time period specified by the Participation Agreement.

A “triggering event” with respect to VendingData shall have occurred if: (a) the VendingData board of directors shall have approved, endorsed or recommended any other acquisition proposal; (b) VendingData shall have executed any letter of intent, memorandum of understanding or similar document relating to the terms and conditions of any other such acquisition proposal; or (c) a tender or exchange offer relating to securities of VendingData shall have been commenced and VendingData shall not have sent to its security holders, within ten business days after the commencement of such tender or exchange offer, a statement disclosing that VendingData recommends rejection of such tender or exchange offer.

Termination Fees and Expenses

Following negotiations, VendingData agreed that it would pay termination fees to Elixir in the event that the transaction is terminated in certain circumstances. The amount of the termination fee was determined based on dollar values acceptable to each of Elixir and VendingData, with reference to what was generally viewed as within the range of acceptable amounts for similar transactions.

Subject to certain exceptions, VendingData has agreed to pay to Elixir a non-refundable cash payment of $500,000 if Elixir terminates the Participation Agreement:


	•	because the VendingData board of directors (i) fails to include in the proxy statement delivered to the stockholders of VendingData its recommendation without modification or qualification that the shareholders approve and adopt the Participation Agreement and the transactions contemplated thereby, including the election to the VendingData board of the Elixir director nominees, (ii) withdraws or modifies in an adverse manner such recommendation or its approval of the Participation Agreement and the transactions contemplated thereby or (iii) fails to reaffirm such approval or recommendation upon Elixir’s request within five business days of such request;

	•	because of a triggering event; or

	•	if the Special Meeting is held and the VendingData stockholders have not approved the Participation Agreement and the transactions contemplated thereby, including the election to the VendingData board of the Elixir director nominees.

However, no termination fee shall be payable by VendingData if the action giving rise to termination was done or omitted to be done based upon, or occurred at a time during which, the VendingData board of directors having withdrawn, modified or changed its approval or recommendation in favor of the Participation Agreement and the transactions contemplated based on the written advice of its outside legal counsel that its favorable approval or recommendation of the agreement and transactions thereunder would not be consistent with the board’s fiduciary duties.

Registration Rights

In connection with the closing of the transactions contemplated by the Participation Agreement described above, VendingData will enter into a registration rights agreement with Elixir. The registration rights agreement requires VendingData to file a selling shareholder registration statement with the SEC within 30 days following the closing of the transactions contemplated by the Participation Agreement, for purposes of registering the resale of the shares of VendingData’s common stock issued to Elixir pursuant to the transaction, including all shares that are issued, or may be issued, upon exercise of the warrants. Pursuant to the registration rights agreement, the holders of the securities are also entitled to certain demand and piggyback registration rights.

A copy of the registration rights agreement is attached as Exhibit B to the Participation Agreement which is attached to this proxy statement as Annex A.

Interests of Directors, Officers and Affiliates

In considering the recommendation of the VendingData board of directors that VendingData stockholders vote in favor of approval of the Participation Agreement and the principal terms of the transaction,

VendingData stockholders should be aware that some VendingData executive officers and directors may have interests in the transactions that may be different from, or in addition to, their interests as stockholders of VendingData. These interests relate to or arise from, among other things:


	•	All rights to indemnification by VendingData existing in favor of each individual who is an officer or director of VendingData as of the date of the Participation Agreement for their acts and omissions as a director or officer of VendingData occurring prior to the closing, as provided in VendingData’s bylaws (as in effect as of the date of the Participation Agreement) and as provided in any indemnification agreement between VendingData and such person (as in effect as of the date of the Participation Agreement), shall survive the closing and shall continue in full force and effect pursuant to the terms thereof.

	•	VendingData will extend its directors’ and officers’ liability insurance to cover former VendingData directors and officers for the next two years, subject to certain limitations.

	•	Elixir’s indication that it intends to retain most of the executive officers of VendingData. Pursuant to their respective employment agreements with VendingData, each agreement provides that in the event of a change in control (defined as the acquisition by a party, in one or a series of related transactions, of 50% or more of the combined voting power of the then outstanding securities of VendingData), VendingData shall pay the officer 18 months salary. The payments are to be made regardless of whether the officer resigns or is terminated in connection with the change in control. Pursuant to Elixir’s request, each executive officer of VendingData, including Mark Newburg, Arnaldo Galassi, Peter Zee and Walter Stowe, has agreed, subject to the closing of the transactions under the Participation Agreement, to waive the change in control triggered by the Participation Agreement in exchange for a one year extension of their employment agreement.

	•	At the close of the transactions under the Participation Agreement, all stock options held by the executive officers and employees that are unvested shall vest and become exercisable.

The board of directors of VendingData took into account these interests in considering the fairness of the transaction to the VendingData stockholders.

PROPOSAL TWO — AUTHORIZE AND APPROVE A GRANT OF OPTIONS TO ACQUIRE 5,000,000 SHARES OF OUR COMMON STOCK TO THE ELIXIR PARTIES

Section 711 of the AMEX Company Guide requires stockholder approval for the establishment of any equity compensation arrangement, with limited exceptions. We are seeking the approval of our stockholders in accordance with Section 711 of the AMEX Company Guide for the issuance of an aggregate of up to 5,000,000 shares of our common stock pursuant to stock options (the “Elixir Options”) issued to certain officers, directors and employees of Elixir and its affiliates. The Elixir Options have been issued outside of our approved stock option plans, and accordingly we are required to obtain stockholder approval pursuant to Section 711 of the AMEX Company Guide.

At a meeting of the board of directors of VendingData held on May 17, 2007, the board approved the grant of options to purchase 5,000,000 shares of our common stock to certain officers, directors and employees of Elixir and Melco, including options to purchase 1,200,000 shares to Gordon Yuen, the chief executive officer of Elixir, and options to purchase 540,000 shares to Joe Pisano, general manager of Elixir. Mr. Yuen and Mr. Pisano have been nominated to our board of directors.

The options have been granted subject to both the approval of our shareholders and the close of the transactions under the Participation Agreement. In the event the options are not approved by our shareholders at the Special Meeting or the transactions under the Participation Agreement fail to close for any reason, the options will terminate unexercised. The exercise price of all options is $2.90 per share, the closing price of our common shares reported by the AMEX on May 17, 2007. All options have a term of five years and vest and first become exercisable in equal installments over three years commencing on the first anniversary of the

close of the transactions under the Participation Agreement. The option agreements include standard anti-dilution provisions.

Recommendation of the VendingData Board of Directors

The VendingData board of directors recommends that VendingData stockholders voteFOR the authorization and approval of a grant of the Elixir Options.

PROPOSAL THREE — AUTHORIZE AND APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 1999 STOCK OPTION PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED UNDER THE PLAN

Section 711 of the AMEX Company Guide requires stockholder approval for the establishment or material amendment of any equity compensation arrangement, with limited exceptions. We are seeking the approval of our stockholders in accordance with Section 711 of the AMEX Company Guide for the amendment of our 1999 Stock Option Plan (the “Option Plan”), to increase the number of common shares authorized for issuance under the plan from 6,000,000 to 15,000,000. Our board of directors has approved the amendment to the Option Plan and recommends the approval of the amendment to increase the authorized shares under the Option Plan.

The Option Plan was originally adopted by our stockholders on March 29, 1999. Through amendments approved by our stockholders on October 5, 2004, July 21, 2005 and December 28, 2006, we may issue stock options pursuant to the Option Plan to purchase up to 6,000,000 shares of our common stock. As of June 30, 2007, we have issued options to purchase 4,069,825 shares of common stock under the Option Plan.

Our board of directors has reviewed the Option Plan and the lack of available shares thereunder and determined that the Option Plan requires additional shares to provide the flexibility with respect to stock-based compensation that our board of directors believes is necessary to establish appropriate long-term incentives to achieve our objectives. Our board of directors believes that it is advisable to increase the 6,000,000 share limit to 15,000,000 shares in order to attract and compensate employees, officers and directors upon whose judgment, initiative and effort we depend. The issuance of stock options to eligible participants is designed to align the interests of such participants with those of our stockholders.

The proposed amendment to the Option Plan increases the number of shares of common stock that may be issued upon the exercise of options by 9,000,000 shares, or approximately 25% of the 36,141,534 shares of common stock outstanding on June 30, 2007. As amended, the Option Plan will continue to provide for appropriate adjustments in the number of shares in the event of a stock dividend, recapitalization, merger or similar transaction.

Recommendation of the VendingData Board of Directors

The VendingData board of directors recommends that VendingData stockholders voteFOR the approval of the amendment to the Option Plan.

PROPOSAL FOUR — APPROVE AN AMENDMENT TO OUR ARTICLES OF INCORPORATION TO INCREASE OUR AUTHORIZED COMMON STOCK

In connection with the transaction described in Proposal One, our board of directors is proposing to amend our articles of incorporation to increase the number of authorized shares of common stock from 70,000,000 shares to 300,000,000 shares, as more fully described below. Other than the proposed increase in the number of authorized shares of common stock, the proposed amendment is not intended to modify the rights of existing stockholders in any material respect. Our board of directors approved the proposed increase in the number of authorized shares of common stock and recommends the approval of the amendment to our articles of incorporation.

The proposed amendment to our articles of incorporation is provided as Annex C to this proxy statement. Amending our articles of incorporation to increase our authorized common stock as described in this Proposal Three is a closing condition under the Participation Agreement described in Proposal One. Upon approval of the amendment by our stockholders, we will file the amendment with the Nevada Secretary of State promptly after the Special Meeting. If the amendment is not approved by our stockholders, our articles of incorporation will not be amended and our authorized capital stock will remain the same. Accordingly, if this proposal is not approved and we cannot amend our articles of incorporation, we may not be able to complete the transaction with Elixir described in Proposal One.

Under Nevada law, we are only permitted to issue shares of our capital stock to the extent such shares have been authorized for issuance under our articles of incorporation. Our articles of incorporation currently authorize the issuance of up to 70,000,000 shares of common stock, $0.001 par value, and up to 10,000,000 shares of preferred stock, $0.001 par value.

Reasons For and Effect Of Amendment

As of June 30, 2007, we had 36,141,534 shares of common stock outstanding. In addition, as of June 30, 2007, we had outstanding options to purchase 4,069,825 shares of common stock and warrants exercisable for 23,249,000 shares of common stock. Pursuant to the transactions described in Proposals One, Two, and Three, we propose to issue up to 157,000,000 additional shares of common stock, subject to stockholder approval. In addition, as described above, we are required to amend our articles of incorporation to increase our authorized common stock as a condition to closing the transactions under the Participation Agreement described in Proposal One. In order to satisfy the closing condition under the Participation Agreement, and to ensure sufficient shares of common stock will be available for issuance to fulfill our obligations described in Proposals One, Two and Three, our board of directors has approved, subject to stockholder approval, the amendment to our articles of incorporation to increase the number of authorized shares of common stock from 70,000,000 shares to 300,000,000 shares.

The increase in authorized shares of common stock will not have any immediate effect on the rights of our stockholders. Although the additional authorized shares of common stock will not change the voting rights, dividend rights, liquidation rights or any other stockholder rights, our board of directors will have the authority to issue additional shares of common stock without requiring future stockholder approval of such issuances, except as may be required by applicable law or the rules of the AMEX or any stock exchange on which our securities may be listed. The issuance of additional shares will decrease the relative percentage equity ownership of our stockholders and, depending on the price at which they are issued, may be dilutive to the existing stockholders. The holders of our common stock have no preemptive rights and our board of directors has no plans to grant such rights with respect to any such shares.

Recommendation of the VendingData Board of Directors

The VendingData board of directors recommends that you voteFOR approval of the amendment to our articles of incorporation to increase our authorized common stock.

PROPOSAL FIVE — RE-ELECTION OF FIVE DIRECTORS AND ELECTION OF
THREE NEW DIRECTORS

Our bylaws provide that our board will consist of between one and ten members, with the number of directors determined from time to time by our board. The number of directors was set at eight in connection with entering into the Participation Agreement with Elixir. The current term of all of our directors expires at the Special Meeting. Accordingly, no more than eight directors will be elected at the Special Meeting to serve until the next annual meeting of stockholders and until their successors are elected and qualified. If any nominee is unable or declines to serve as director at the time of the Special Meeting, an event not now anticipated, proxies will be voted for any nominee designated by the board of directors to fill the vacancy.

Information About Nominees

Names of the board of directors’ nominees and certain biographical information about the nominees are set forth below.


Mark R. Newburg Age 52 Director since 2005		Mark R. Newburgjoined our board of directors as Executive Director in March 2005, was appointed Treasurer in April, 2005, and has served as our president and chief executive officer since October 2005. Mr. Newburg previously served as the president and chief executive officer and as a member of the board of directors of VirtGame Corp., a developer of software and networking applications for the gaming industry, from August 2004 to October 2005. From March 2004 to November 2004, Mr. Newburg served as chief operating officer to Left Right Marketing Technologies, an internet retailingstart-up in Las Vegas. From March 2003 to March 2004, Mr. Newburg was president and chief executive officer of C2Consulting Inc., a firm specializing in areas such as strategic planning, change management, organizational integration, international operations, and organizational alignment. From July 2001 to March 2003, Mr. Newburg served as president of Aristocrat Technologies Inc, an Australia-based designer, builder and marketer of proprietary software and hardware to the international gaming market. Previously, Mr. Newburg had a 20 year career at NCR Corporation, a $5.9 billion provider of store automation, self-service, payment, and data-warehousing solutions. Mr. Newburg earned his MBA from the University of Dayton in June 1985, and dual undergraduate majors with a BS in both Accounting & Business Administration from the University of Findlay in June 1976.

James E. Crabbe Age 61 Director since 2000		James E. Crabbehas served on our board of directors since May 2000 and was elected chairman of our board in August 2001. Mr. Crabbe is currently engaged in the active management of his personal investment portfolio. He spent 34 years in the money management business. In 1980, he co-founded the Crabbe-Huson Group, Inc., an investment management company, of which he served as president, portfolio manager and analyst until his retirement in 2000. Mr. Crabbe earned his bachelor’s degree from the University of Oregon in 1967.

Maj. Gen. Paul A. Harvey Age 69 Director since 2005		Major General Paul A. Harveyhas served on our board of directors since October 2005 and he chairs the compliance committee of the board. General Harvey has served as a consultant to the gaming, hotel and resort industry for the past five years. General Harvey spent 32 years on active duty in the United States Air Force where he held numerous command positions throughout the United States, Europe, Africa and the Middle East. Following retirement, he was the executive director of the Mississippi Gaming Commission from 1993 through 1998. General Harvey served on the board of directors of the National Center for Responsible Gaming from 1996 to 2004 (and is on the advisory board to the current chairman), Riviera Holdings Corporation, the owner and operator of Riviera Hotel & Casino in Las Vegas, Nevada, and Progressive Gaming International Corporation, a Las Vegas, Nevada based developer of table and slot game content and software products for the gaming industry.

Vincent L. DiVito Age 47 Director since 2005		Vincent L. DiVitohas served on our board of directors since October 2005 and he chairs the audit committee of the board. Mr. DiVito has served as vice president, chief financial officer and treasurer of Lonza, a Swiss-based life sciences chemical company headquartered in Allendale, New Jersey, since 2000. Previously, Mr. DiVito was the vice president and chief financial officer of Algroup Wheaton, a global pharmaceutical and cosmetics packaging company. Mr. DiVito spent two years on the audit team of Ernst & Whinney (now Ernst & Young). Mr. DiVito is a certified public accountant and certified management accountant. He is also a member of the board of directors of Riviera Holdings Corporation.



Robert L. Miodunski Age 56 Director since 2005		Robert L. Miodunskihas served on our board of directors since October 2005 and he chairs the compensation committee of the board. Mr. Miodunski served as president and chief executive officer of Alliance Gaming Corporation from 1999 through 2004. Since 2004, Mr. Miodunski serves as a consultant to Alliance Gaming’s board of directors and chief executive officer. From 1994 until 2002, Mr. Miodunski served as president of United Coin Machine Company, a subsidiary of Alliance Gaming.

Gordon Yuen Age 50 Director Nominee		Gordon Yuenhas served as chief executive officer of Elixir since 2002. Mr. Yuen has extensive experience in key management positions in IT companies and financial institutions, including Hong Kong Shanghai Bank (HSBC), American Express International, Inc., and American Express Bank. Mr. Yuen graduated from York University, Ontario, Canada, with a BA in Business Administration.

Joe Pisano Age 50 Director Nominee		Joe Pisanohas served as general manager of gaming operations for Elixir since August 2006. From March 2002 to July 2006, Mr. Pisano served as business development manager-Asia Pacific for IGT (Australia) Pty Ltd, a wholly-owned subsidiary of International Game Technology (NYSE:IGT), a designer, developer and manufacturer of microprocessor based gaming products. Mr. Pisano has a Masters in Business and Technology from the University of New South Wales in Australia.

Lorna Patajo-Kapunan Age 55 Director Nominee		Lorna Patajo-Kapunanhas served as a senior partner of Kapunan Lotilla Flores Garcia & Castillo Law Offices, a law firm located in Manila, Philippines, since October 2006. From October 2001 to September 2006, Ms. Patajo-Kapunan served as a partner of Roco Kapunan Migallos & Luna Law Offices, also a Manila based law firm.

Additional Information About our Board and its Committees

We continue to monitor the rules and regulations of the SEC and the AMEX to ensure that a majority of our board remains composed of “independent” directors. All of our directors except Mark Newburg are “independent” as defined in Section 121A of the AMEX Company Guide.

Our board met four times in 2006. During fiscal 2006, all of our directors attended all meetings during the periods for which they served on our board, and all of the meetings held by committees of the board on which they serve. The board of directors has formed an audit committee, a nominating committee, and a compensation committee, all of which operate under written charters. The committee charters are not available on our website. However, the charters for the audit committee and the nominating committee were included as appendices to the proxy statement filed with the SEC on September 3, 2004. Our board of directors does not have a policy regarding board members’ attendance at meetings of our stockholders.

Audit Committee

During fiscal 2006, our audit committee was initially comprised of Vincent DiVito, Bob Smith, Ron Keil, and Robert Miodunski. Messrs. Smith and Keil resigned from our board of directors on June 26, 2006. Our audit committee charter and the rules of the AMEX require us to have at least two members on our audit committee. In August 2006, Maj. Gen. Paul Harvey was appointed to serve on our audit committee. Mr. DiVito serves as the audit committee chair. Our audit committee generally meets quarterly, and in 2006 our audit committee held four meetings. Our audit committee has the responsibility of selecting the firm that will serve as our independent public accountants, approving and reviewing the scope and results of the audit and any non-audit services provided by the independent public accountants and meeting with our financial staff to review internal control, procedures and policies.

We have identified Mr DiVito as the audit committee financial expert. Mr DiVito is the chief financial officer of Lonza, a Swiss life sciences chemical company, and he is also a certified public accountant and a certified management accountant. All members of our audit committee are independent, as independence for audit committee members is defined in Section 121A of the AMEX Company Guide. In addition,

Mr. Miodunski and General Harvey each meet the definition of “financially sophisticated” as defined in Section 121B of the AMEX Company Guide.

Nominating Committee

During fiscal 2006, our nominating committee was initially comprised of Maj. Gen. Paul Harvey, Vincent DiVito, Bob Smith, and Ron Keil. Messrs. Smith and Keil resigned from our board of directors on June 26, 2006. Our nominating committee charter requires us to have at least two members on our nominating committee. In August 2006, James Crabbe was appointed to serve on our nominating committee. Mr. Crabbe serves as the nominating committee chair. The nominating committee is responsible for assisting our board with respect to the appropriate size and composition of our board and monitoring and making recommendations regarding the performance of our board. In this regard, our nominating committee evaluates the qualifications of all proposed candidates for election to our board, including capability, availability to serve, conflicts of interest and other relevant factors, and makes recommendations to our board concerning the size and composition of our board of directors.

Our nominating committee was formed in May 2006 and held one meeting in 2006. The members of our nominating committee are independent, as independence for directors is defined in Section 121A of the AMEX Company Guide.

The charter of our nominating committee allows the nominating committee to consider for directorships candidates nominated by third parties, including stockholders. For a third party to suggest a candidate, one must provide our legal department with the name of the candidate, together with a brief biographical sketch and a document indicating the candidate’s willingness to serve if elected.

Our nominating committee has recommended James E. Crabbe, Mark R. Newburg, Maj. Gen. Paul Harvey, Robert L. Miodunski, Vincent DiVito, Gordon Yuen, Joe Pisano and Lorna Patajo-Kapunan as nominees for election to our board of directors at the Special Meeting.

Director Compensation

Non-Employee Director Compensation. Non-employee members of our board of directors, with the exception of Mr. Crabbe, receive an initial grant of 100,000 options and, effective as of March 2007, an annual grant of 15,000 options on the date of the annual or special meeting of stockholders at which directors are elected. Mr. Crabbe receives options to acquire 8,000 shares annually. The exercise price of such options is the market price of our common stock on the date of grant. Our directors are reimbursed for their out-of-pocket expenses related to their services as directors or meeting attendance. Commencing April 2007, members of our board of directors who are not employees, with the exception of Mr. Crabbe, receive a quarterly fee of $7,500. The chairman of our audit committee receives an additional $7,500 per quarter. In addition, upon joining the board, Messrs. DiVito, Harvey and Miodunski each received options to purchase 100,000 shares of common stock at an exercise price of $1.34 per share over a three year term pursuant to our Amended and Restated 1999 Stock Option Plan; and each received a grant of 50,000 shares of common stock which accrued in increments of 10,000 shares over five calendar quarters beginning in September 2005.

Employee Director Compensation. Directors who are employees of VendingData receive no compensation for services provided in that capacity, but are reimbursed for out-of-pocket expenses in connection with attendance at meetings of our board and its committees.

Committee Interlocks and Insider Participation

No member of our board of directors is employed by VendingData or our subsidiaries except for Mark R. Newburg, who is presently employed as our president and chief executive officer.

Process for Stockholders to Send Communications to Our Board

Because we have always maintained open channels of communication with our stockholders, we do not have a formal policy that provides a process for stockholders to send communications to our board. However,

if a stockholder would like to send a communication to our board, please address the letter to the attention of our legal department and it will be distributed to each director.

Recommendation of the VendingData Board of Directors

The VendingData board of directors recommends that VendingData stockholders voteFOR the election of all director nominees listed in this proxy statement.

Audit Committee Report

The audit committee reviewed and discussed VendingData’s audited financial statements for the year ended December 31, 2006 with our management. The audit committee discussed with Piercy Bowler Taylor & Kern, VendingData’s independent registered public accounting firm, the matters required to be discussed by Statement on Auditing Standards No. 61Communication with Audit Committees as amended, and Statement on Auditing Standards No. 90Audit Committee Communications. The audit committee also received the written disclosures and the letter from Piercy Bowler Taylor & Kern required by Independence Standards Board Standard No. 1Independence Discussion with Audit Committees, and the audit committee has discussed the independence of Piercy Bowler Taylor & Kern with them.

Based on the audit committee’s review and discussions noted above, the audit committee recommended to our board of directors that VendingData’s audited financial statements be included in our annual report onForm 10-KSB for the year ended December 31, 2006 for filing with the SEC.

THE AUDIT COMMITTEE*

Vincent DiVito
Robert Miodunski
Maj. Gen. Paul Harvey

PROPOSAL SIX — AUTHORIZATION TO ADJOURN OR POSTPONE THE MEETING TO SOLICIT ADDITIONAL VOTES FOR APPROVAL

If at the Special Meeting the number of shares of our common stock voting in favor of all other proposals is insufficient to approve those proposals under applicable law, our management intends to move to adjourn or postpone the meeting in order to enable it to solicit additional proxies in favor of those proposals. In that event, we will ask our stockholders to vote only upon the adjournment proposal.

In the adjournment proposal, we are asking our stockholders to authorize the holder of any proxy solicited by our board of directors to vote in favor of granting management the discretionary authority to adjourn or postpone the Special Meeting and any later adjournments of that meeting to a later date in order to enable our board of directors to solicit additional proxies in favor of all other proposals presented if those proposals initially lack a sufficient number of shares voting in favor. If our stockholders approve the adjournment proposal, our management could adjourn the Special Meeting and any adjourned session of the Special Meeting to a later date and use the additional time to solicit additional proxies in favor of all proposals presented, including solicitation of proxies from stockholders that have previously voted against those proposals.

Recommendation of the VendingData Board of Directors

The VendingData board of directors recommends that you voteFOR the authorization to adjourn or postpone the meeting to solicit additional votes.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The table below sets forth the beneficial ownership of our common stock, as of June 30, 2007, by:


	•	All of our directors and executive officers, individually;

	•	All nominees to our board of directors, individually;

	•	All of our directors, executive officers and director nominees, as a group; and

	•	All persons who beneficially owned more than 5% of our outstanding common stock.

The beneficial ownership of each person was calculated based on 36,141,534 shares of our common stock outstanding as of June 30, 2007, according to the record ownership listings as of that date and the verifications we solicited and received from each director, executive officer and director nominee. The SEC has defined “beneficial ownership” to mean more than ownership in the usual sense. For example, a person has beneficial ownership of a share not only if he owns it in the usual sense, but also if he has the power to vote, sell or otherwise dispose of the share. Beneficial ownership also includes the number of shares that a person has the right to acquire within 60 days of June 30, 2007, pursuant to the exercise of options or warrants or the conversion of notes, debentures or other indebtedness, but excludes stock appreciation rights. Two or more persons might count as beneficial owners of the same share. Unless otherwise noted, the address of the following persons listed below isc/o VendingData Corporation, 1120 Town Center Drive, Suite 260, Las Vegas, Nevada 89144.


Name of Director,
Executive Officer
or Nominee	Shares(1)			Percentage

James E. Crabbe		7,115,073	(2)		19.69	%
Paul A. Harvey		84,000	(3)		0.23	%
Vincent L. DiVito		84,000	(3)		0.23	%
Robert L. Miodunski		84,000	(3)		0.23	%
Mark R. Newburg		1,590,772	(4)		4.40	%
Arnaldo F. Galassi		100,000	(5)		0.28	%
Peter Zee		100,000	(6)		0.28	%
Walter B. Stowe, Jr.		33,333	(7)		0.09	%
Gordon Yuen		1,000,000	(8)		2.77	%
Joe Pisano		—			—
Lorna Patajo-Kapunan		—			—
All directors, executive officers and director nominees as a group (11 persons)		10,191,178	(9)		28.20	%
Name and Address of 5% Holder
LC Capital Master Fund LP		2,844,848	(10)		7.87	%
c/o Lampe Conway & Co., LLC
680 5th Avenue, Suite 1201
New York, NY 10019
Leonid Frenkel		2,715,106	(11)		7.51	%
c/o Triage Capital LF Group, LLC
401 City Ave, Suite 800
Bala Cynwyd, PA 19004
Bricoleur Capital Management LLC		5,194,325	(12)		14.37	%
12230 El Camino Real #100
San Diego, CA 92130


(1)		Unless otherwise noted, the persons identified in this table have sole voting and sole investment power with regard to the shares beneficially owned by them.


(2)		Includes 4,574,066 shares held directly by Mr. Crabbe, 80,600 shares issuable upon the exercise of stock options and 2,460,407 shares held by Mr. Crabbe, as Trustee of the James E. Crabbe Revocable Trust. Mr. Crabbe disclaims any ownership of any shares of common stock beneficially owned by Phileo Foundation, a charitable foundation of which Mr. Crabbe is a trustee and president, or by Yvonne M. Huson, or her related trusts, for which Mr. Crabbe formerly held voting power.

(3)		Includes 50,000 shares held directly and 34,000 shares issuable upon the exercise of stock options.

(4)		Includes 425,666 shares issuable upon the exercise of stock options and 1,165,106 outstanding common shares over which Mr. Newburg exercises sole voting control pursuant to a voting trust agreement dated August 28, 2006, by and among Mr. Newburg and the Triage entities.

(5)		Includes 1,000 shares held directly by Mr. Galassi and 100,000 shares issuable upon the exercise of stock options.

(6)		Includes 100,000 shares issuable upon the exercise of stock options.

(7)		Includes 33,333 shares issuable upon the exercise of stock options.

(8)		Represents 1,000,000 shares held by Elixir. Mr. Yuen is the chief executive officer of Elixir.

(9)		Includes 9,013,059 shares issued directly, 841,599 shares issuable upon the exercise of stock options.

(10)		Includes 2,484,848 shares held by LC Capital Master Fund, Ltd. and shares beneficially owned by LC Capital Master Fund, Ltd. upon the exercise of 360,000 warrant shares.

(11)		Includes 953,849 shares held by Triage Capital Management LP; 185,757 shares held by Periscope Partners LP; 25,500 shares held by Leonid Frenkel; 1,050,000 shares issuable upon exercise of warrants beneficially owned by Triage Capital Management LP; and 500,000 shares issuable upon exercise of warrants beneficially owned by Leonid Frenkel. Mr. Newburg exercises sole voting control over the 1,165,000 outstanding common shares pursuant to a voting trust agreement dated August 28, 2006, by and among Mr. Newburg and the Triage entities.

(12)		Includes 104,432 shares held by Bric 6 LP; 553,204 shares held by Bricoleur Enhanced LP; 742,468 shares held by Bricoleur Offshore Ltd.; 1,194,221 shares held by Bricoleur Partners LP; shares beneficially owned by Bricoleur Enhanced LP issuable upon the exercise of 1,200,000 common stock purchase warrants; and shares beneficially owned by Bricoleur Offshore Ltd issuable upon the exercise of 1,400,000 common stock purchase warrants.

EQUITY COMPENSATION PLAN INFORMATION

We have two stock options plans, the Amended and Restated 1999 Stock Option Plan and the Amended and Restated 1999 Directors’ Stock Option Plan, under which 6,000,000 shares and 300,000 shares are authorized, respectively. Pursuant to our stock option plans, as of December 31, 2006, there were options outstanding to purchase 4,804,412 shares of our common stock with a weighted average exercise price per share of $2.17 and options remaining to purchase 1,495,588 shares of our common stock.

The following table sets forth certain information as of December 31, 2006 about our stock option plans under which our equity securities are authorized for issuance.

(a)

(b)

(c)

Number of Securities

Weighed-Average

Number of Securities

to be Issued Upon

Exercise Price of

Remaining Available for

Exercise of

Outstanding

Future Issuance Under

Outstanding

Options,

Equity Compensation Plans

Options, Warrants

Warrants and

(Excluding Securities

Plan Category

and Rights

Notes Rights

Reflected In Column (A))

Equity compensation plans approved by security holders

11,192,465

1.79

1,495,588

Equity compensation plans not approved by security holders

—

Total

11,192,465

1.79

1,495,588

The first column reflects outstanding stock options to purchase 4,719,612 shares, outstanding warrants to purchase 6,388,053 warrants, and 84,800 shares of common stock pursuant to our Amended and Restated 1999 Stock Option Plan and our Amended and Restated 1999 Directors’ Stock Option Plan, respectively, which have been approved by our stockholders.

The third column reflects 1,280,388 shares remaining for issuance under our Amended and Restated 1999 Stock Option Plan and 215,200 shares available under our Amended and Restated 1999 Directors’ Stock Option Plan.

EXECUTIVE COMPENSATION

Summary Compensation Table

The following table sets forth the compensation awarded to, earned by or paid to, our chief executive officer and our other two highest paid executive officers earning in excess of $100,000 for services rendered in all capacities during fiscal years ended December 31, 2006.


							Option
			Salary		Bonus		Awards		All Other
Name and Principal	Year		($)		($)		($)		Compensation		Total
Position(a)	(b)		(c)		(d)		(e)		(f)		(g)

Mark Newburg, CEO		2006		286,538		150,000		282,976		33,571		753,085
Arnaldo Galassi, CFO		2006		186,539		50,000		90,354		12,634		339,527
Peter Zee, VP Engineering		2006		193,269		100,000		90,354		16,725		400,348

The dollar amounts in column (e) reflect the dollar amounts recognized for financial statement reporting purposes for the fiscal year ended December 31, 2006, in accordance with FAS 123(R). Assumptions used in the calculation of this amount are included in footnote (1) to our audited financial statement for the fiscal year ended December 31, 2006 included elsewhere in this proxy statement.

Narrative disclosure to Summary Compensation Table

Mark Newburg.

General Terms. On September 29, 2005 we entered into a two year employment agreement with Mr. Newburg. Terms of the agreement provided for:


	•	an annual salary of $250,000,

	•	a signing bonus of $75,000 split in two equal payments to be made on the signing of the employment agreement and on December 15, 2005,

	•	750,000 stock options priced at $1.34 which shall vest and first become exercisable upon a change of control,

	•	in the event of a change of control, a payment equal to 12 months base salary in effect on the date of the change of control and an amount equal to 50% of his annual base pay (however, Mr. Newburg has waived any change in control payment triggered by the transactions under the Participation Agreement), and,

	•	annual bonuses of up to 50% of his salary provided certain performance milestones are met.

In April 2006, Mr. Newburg’s annual salary was increased to $300,000 and Mr. Newburg was granted an additional option to purchase 300,000 shares of our common stock at an exercise price of $2.48 per share. In March 2007, Mr. Newburg’s annual salary was increased to $325,000. Additionally, he received a $150,000 bonus and was granted an additional option to purchase 200,000 shares of our common stock at an exercise price of $2.40 per share.

Perquisites. Mr. Newburg is also entitled to certain perquisites:


	•	ability to participate in, at the Company’s expense, whatever employee benefit plans (medical, dental, vision) the Company maintains. Additionally, the Company reimburses Mr. Newburg for all out-of-pocket medical, dental and vision expenses not paid under the benefit plans. In 2006, these health benefits amounted to $15,304 and are included in Column I above.

Arnaldo Galassi

General Terms. On September 29, 2005 we entered into a two year employment agreement with Mr. Galassi. Terms of the agreement provided for:


	•	an annual salary of $150,000,

	•	150,000 stock options priced at $1.34 which shall vest and first become exercisable upon a change of control,

	•	in the event of a change of control, a payment equal to 12 months base salary in effect on the date of the change of control and an amount equal to 50% of his annual base pay (however, Mr. Galassi has waived any change in control payment triggered by the transactions under the Participation Agreement), and,

	•	annual bonuses of up to 50% of his salary provided certain performance milestones are met.

In April 2006, Mr. Galassi’s annual salary was increased to $200,000 and Mr. Galassi was granted an additional option to purchase 100,000 shares of our common stock at an exercise price of $2.48 per share. In March 2007, Mr. Galassi’s annual salary was increased to $230,000. Additionally, he received a $50,000 bonus and was granted an additional option to purchase 50,000 shares of our common stock at an exercise price of $2.40 per share.

Perquisites. Mr. Galassi is also entitled to certain perquisites:


	•	ability to participate in, at the Company’s expense, whatever employee benefit plans (medical, dental, vision) the Company maintains. In 2006, these health benefits amounted to $13,892 and are included in Column I above.

Peter Zee

General Terms. On October 1, 2005 we entered into a two year employment agreement with Mr. Zee. Terms of the agreement provided for:


	•	an annual salary of $175,000.

	•	150,000 stock options priced at $1.34 which shall vest and first become exercisable upon a change of control,

	•	in the event of a change of control, a payment equal to 12 months base salary in effect on the date of the change of control and an amount equal to 50% of his annual base pay (however, Mr. Zee has waived any change in control payment triggered by the transactions under the Participation Agreement), and,

	•	annual bonuses of up to 50% of his salary provided certain performance milestones are met.

In April 2006, Mr. Zee’s annual salary was increased to $200,000 and Mr. Zee was granted an additional option to purchase 100,000 shares of our common stock at an exercise price of $2.48 per share. In March 2007, Mr. Zee’s annual salary was increased to $230,000. Additionally, he received a $100,000 bonus and was granted an additional option to purchase 60,000 shares of our common stock at an exercise price of $2.40 per share.

Perquisites. Mr. Zee is also entitled to certain perquisites:


	•	ability to participate in, at the Company’s expense, whatever employee benefit plans (medical, dental, vision) the Company maintains. In 2006, these health benefits amounted to $12,634 and are included in Column I above.

Outstanding Equity Awards at Fiscal Year-End


	Option Awards
							Equity
							Incentive
							Plan
							Awards:
	Number of			Number of			Number of
	Securities			Securities			Securities
	Underlying			Underlying			Underlying	Option
	Unexercised			Unexercised			Unexercised	Exercise		Option
	Options (#)			Options (#)			Unearned	Price		Expiration
	Exercisable			Unexercisable			Option (#)	($)		Date
Name (a)	(b)			(c)			(d)	(e)		(f)

Mark Newburg		191,666	(1)		108,334	(1)		$	1.49		1/31/15
		67,000	(2)						1.85		4/28/08
					67,000	(2)			1.85		4/28/09
					66,000	(2)			1.85		4/28/10
					750,000	(3)			1.34		(3	)
					200,000	(4)			2.48		4/7/12
					200,000	(5)			2.40		3/7/13
Arnaldo Galassi		34,000	(6)						1.92		3/1/08
					33,000	(6)			1.92		3/1/09
					33,000	(6)			1.92		3/1/10
					150,000	(3)			1.34		(3	)
					100,000	(4)			2.48		4/7/12
					50,000	(5)			2.40		3/7/13
Peter Zee		34,000	(6)						1.92		3/1/08
					33,000	(6)			1.92		3/1/09
					33,000	(6)			1.92		3/1/10
					150,000	(3)			1.34		(3	)
					100,000	(4)			2.48		4/7/12
					60,000	(5)			2.40		3/7/13


(1)		300,000 options granted as consultant on 1/31/05. Options vest monthly over three years starting on 1/31/06.

(2)		200,000 options granted on 4/28/05. One third of options vest every year.

(3)		Options vest and first become exercisable upon a change of control of the Company.

(4)		Options granted on 4/7/06. One third of options vest every year.

(5)		Options granted on 3/7/07. One third of options vest every year

(6)		Options granted as consultant on 3/1/05. Options vest annually over three years starting on 3/1/06

Director Compensation Table

Change in

Pension

Value and

Nonqualified

Fees Earned

Non-Equity

Deferred

or Paid

Stock

Option

Incentive Plan

Compensation

All Other

in Cash

Awards

Compensation

Earnings

Compensation

Total

($)

Name

(b)

(c)

(d)(1)

(e)

(f)

(g)

(h)

James Crabbe

8,000

Vincent DiVito

Paul Harvey

Robert Miodunski

William Purton

Ron Keil

21,152

Robert Smith

21,152

The dollar amounts in column (d) reflect the dollar amount recognized for financial statement reporting purposes for the fiscal year ended December 31, 2006, in accordance with FAS 123(R). Assumptions used in the calculation of this amount are included in footnote (1) to our audited financial statement for the fiscal year ended December 31, 2006 included elsewhere in this proxy statement.

Non-employee members of our board of directors, with the exception of Mr. Crabbe, receive an initial grant of 100,000 options and, effective as of March 2007, an annual grant of 15,000 options on the date of the annual or special meeting of stockholders at which directors are elected. Mr. Crabbe receives options to acquire 8,000 shares annually. The exercise price of such options is the market price of our common stock on the date of grant. Our directors are reimbursed for their out-of-pocket expenses related to their services as directors or meeting attendance. Commencing April 2007, members of our board of directors that are not employees, with the exception of Mr. Crabbe, receive a quarterly fee of $7,500. The chairman of our audit committee receives an additional $7,500 per quarter. In addition, upon joining the board, Messrs. DiVito, Harvey and Miodunski each received options to purchase 100,000 shares of common stock at an exercise price of $1.34 per share over a three year term pursuant to our Amended and Restated 1999 Stock Option Plan; and each received a grant of 50,000 shares of common stock which accrued in increments of 10,000 shares over the five fiscal quarters beginning in September 2005.

Messrs. Keil and Smith resigned from the board on June 26, 2006. Mr. Purton resigned from the board on December 31, 2006.

SEC Position on Certain Indemnification Arrangement

Our articles of incorporation obligate us to indemnify our directors and officers to the fullest extent permitted under Nevada law. Chapter 78 of the Nevada Revised Statutes provides for indemnification by a corporation of costs incurred by directors, employees, and agents in connection with an action, suit, or proceeding brought by reason of their position as a director, employee, or agent. The person being indemnified must have acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us pursuant to the provisions contained in our amended and restated articles of incorporation, our amended and restated bylaws, Nevada law or otherwise, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. If a claim for indemnification against such liabilities, other than the payment by us of expenses incurred or paid by one of our directors, officers or controlling persons in the successful defense of any action, suit, or proceeding, is asserted by such director, officer or controlling person, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a

court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of this issue.

Indemnification Agreements

We have entered into indemnification agreements with members of our board of directors and certain other employees in which we agreed to hold harmless and indemnify such directors, officers and employees to the fullest extent authorized under Nevada law, and to pay any and all related expenses reasonably incurred by the indemnitee. The relevant members of our board of directors are James E. Crabbe, Mark R. Newburg, Vincent L. DiVito, Maj. Gen. Paul A. Harvey, Robert L. Miodunski and William Purton.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS WITH THE COMPANY

Transaction Review

We have adopted a policy that any transactions with directors, officers or entities of which they are also officers or directors or in which they have a financial interest, will only be on terms consistent with industry standards and approved by a majority of the disinterested directors of our board. Our bylaws provide that no such transactions by us shall be either void or voidable solely because of such relationship or interest of directors or officers or solely because such directors are present at the meeting of our board or a committee thereof which approves such transactions, or solely because their votes are counted for such purpose if:


	•	The fact of such common directorship or financial interest is disclosed or known by our board or committee and noted in the minutes, and our board or committee authorizes, approves or ratifies the contract or transaction in good faith by a vote for that purpose without counting the vote or votes of such interested directors; or

	•	The fact of such common directorship or financial interest is disclosed to or known by the stockholders entitled to vote, and they approve or ratify the contract or transaction in good faith by a majority vote or written consent of stockholders holding a majority of the shares of common stock entitled to vote (the votes of the interested directors or officers shall be counted in any such vote of stockholders); or

	•	The contract or transaction is fair and reasonable to us at the time it is authorized or approved.

In addition, interested directors may be counted in determining the presence of a quorum at a meeting of our board or a committee thereof that approves such transactions. If there are no disinterested directors, we shall obtain a majority vote of the stockholders approving the transaction.

As of December 31, 2006, William Purton, the owner of Dolphin prior to our acquisition of the company, owed Dolphin $514,260 for funds Dolphin had advanced to Mr. Purton. It is anticipated that Mr. Purton will repay this outstanding before the end of fiscal 2007.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Rules adopted by the SEC under Section 16(a) of the Securities Exchange Act of 1934, or the Exchange Act, require our officers and directors, and persons who own more than 10% of the issued and outstanding shares of our equity securities, to file reports of their ownership, and changes in ownership, of such securities with the SEC on Forms 3, 4 or 5, as appropriate. Such persons are required by the regulations of the SEC to furnish us with copies of all forms they file pursuant to Section 16(a).

Based solely upon a review of Forms 3, 4 and 5 and amendments thereto furnished to us during our most recent fiscal year, and any written representations provided to us, we believe that all of the officers, directors, and owners of more than ten percent of the outstanding shares of our common stock complied with Section 16(a) of the Exchange Act for the year ended December 31, 2006.

OTHER BUSINESS

We know of no business that will be presented for consideration at the Special Meeting other than that described in this proxy statement. As to other business, if any, that may properly come before the Special Meeting, it is intended that proxies solicited by our board will be voted according to the judgment of the person or persons voting the proxies.

HOUSEHOLDING OF SPECIAL MEETING MATERIALS

Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of the company’s Proxy Statement or Annual Report to Stockholders may have been sent to multiple stockholders in each household. The company will promptly deliver a separate copy of either document to any stockholder upon written or oral request to Investor Relations, VendingData Corporation, 1120 Town Center Drive, Suite 260, Las Vegas, Nevada 89144; telephone:(702) 733-7195.

Any stockholder who wants to receive separate copies of our Proxy Statement or Annual Report in the future, or any stockholder who is receiving multiple copies and would like to receive only one copy per household, should contact the stockholder’s bank, broker, or other nominee record holder, or the stockholder may contact the Company at the above address and phone number.

PROPOSALS FOR THE NEXT ANNUAL MEETING

We must receive proposals of stockholders intended to be presented at our next annual meeting a reasonable time before we begin to print and mail our proxy materials relating to such meeting, to be considered for inclusion in our proxy statement relating to that meeting. Our board of directors will review any proposals from eligible stockholders that it receives by that date and will make a determination whether any such proposals will be included in our proxy materials. Any proposal received after a reasonable time before we begin to print and mail our proxy materials relating to such meeting shall be considered untimely and shall not be made a part of our proxy materials.

A stockholder who wishes to make a proposal at the next annual meeting without including the proposal in our proxy statement must also notify us within a reasonable time before we print and mail the proxy materials. If a stockholder fails to give reasonable advance notice, then the persons named as proxies in the proxies solicited by us for the next annual meeting will have discretionary authority to vote on the proposal.

BY ORDER OF THE BOARD OF DIRECTORS

Mark R. Newburg,

President and Chief Executive Officer

August 17, 2007

Las Vegas, Nevada

ANNEX A — SECURITIES PURCHASE AND PRODUCT PARTICIPATION AGREEMENT

This Securities Purchase and Product Participation Agreement (this ‘‘Agreement”) is entered into this 12th of June 2007 between VendingData Corporation, a Nevada corporation (the “Company”), and Elixir Group Limited, a Hong Kong company (“Elixir”).

R E C I T A L S

A. The parties have previously entered into that certain Alliance Agreement (“Alliance Agreement”), Amended and Restated Sales Representative Agreement (“Sales Representative Agreement”), and Securities Purchase Agreement (“2006 Purchase Agreement”) each dated October 11, 2006 (collectively, the “October 2006 Agreements”).

B. The parties now wish to expand the scope of the commercial relationships established by the October 2006 Agreements by way of (a) the Company’s issuance of certain equity securities and (b) amendment of the terms of the 2006 Warrants (as defined below), subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 promulgated thereunder, in consideration of Elixir’sand/or its subsidiaries’ referral of the relevant gaming operator(s) to the Company for the entering into of certain electronic gaming machine leases on a revenue sharing basis directly with the Company and the provision of the necessary electronic gaming machines by Elixirand/or its subsidiaries to the Company for the fulfillment of its obligations under such leases.

A G R E E M E N T

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and Elixir agree as follows:

ARTICLE I

DEFINITIONS

1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings indicated in this Section 1.1:

“2006 Warrants” means the following Common Stock purchase warrants sold by the Company to Elixir pursuant to the 2006 Purchase Agreement, each represented by a written warrant agreement, as amended, and expiring December 31, 2010:

(i) 6,000,000 shares of Common Stock at $2.65 per share (the “$2.65 Warrants”);

(ii) 4,000,000 shares of Common Stock at $3.00 per share;

(iii) 2,000,000 shares of Common Stock at $3.50 per share;

(iv) 1,000,000 shares of Common Stock at $4.00 per share;

(v) 1,000,000 shares of Common Stock at $4.50 per share;

(vi) 1,000,000 shares of Common Stock at $5.00 per share; and

(vii) 1,000,000 shares of Common Stock at $5.50 per share.

“2006 Warrant Shares” means the shares of Common Stock underlying the 2006 Warrants issuable upon exercise of the 2006 Warrants.

“Action” shall have the meaning ascribed to such term in Section 3.1(j).

A-1

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 144 under the Securities Act.

“Amendment” means the filing of an amendment to the Company’s articles of incorporation, in form and substance acceptable to Elixir in its reasonable discretion, with the Nevada Secretary of State for purposes of increasing the Company’s authorized Common Stock to an amount sufficient to provide for the Company’s issuance of all of the Securities pursuant to this Agreement.

“AMEX Approval” means the approval of the American Stock Exchange of an application for the listing of the Shares and Warrant Shares, which may include an original listing application pursuant to Section 341 of the American Stock Exchange Company Guide.

“Acquisition Proposal” means any offer or proposal (other than an offer or proposal made or submitted by Elixir) contemplating or otherwise relating to any Acquisition Transaction.

“Acquisition Transaction” mean any transaction or series of related transactions involving:

(i) any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which the Company is a constituent corporation; (ii) in which a Person or “group” (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 50% of the outstanding securities of any class of voting securities of the Company; or (iii) in which the Company issues securities representing more than 50% of the outstanding securities of any class of voting securities of the Company; or

(ii) any sale, lease, exchange, transfer, license, acquisition or disposition of any business or assets that constitute or account for: (i) more than 50% of the consolidated net revenues of the Company, consolidated net income of the Company or consolidated book value of the assets of the Company; or (ii) more than 50% of the fair market value of the assets of the Company.

“Business Day” means any day except Saturday, Sunday and any day which shall be a federal legal holiday in the United States.

“Closing” means the Closing of the issuance of the Initial Shares and New Warrants pursuant to Section 2.2.

“Closing Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to the Company’s obligations to deliver the Initial Shares and New Warrants have been satisfied or waived.

“Code” means the Internal Revenue Code of 1986, as amended.

“Commission” means the Securities and Exchange Commission.

“Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed into.

“Common Stock Equivalents” means any securities of the Company or any Subsidiary which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instruments that are at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

“Company Board” shall have the meaning ascribed to such term in Section 3.1(c).

“Company Counsel” means Greenberg Traurig, LLP.

“Company Nominees” shall have the meaning ascribed to such term in Section 4.11(a).

“Company Shareholder Meeting” shall have the meaning ascribed to such term in Section 4.9.

A-2

“Conflicts Committee” shall have the meaning ascribed to such term in Section 4.11(d).

“Cumulative Total” means (a) when used in the context of Participation Agreements for the Placement of EGMs, the total number of EGMs subject to Placement under Participation Agreements that are in full force and effect, and where the Qualified Lessee is not then in material breach thereof, and (b) when used in the context of the Placement of EGMs, the total number of EGMs subject to Placement net of any EGMs previously subject to Placement that have been removed from operation by the Qualified Lessee.

“Disclosure Schedules” means the Disclosure Schedules of the Company delivered to Elixir prior to the date hereof.

“EGM” means an electronic gaming machine commonly known as an electronic slot machine.

“Elixir Counsel” means Latham & Watkins, with offices located at 41st Floor, One Exchange Square, 8 Connaught Place, Central, Hong Kong.

“Elixir Nevada Counsel” means Kummer Kaempfer Bonner Renshaw & Ferrario with offices at 3800 Howard Hughes Parkway, Seventh Floor, Las Vegas, NV 89169, United States.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Exclusive Territory” shall have the meaning ascribed to such term in the Sales Representative Agreement.

“Existing D&O Policies” shall have the meaning ascribed to such term in Section 4.11(c).

“Financial Advisor” shall have the meaning ascribed to such term in Section 3.1(ff).

“GAAP” shall have the meaning ascribed to such term in Section 3.1(h).

“Gaming Authorities” means any or all licensing, gaming and regulatory authorities or governmental bodies in any jurisdiction whose consent is necessary or advisable under Gaming Laws for the ownership of an interest in any party, the operation of any party’s business or for the consummation of any of the transactions contemplated by the Transaction Documents.

“Gaming Laws” means, with respect to any Person, any federal, local, municipal, tribal, foreign or other law, statute, constitution, resolution, ordinance, code, edict, decree, rule, regulation, permit, consent, approval, license, judgment, order, injunction, authorization, ruling or requirement issued, enacted, adopted, promulgated, implemented, governing or otherwise put into effect by or under the authority of any Gaming Authorities relating to the current or contemplated gaming activities and operations of such Person and its Affiliates.

“Governmental Authorization” means any: (a) permit, license, certificate, franchise, finding of suitability, exemption, entitlement, approval, permission, variance, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any governmental body (including the Gaming Authorities) or pursuant to any Legal Requirement (including any Gaming Laws); or (b) right under any written or oral contract, agreement or undertaking with any Governmental Authority.

“HSR Act” means theHart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

“Initial Shares” means the 25,000,000 shares of Common Stock to be issued to Elixir at the Closing.

“Intellectual Property Rights” shall have the meaning ascribed to such term in Section 3.1(s).

“Legal Requirement” means any federal, state, local, municipal, tribal, foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, permit, consent, approval, license, judgment, order, injunction, authorization, ruling or requirement issued,

A-3

enacted, adopted, promulgated, implemented, governing or otherwise put into effect by or under the authority of any governmental body (or under the authority of the American Stock Exchange), including Gaming Laws.

“Liens” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction of any kind.

“Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

“Material Contract” shall mean any contract (written or oral), undertaking, commitment, arrangement, plan or other legally binding agreement or understanding (“Contract”) of the following categories to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or any of their respective assets or properties is bound: (i) employment Contracts, including, without limitation, Contracts to employ executive officers and other Contracts with officers, directors or shareholders, and all severance, change in control or similar arrangements with any officers, employees or agents that will result in any obligation (absolute or contingent) to make any payment to any officers, employees or agents following either the consummation of the transactions contemplated hereby, termination of employment, or both; (ii) Contracts with organizations representing employees; (iii) Contracts involving annual expenditures or liabilities in excess of $200,000 in the aggregate which are not cancelable (without material penalty, cost or other liability) within 90 days; (iv) Contracts (including promissory notes, loan agreements, indentures or other evidences of indebtedness) providing for the lending of money, whether as borrower, lender or guarantor, in excess of $200,000; (v) Contracts containing covenants limiting the freedom to engage in any line of business or compete with any Person or operate at any location; (vi) Contracts providing for the acquisition, directly or indirectly (by merger or otherwise), of substantially all of the assets or any part of the capital stock of another Person; (vii) Contracts containing any obligation to make payments, contingent or otherwise, arising out of the prior acquisition of the business of another Person; and (viii) Contracts containing any obligation to sell or to register the sale of any shares of Common Stock or other securities of the Company or any of its Subsidiaries.

“Melco” means Melco International Development Limited, a Hong Kong company listed on the Main Board of the Hong Kong Stock Exchange and parent of Elixir.

“Net Win” means, with respect to an EGM, all amounts played in or wagered on the EGM during the relevant period minus the amount of money paid out of the EGM to players, after deduction of all applicable gaming taxes levied by any governmental authority.

“New Warrants” means the Common Stock purchase warrants, substantially in the form ofExhibit A attached hereto, to be issued to Elixir at the Closing pursuant to which Elixir shall have the right, over a five year term, to purchase up to 88,000,000 shares of Common Stock, at an exercise price of $2.65 per share, of which:

(i) Warrants to purchase 22,000,000 shares of Common Stock shall vest and first become exercisable subject to both (a) the Company having entered into Participation Agreements on or before December 31, 2009 for the Placement of a Cumulative Total of 2,000 EGMs and (b) the actual Placement of a Cumulative Total of 1,000 EGMs on or before December 31, 2009;

(ii) Warrants to purchase 22,000,000 shares of Common Stock (and, to the extent they have not previously vested and become exercisable, the Warrants referenced in clause (i) hereof) shall vest and first become exercisable subject to both (a) the Company having entered into Participation Agreements on or before December 31, 2010 for the Placement of a Cumulative Total of 3,000 EGMs and (b) the actual Placement of a Cumulative Total of 2,000 EGMs on or before December 31, 2010;

(iii) Warrants to purchase 22,000,000 shares of Common Stock (and, to the extent they have not previously vested and become exercisable, the Warrants referenced in clauses (i) and (ii) hereof) shall vest and first become exercisable subject to both (a) the Company having entered into

A-4

Participation Agreements on or before December 31, 2011 for the Placement of a Cumulative Total of 4,000 EGMs and (b) the actual Placement of a Cumulative Total of 3,000 EGMs on or before December 31, 2011; and

(iv) Warrants to purchase 22,000,000 shares of Common Stock (and, to the extent they have not previously vested and become exercisable, the Warrants referenced in clauses (i) through (iii) hereof) shall vest and first become exercisable subject to both (a) the Company having entered into Participation Agreements on or before December 31, 2012 for the Placement of a Cumulative Total of 5,000 EGMs and (b) the actual Placement of a Cumulative Total of 4,000 EGMs on or before December 31, 2012.

“Participation Agreement” means, in accordance with the procedures set forth in Section 5.3 hereof, a written lease agreement between the Company and a Qualified Lessee, pursuant to which the Company leases an EGM to the Qualified Lessee, for a minimum period of three years, and the Qualified Lessee agrees to (a) locate in the Qualified Lessee’s public gaming area and make available to the gaming public the EGM, and (b) pay to the Company at least 20% of the Net Win from the operation of the EGM.

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Placement” means a Qualified Lessee’s full-time operation of an EGM in its public gaming area pursuant to a Participation Agreement (subject to any temporary closure of such public gaming area for a period of up to three months as may be required in order to comply with applicable Legal Requirements or due to any public safety reasons or such other causes which are beyond the reasonable control of the relevant Qualified Lessee).

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened.

“Pro Rata Share” means the product of (x) Elixir’s percentage ownership of voting securities of the Company multiplied by (y) the number of authorized directors as set forth in the organizational documents of the Company; provided, however, that the Pro Rata Share shall not be less than three. The Pro Rata Share shall be automatically increased or decreased from time to time upon any increase or decrease in the number of authorized directors of the Company or any increase or decrease in Elixir’s percentage ownership of voting securities of the Company. Any fraction resulting from the calculation of Pro Rata Share shall be rounded up to the next whole number if it is equal to or greater than1/2 and down to the preceding whole number if it is less than1/2.

“Qualified Lessee” means a gaming operation located in the Exclusive Territory that is operating in compliance with all material Legal Requirements.

“Required Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

“Registration Rights Agreement” means the Registration Rights Agreement, to be delivered at the Closing, between the Company and Elixir, substantially in the form ofExhibit B attached hereto.

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

“SEC Reports” shall have the meaning ascribed to such term in Section 3.1(h).

“Securities” means the Shares, the New Warrants and the Warrant Shares.

“Shares” means the 55,000,000 shares of Common Stock to be issued to Elixir pursuant to Section 2.1 of this Agreement, including the Initial Shares.

“Shareholder Approval” means such approval from the shareholders of the Company as may be required under the articles of incorporation and bylaws of the Company, applicable Nevada law and by

A-5

the applicable rules and regulations of the American Stock Exchange (or any successor entity) and obtained in accordance with Section 14 of the Exchange Act with respect to the transactions contemplated by this Agreement and the other Transaction Documents, including (i) the Company’s issuance of the Shares and the New Warrants, (ii) the Amendment and (iii) the election to the Company Board, effective as of the Closing Date, of the initial Elixir Nominees (as hereinafter defined).

“Short Sales” shall include all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the locationand/or reservation of borrowable shares of Common Stock).

“Subsidiary” means any subsidiary of the Company as set forth onSchedule3.1(a).

“Tax” or “Taxes” means (a) all federal, state, local, foreign and other taxes, levies, imposts, assessments, impositions or other similar government charges, including, without limitation, income, estimated income, business, occupation, franchise, real property, payroll, personal property, sales, transfer, stamp, use, employment, commercial rent or withholding, occupancy, premium, gross receipts, profits, windfall profits, deemed profits, license, lease, severance, capital, production, corporation, ad valorem, excise, duty or other taxes, including interest, penalties and additions thereto, whether disputed or not and (b) any obligation with respect to Taxes described in the foregoing clause (a) payable by reason of being a transferee, successor or indemnitor or by reason of contract, assumption, transferee liability, operation of law or otherwise.

“Trading Day” means a day on which the Common Stock is traded on a Trading Market provided that, in the event that the Common Stock is not listed or quoted on a Trading Market, Trading Day shall mean a Business Day.

“Trading Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the Nasdaq Capital Market, the American Stock Exchange, the New York Stock Exchange, the Nasdaq National Market or the OTC Bulletin Board.

“Transaction Documents” means this Agreement, the New Warrants, the Registration Rights Agreement and any other documents or agreements executed in connection with this Agreement.

“Triggering Event” means any one of following: (a) the Company Board shall have approved, endorsed or recommended any Acquisition Proposal; (b) the Company shall have executed any letter of intent, memorandum of understanding or similar document relating to the terms and conditions of any Acquisition Proposal; or (c) a tender or exchange offer relating to securities of the Company shall have been commenced and the Company shall not have sent to its security holders, within ten Business Days after the commencement of such tender or exchange offer, a statement disclosing that the Company recommends rejection of such tender or exchange offer.

“Warrant Shares” means the shares of Common Stock underlying the New Warrants issuable upon exercise of the New Warrants.

ARTICLE II

PURCHASE AND SALE

2.1 Equity Compensation for Placement of EGMs. Upon the terms and subject to the conditions set forth herein, the Company agrees to issue and sell to Elixir the Shares and the New Warrants, and amend the terms of the 2006 Warrants, in consideration of the Placement of EGMs pursuant to Section 5 of this Agreement. As an inducement to Elixir to successfully promote the Placement of EGMs pursuant to this Agreement, the Company hereby agrees that:

(i) Subject to the Placement of 1,000 EGMs on or before the Closing Date, the Company shall (a) issue to Elixir 25,000,000 shares of Common Stock (referred to herein as the “Initial Shares”) and the Warrants, (b) reduce the exercise price of all of the 2006 Warrants (other than the $2.65 Warrants) by

A-6

$1.00 and (c) amend the terms of the 2006 Warrants so that they are freely transferable, subject to applicable law;

(ii) Subject to both (a) the Company having entered into Participation Agreements for the Placement of a Cumulative Total of 2,000 EGMs and (b) the actual Placement of a Cumulative Total of 1,000 EGMs, the Company shall issue to Elixir an additional 15,000,000 shares of Common Stock and further reduce the exercise price of all of the 2006 Warrants (other than the $2.65 Warrants) by $1.00;

(iii) Subject to both (a) the Company having entered into Participation Agreements for the Placement of a Cumulative Total of 3,000 EGMs and (b) the actual Placement of a Cumulative Total of 2,000 EGMs, the Company shall issue to Elixir an additional 10,000,000 shares of Common Stock (and, to the extent not previously performed, (y) issue the shares of Common Stock and (z) implement the reduction in the exercise price of all of the 2006 Warrants, referenced in clause (ii) hereof) and further reduce the exercise price of all of the 2006 Warrants (other than the $2.65 Warrants) by $1.00; and

(iv) Subject to both (a) the Company having entered into Participation Agreements for the Placement of a Cumulative Total of 4,000 EGMs and (b) the actual Placement of a Cumulative Total of 3,000 EGMs, the Company shall issue to Elixir an additional 5,000,000 shares of Common Stock (and, to the extent not previously performed, (y) issue the shares of Common Stock and (z) implement the reductions in the exercise price of all of the 2006 Warrants, referenced in clauses (ii) and (iii) hereof).

The parties acknowledge and agree that as of the date of this Agreement the Company has not entered into any Participation Agreements and there has been no Placement of EGMs. The parties agree that, notwithstanding the terms of the Sales Representative Agreement, the Placement of the EGMs shall be conducted pursuant to Section 5 of this Agreement and shall not be governed by the Sales Representative Agreement. To that end, the parties expressly agree that the Sales Representative Agreement is amended hereby to exclude EGMs from the definitions “Products”, “Services” and “Products & Services”, as such terms are defined in the Sales Representative Agreement. Except as expressly provided herein, nothing in this Agreement shall be deemed to amend, modify or waive the rights or obligations of the parties under the Sales Representative Agreement, and the Sales Representative Agreement shall continue as a stand alone agreement in full force and effect.

2.2 Closing. The initial closing (“Closing”) of the transactions under this Agreement shall be subject to the Placement of 1,000 EGMs, along with the satisfaction of all other conditions set forth in Sections 2.3 and 2.4,on or before the Closing Date. On the Closing Date (the ‘‘Closing Date”), the Company shall deliver to Elixir full legal and beneficial ownership of the Initial Shares and the New Warrants and amend the terms of the 2006 Warrants as provided in Section 2.1(i). Upon satisfaction of the conditions set forth in this Section and in Sections 2.3 and 2.4,the Closing shall occur at the offices of Greenberg Traurig, LLP, 650 Town Center Drive, Suite 1700, Costa Mesa, CA 92626, or such other location as the parties shall mutually agree.

From time to time following the Closing, the Company shall issue to Elixir, within ten (10) Business Days of the Company’s satisfaction of the appropriate milestones, one or more certificates evidencing the Shares attributable to the level of Participation Agreements and Placement of EGMs under Section 2.1, shall cause applicable New Warrants to vest and become exercisable and shall make the applicable reduction in the exercise price of the 2006 Warrants, as the case may be.

2.3 Deliveries.

(a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to Elixir the following:

(i) this Agreement duly executed by the Company;

(ii) one or more certificates evidencing the Initial Shares;

(iii) the New Warrants registered in the name of Elixir and duly executed by the Company;

(iv) the amended 2006 Warrants;

A-7

(v) the Registration Rights Agreement duly executed by the Company; and

(vi) an affidavit of an officer of the Company certifying that the Company is not a “United States real property holding corporation” as defined in Section 897 of the Code.

(b) On or prior to the Closing Date, Elixir shall deliver or cause to be delivered to the Company the following:

(i) this Agreement duly executed by Elixir; and

(ii) the Registration Rights Agreement duly executed by Elixir.

2.4 Closing Conditions.

(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

(i) the representations and warranties of Elixir contained in the Transaction Documents and qualified as to materiality shall be true and correct and any such representations and warranties not so qualified shall be true and correct in all material respects, as of the date hereof and as of the Closing Date;

(ii) all obligations, covenants and agreements of Elixir required to be performed at or prior to the Closing Date shall have been performed, including, but not limited to, the Placement of at least 1,000 EGMs;

(iii) the delivery by Elixir of the items set forth in Section 2.3(b) of this Agreement;

(iv) the Company’s receipt of Shareholder Approval and, if necessary, the approval by the shareholders of Melco of the terms of the Transaction Documents and the transactions contemplated thereunder;

(v) If applicable, the waiting period applicable to the consummation of the transaction contemplated by the Transaction Documents under the HSR Act shall have expired or been terminated, and there shall not be in effect any voluntary agreement between the Company, Melco or Elixir and the Federal Trade Commission or the Department of Justice pursuant to which the Company, Melco or Elixir has agreed not to consummate the transaction contemplated by the Transaction Documents for any period of time (“HSR Clearance”);

(vi) the Company’s receipt of AMEX Approval;

(vii) the filing of the Amendment by the Company with the Nevada Secretary of State and the effectiveness of the Amendment; and

(viii) on the Closing Date, (A) no legal action, suit or proceeding shall be pending or threatened which seeks to restrain or prohibit the transactions contemplated by the Transaction Documents and (B) there shall exist no actual or potential regulatory impediment to the legal and beneficial ownership of the Securities by Elixir.

(b) The obligations of Elixir hereunder in connection with the Closing are subject to the following conditions being met:

(i) the representations and warranties of the Company contained in the Transaction Documents and qualified as to materiality shall be true and correct and any such representations and warranties not so qualified shall be true and correct in all material respects, as of the date hereof and as of the Closing Date;

(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;

(iii) on the Closing Date, (A) no legal action, suit or proceeding shall be pending or threatened which seeks to restrain or prohibit the transactions contemplated by the Transaction Documents and (B) there shall exist no actual or potential regulatory impediment to the legal and beneficial ownership of the Securities by Elixir;

A-8

(v) the receipt of HSR Clearance;

(vi) the Company’s receipt of AMEX Approval;

(vii) the filing of the Amendment by the Company with the Nevada Secretary of State and the effectiveness of the Amendment;

(viii) the delivery by the Company of the items set forth in Section 2.3(a) of this Agreement;

(ix) a legal opinion of Elixir Nevada Counsel, in form and substance reasonably satisfactory to Elixir;

(x) the initial Elixir Nominees shall have been elected to the Company Board effective as of the Closing Date;

(xi) the completion by Elixir and its advisors of legal, financial and business due diligence to its reasonable satisfaction;

(xii) in connection with that certain 8% Senior Secured Promissory Notes Agreement (the “8% Notes Agreement”), Bricoleur Capital Management shall have executed a waiver, which shall be in full force and effect, to the effect that the transactions contemplated under this Agreement and the other Transaction Documents do not constitute a change in control of the Company pursuant to the 8% Notes Agreement;.

(xiii) the Company shall have delivered to Elixir a certificate, dated the Closing Date, duly executed by its Chief Executive Officer to the effect set forth in clauses (i) and (ii) above; and

(xiv) the Company shall have delivered to Elixir a certificate, dated the Closing Date, of the Secretary or Assistant Secretary of the Company certifying as to (i) the certificate of incorporation and bylaws of the Company as in effect on the Closing Date, (ii) all resolutions of the board of directors (and committees thereof) of the Company relating to the Transaction Documents and the transactions contemplated thereby, and (iii) the incumbency of all officers of the Company executing the Transaction Documents and any other agreement or document contemplated thereby.

ARTICLE III

REPRESENTATIONS AND WARRANTIES

3.1 Representations and Warranties of the Company. Except as set forth under the corresponding section of the disclosure schedules delivered to Elixir prior to the date hereof (the “Disclosure Schedules”) which Disclosure Schedules shall be deemed a part hereof, the Company hereby makes the representations and warranties set forth below to Elixir:

(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth onSchedule 3.1(a). The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite power and authority to own, lease and operate its properties and assets and to carry on its business as currently conducted and as proposed to be conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified or licensed to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the

A-9

nature of the business conducted or property owned, leased or operated by it makes such qualification or licensing necessary, except where the failure to be so qualified or in good standing, as the case may be, could not, individually or in the aggregate, have or reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, liabilities, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to consummate the transactions contemplated by the Transaction Documents or to perform its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

(c) Authorization; Enforcement. (i) The Company has all requisite power and authority to execute, deliver and, subject to Shareholder Approval, perform its obligations under this Agreement and each other Transaction Document and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated herein and therein have been duly authorized by all necessary action on the part of the Company and no further corporate proceedings by the Company are necessary to authorize this Agreement or the other Transaction Documents (other than the Shareholder Approval). This Agreement and each other Transaction Document has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms except (A) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (B) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (C) insofar as indemnification and contribution provisions may be limited by applicable law.

(ii) The board of directors of the Company (the “Company Board”) has duly and validly authorized the execution and delivery of this Agreement and the other Transaction Documents and approved the consummation of the transactions contemplated hereby and thereby, and taken all corporate actions required to be taken by the Company Board for the consummation of such transactions and has resolved (y) to deem this Agreement and the other Transaction Documents, and the transactions contemplated hereby and thereby (including the Amendment), taken together advisable and in the best interest of the Company and its shareholders; and (z) to recommend that the shareholders of the Company approve and adopt this Agreement, the other Transaction Documents and the Amendment and elect to the Company Board, effective as of the Closing Date, the initial Elixir Nominees. Pursuant to the Company’s bylaws and the Nevada Revised Statutes the Company Board has directed that this Agreement, the other Transaction Documents, the Amendment and the election to the Company Board, effective as of the Closing Date, of the initial Elixir Nominees be submitted to the shareholders of the Company for their approval. The affirmative vote of the holders of at more than 50% of the outstanding shares of Common Stock (voting as a single class) as of the record date for the Company Shareholder Meeting (as hereinafter defined) is the only vote of the holders of any class or series of capital stock of the Company necessary to adopt this Agreement and the other Transaction Documents and approve the transactions contemplated hereby and thereby, including the Amendment.

(d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company, the amendment of the terms of the 2006 Warrants and the issuance of the Securities and the consummation by the Company of the other transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement (including, without limitation, the Gaming Chip

A-10

Manufacturing and License Agreement between Progressive Gaming International Corporation and Dolphin Advanced Technologies Pty Limited dated June 22, 2006), license, authorization, permit, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) assuming receipt of the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not individually or in the aggregate have or reasonably be expected to result in a Material Adverse Effect.

(e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than (i) filings required pursuant to Section 4.4 of this Agreement, (ii) the Company’s filing of a proxy statement (“Proxy Statement”) with the Commission pursuant to Section 14 of the Exchange Act for purposes of obtaining Shareholder Approval; (iii) the Company’s receipt of Shareholder Approval; (iv) the Company’s receipt of AMEX Approval; (v) the filing of the Amendment by the Company with the Nevada Secretary of State (vi) the filing with the Commission of the Registration Statement, (vii) the receipt of HSR Clearance and (viii) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”).

(f) Issuance of the Securities. Upon the filing of the Amendment by the Company with the Nevada Secretary of State, and no later than the Closing, the Securities will be duly authorized and, when issued and paid for (or deemed paid for) in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens (except as resulting from the restrictions on transfer set forth in the Transaction Documents). Upon the filing of the Amendment with the Nevada Secretary of State, and no later than the Closing, the Company will have reserved from its duly authorized capital stock, all of the shares of Common Stock issuable pursuant to this Agreement, the 2006 Warrants and the New Warrants.

(g) Capitalization. The capitalization of the Company is as set forth onSchedule 3.1(g). No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except for the Securities, the 2006 Warrants and the 2006 Warrant Shares or as set forth onSchedule 3.1(g), there are no outstanding options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance of the Shares and the New Warrants and the amendment of the terms of the 2006 Warrants will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than Elixir) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized and validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Other than the Shareholder Approval and AMEX Approval, no further approval or authorization of any stockholder, the Company Board or any other Person is required for the issuance of the Securities and the amendment of the terms of the 2006 Warrants. Except as set forth onSchedule 3.1(g), there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the

A-11

Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

(h) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents, together with any amendments required to be made with respect thereto, required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the period commencing January 1, 2005 through the date hereof (the foregoing materials, including the exhibits and schedules thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. Except as set forth onSchedule3.1(h),as of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Except as set forth onSchedule 3.1(h), the financial statements of the Company included in the SEC Reports complied in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Except as set forth onSchedule 3.1(h), such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(i) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, the business of the Company and its Subsidiaries has been conducted in the ordinary course and consistent with past practice and, except as specifically disclosed in a subsequent SEC Report; (i) there has been no event, occurrence or development that, individually or in the aggregate, has had or that could reasonably be expected to result in a Material Adverse Effect; (ii) none of the Company or any of its Subsidiaries has incurred any liabilities (contingent or otherwise) other than trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice that could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; (iii) none of the Company or any of its Subsidiaries has altered its method of accounting; (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock; (v) none of the Company nor any of its Subsidiaries has (A) sold, assigned, transferred, abandoned, mortgaged, pledged or subjected to Lien any of its material properties, tangible or intangible, or rights under any material contract, permit, license, franchise or other agreement or (B) waived or cancelled any material amounts of indebtedness or other obligations owed to the Company or any such Subsidiary; (vi) other than in the ordinary and usual course of business consistent with past practice, none of the Company or any of its Subsidiaries has (A) granted any material severance or termination pay to any director, officer or employee of the Company or any of its Subsidiaries, (B) entered into any material employment, deferred compensation or other similar agreement (or any amendment to any such existing agreement) with any director, officer or employee of the Company or any of its Subsidiaries, (C) materially increased benefits payable under any existing severance or termination pay policies or employment agreements, or (D) materially increased the compensation, bonus or other benefits payable to directors, officers or employees of the Company or any of its Subsidiaries other than merit increases in salaries of employees at regularly scheduled times in customary amounts consistent with past practices; or (vii) none of the Company or any of its Subsidiaries has amended any term of any outstanding security of the Company or any Subsidiary that would materially increase the obligations of the Company or such Subsidiary under such security; and (viii) the Company has not issued any equity

A-12

securities to any person, except (A) grants made and disclosed prior to the date hereof pursuant to existing Company stock option plans and in amounts in accordance with past practice; and (B) issuances of Common Stock upon the exercise of options or warrants outstanding on the date of this Agreement. The Company does not have pending before the Commission any request for confidential treatment of information.

(j) Litigation. Except as set forth onSchedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”). None of the matters set forth inSchedule 3.1(j) has had or could have, individually or in the aggregate, a Material Adverse Effect or could affect the legality, validity or enforceability of any of the Transaction Documents or the consummation of the transactions contemplated hereby or thereby. Except as disclosed in writing to Elixir Counsel prior to the date hereof and referencing this Section 3.1(j), neither the Company nor any Subsidiary, nor any current or former director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, nor has there been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

(k) Employee Benefit Plans.

(a) For purposes of this Agreement, the following terms have the definitions given below:

(i) “Controlled Group Liability” means any and all liabilities, contingent or otherwise (A) under Title IV of ERISA, (B) under Section 302 of ERISA, (C) under Sections 412 and 4971 of the Code, (D) resulting from a violation of the continuation coverage requirements of Section 601 et seq. of ERISA and Section 4980B of the Code or the group health plan requirements of Sections 601 et seq. of the Code and Section 601 et seq. of ERISA, and (E) under corresponding or similar provisions of foreign laws or regulations, in each case, other than pursuant to the Company Benefit Plans and Company Foreign Plans in the case of the Company and Company Benefit Plans and Company Foreign Plans in the case of the Company.

(ii) “ERISA” means the Employee Retirement Income Security Act of 1974, as amended, together with the rules and regulations thereunder.

(iii) “ERISA Affiliate” means, with respect to any entity, trade or business, any other entity, trade or business that is a member of a group described in Section 414(b), (c), (m) or (o) of the Code or Section 4001(b)(1) of ERISA that includes the first entity, trade or business, or that is a member of the same “controlled group” as the first entity, trade or business pursuant to Section 4001(a)(14) of ERISA.

(iv) “Company Benefit Plans” means all employee benefit plans, programs, policies, agreements, and other arrangements providing compensation or benefits to any current or former employee, consultant or director in respect of services provided to Company or any of its Subsidiaries or to any beneficiary or dependent thereof, and whether covering one individual or more than one individual, sponsored or maintained by Company or any of its Subsidiaries, as the case may be, or to which Company or any of its Subsidiaries contributes or is obligated to contribute or could have any liability or is party;provided, however, that Company Benefit Plans shall not include any Company Foreign Plan or any “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA or any other plan, program or arrangement maintained by an entity other than Company or any of its Subsidiaries pursuant to any collective bargaining agreements. Without limiting the generality of the foregoing, the term “Company Benefit Plans” includes any defined benefit or defined contribution pension plan, profit sharing plan, stock ownership plan, deferred compensation

A-13

agreement or arrangement, vacation pay, health, sickness, life, disability or death benefit plan (whether provided through insurance, on a funded or unfunded basis or otherwise), employee stock option or stock purchase plan, bonus or incentive plan or program, severance pay plan, agreement, arrangement or policy (including statutory severance and termination indemnity plans), practice or agreement, employment agreement, retiree medical benefits plan and each other employee benefit plan, program or arrangement, including each “employee benefit plan” (within the meaning of Section 3(3) of ERISA). For purposes of this Agreement, the term “Company Foreign Plan” shall refer to each material plan, program or contract that is subject to or governed by the laws of any jurisdiction other than the United States, and which would have been treated as a Company Benefit Plan had it been a United States plan, program or contract.Schedule 3.1(k)(a) lists all Company Benefit Plans and Company Foreign Plans.

(b) The Internal Revenue Service has issued a favorable determination letter with respect to each Company Benefit Plan that is intended to be a “qualified plan” (within the meaning of Section 401(a) of the Code). To the knowledge of Company, there are no existing circumstances nor any events that have occurred that could reasonably be expected to adversely affect the qualified status of any Qualified Company Benefit Plan or the related trust.

(c) All material contributions required to be made by the Company or any of its Subsidiaries to any Company Benefit Plan by applicable Legal Requirements or by any plan document or other contractual undertaking, and all material premiums due or payable with respect to insurance policies funding any Company Benefit Plan, for any period through the date of this Agreement have been timely made or paid in full and through the Closing Date will be timely made or paid in full.

(d) Except as set forth inSchedule 3.1(k)(a), the Company and its Subsidiaries have complied in all material respects, and are now in compliance, in all material respects, with all provisions of ERISA, the Code and all laws and regulations (including any local applicable Legal Requirements) applicable to the Company Benefit Plans. Each Company Benefit Plan has been operated in compliance with its terms in all material respects. There is not now, and there are no existing circumstances that would reasonably be expected to give rise to, any requirement for the posting of security with respect to a Company Benefit Plan or the imposition of any pledge, lien, security interest or encumbrance on the assets of Company or any of its Subsidiaries under ERISA or the Code, except for any such security, pledge, lien, security interest or encumbrances as would not result in any material liability to Company and its Subsidiaries taken as a whole.

(e) Except as set forth inSchedule 3.1(k)(e), no employee benefit plan of Company, its Subsidiaries or any of their respective ERISA Affiliates is a “multiemployer plan” (within the meaning of Section 4001(a)(3) of ERISA) (a “Multiemployer Company Benefit Plan”), or a plan that has two or more contributing sponsors at least two of whom are not under common control (within the meaning of Section 4063 of ERISA) (a “Multiple Employer Company Benefit Plan”), or that is subject to Title IV or Section 302 of ERISA or Section 412 or 4971 of the Code (a “Company Pension Plan”), nor has Company or any of its Subsidiaries or any of their respective ERISA Affiliates, at any time within six years before the date of this Agreement, contributed to or been obligated to contribute to any Multiemployer Company Benefit Plan, Multiple Employer Company Benefit Plan or Company Pension Plan.

(f) There does not now exist, and there are no existing circumstances that could reasonably be expected to result in, any Controlled Group Liability that would be a liability of Company or any of its Subsidiaries following the Closing.

(g) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated by this Agreement will result in, cause the accelerated vesting or delivery of, or increase the amount or value of, any payment or benefit to any current or former employee, officer, director or consultant of Company or any of its Subsidiaries (either alone or in conjunction with any other event) under any Company Benefit Plan or Company Foreign Plan.

A-14

(h) All Company Foreign Plans (i) have been maintained in all material respects in accordance with all applicable requirements, (ii) if they are intended to qualify for special tax treatment meet all material requirements for such treatment, (iii) if they are required to be fundedand/or book-reserved are fundedand/or book-reserved, as appropriate, based upon reasonable actuarial assumptions and in accordance with applicable Legal Requirements and (iv) to the knowledge of the Company, there are no existing circumstances that have occurred that could reasonably be expected to adversely affect the qualified or registered status of any Company Foreign Plan or related trust.

(i) Since December 31, 2006, there has been no material amendment to or material modification of any material Company Benefit Plan or Company Foreign Plan, except as required by applicable Legal Requirements, or any broad-based announcement or other broad-based communication of the intention to effect any of the actions described in this Section 3.1(k)(i).

(j) All options to purchase shares of Common Stock granted under the Company Benefit Plans have been granted in compliance with the terms of applicable Legal Requirements and the applicable Company Benefit Plan and have (or with respect to such options which have been exercised as of the date of this Agreement, had) a per share exercise price that is (or with respect to such options which have been exercised as of the date of this Agreement, was) at least equal to the fair market value of a share of Common Stock as of the date the option was granted.

(l) Labor Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company and its Subsidiaries which, individually or in the aggregate, could reasonably be expected to result in a material liability to the Company and its Subsidiaries taken as a whole. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company, and neither the Company or any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. No executive officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, result in any material liability to the Company and its Subsidiaries taken as a whole.

(m) Business Relationships. (i) No major customer of the Company or any Subsidiary has, since December 31, 2006, canceled or otherwise terminated or indicated an intent to cancel or otherwise terminate its relationship with the Company or any Subsidiary or to materially decrease the volume of business it conducts with the Company or any Subsidiary. (ii) No major supplier of the Company or any Subsidiary has stopped or indicated an intent to stop or materially reduce the rate at which it supplies materials, products or services to the Company or any Subsidiary.

(n) Solvency. Based on the financial condition of the Company as of the date hereof and as of the Closing the Company’s fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature.

(o) Compliance. Neither the Company nor any Subsidiary (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any license, authorization, permit, indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is or has been in violation of any Legal Requirement, including without limitation all foreign, federal,

A-15

state and local laws relating to taxes, occupational health and safety and gaming matters, except in each case as could not have or reasonably be expected to result in, individually or in the aggregate, a Material Adverse Effect.

(p) Environmental Matters. Except as set forth inSchedule 3.1(p),(i) The Company and the Subsidiaries are each in compliance with all Legal Requirements relating to the environment (“Environmental Laws”) and all permits, approvals, licenses and other authorizations required under or issued pursuant to any applicable Environmental Law (“Environmental Permits”), (ii) there has been no release of any hazardous material on any real property leased or owned by the Company or any of its Subsidiaries (“Real Property”) or, during the period of the Company’s or any Subsidiary’s ownership, lease, use or occupancy thereof, on any property formerly owned, leased, used or occupied by the Company or any Subsidiary, (iii) there are no environmental claims pending or threatened against the Company, any Subsidiary or any Real Property, and there are no circumstances that can reasonably be expected to form the basis of any such environmental claim and (iv) neither the Company nor any Subsidiary has any actual or alleged liability, whether fixed or contingent, under any Environmental Law.

(q) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits, individually or in the aggregate, could not have or reasonably be expected to result in a Material Adverse Effect (“Material Permits”). The Company and its Subsidiaries are in compliance with the terms of the Material Permits, except where the failure to so comply does not or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company, and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.

(r) Title to Assets; Sufficiency. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them that is material to the business of the Company and the Subsidiaries and good and marketable title to all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. The assets and properties of the Company and its Subsidiaries (including the Intellectual Property Rights) (the “Assets”) constitute all the properties, assets and rights forming a part of, used, held or intended to be used in, and all such properties, assets and rights as are necessary in the conduct of, the business of the Company and its Subsidiaries. The Company and its Subsidiaries have caused the Assets to be maintained in accordance with good business practice, and all the Assets are in good operating condition and repair and are suitable for the purposes for which they are used and intended. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in full compliance.

(s) Intellectual Property.

(i) Schedule 3.1(s) sets forth a true and complete list of all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or material for use by the Company and its Subsidiaries in connection with their respective businesses as currently conducted (collectively, the “Intellectual Property Rights”).

(ii) The Company or a Subsidiary is the exclusive owner of the entire right, title and interest in and to, or has a valid license to use, the Intellectual Property Rights in connection with the business. The Company or a Subsidiary is entitled to use all Intellectual Property Rights in the continued operation of the business without limitation, subject only to the terms of any licenses with respect

A-16

thereto. The Intellectual Property Rights have not been adjudged invalid or unenforceable in whole or in part, and are valid and enforceable.

(iii) The conduct of the business as currently conducted does not infringe or misappropriate the intellectual property of any third party, and no Action alleging any of the foregoing is pending, and no administrative, regulatory or judicial petition, appeal, demand, claim, lien, notice of noncompliance or violation has been threatened or asserted against the Company or any Subsidiary alleging any of the foregoing. Neither the Company nor any Subsidiary has received a notice (written or otherwise) that the Intellectual Property Rights violate or infringe upon the asserted rights of any Person. No Person is engaging in any activity that infringes the Intellectual Property Rights.

(iv) No Intellectual Property Right is subject to any outstanding decree, order, injunction, judgment or ruling restricting the use of such Intellectual Property Right or that would impair the validity or enforceability of such Intellectual Property Right.

(v) The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(t) Insurance. The Company and the Subsidiaries are insured by insurers that are reputable and financially sound against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

(u) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $60,000, other than (i) for payment of salary, (ii) reimbursement for expenses properly incurred on behalf of the Company and (iii) for other employee benefits, including stock option agreements under any stock option plan of the Company.

(v) Sarbanes-Oxley; Internal Accounting Controls. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. Except as disclosed in the SEC Reports, the Company and its Subsidiaries maintain a system of controls and procedures sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiaries, required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the certifying officers by others within those entities, including during the period in which the Company’s most recently filed periodic report under the Exchange Act was prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,

A-17

the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there has not been any material reduction in the Company’s internal controls over financial reporting. Piercy Bowler Taylor & Kern, which expressed its opinion with respect to the consolidated financial statements included in the Company’s Annual Report onForm 10-KSB for the year ended December 31, 2006, have advised the Company that they are, and to the knowledge of the Company they are, independent accountants as required by the Securities Act and the rules and regulations promulgated thereunder.

(w) Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. Elixir shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons (save and except for Elixir’s own financial advisor) for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents as a result of any action taken by the Company or its Affiliates.

(x) Private Placement. Assuming the accuracy of Elixir’s representations and warranties set forth in Section 3.2(b) through (e),no registration under the Securities Act is required for the issuance of the Securities by the Company to Elixir under the Transaction Documents. Assuming Shareholder Approval and AMEX Approval are obtained, the issuance and sale of the Securities hereunder does not and will not contravene the rules and regulations of the Trading Market.

(y) Investment Company. The Company is not, and is not an Affiliate of, and immediately after giving effect to the transactions contemplated by this Agreement, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act.

(z) Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the two years preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Subject to the Company’s receipt of Shareholder Approval, if required, and the AMEX Approval, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

(aa) Application of Takeover Protections. The Company and the Company Board have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents), the Company’s bylaws (as amended and in effect) or the laws of its state of incorporation that is or could become applicable to Elixir as a result of Elixir and the Company performing their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the amendment of the terms of the 2006 Warrants, the Company’s issuance of the Securities and Elixir’s ownership of the Securities.

(bb) No Integrated Offering. Assuming the accuracy of Elixir’s representations and warranties set forth in Section 3.2(b) through (e),neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable

A-18

shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.

(cc) Tax Status. The Company and each Subsidiary has filed all tax returns required to be filed and has timely paid all material Taxes due. No waivers of statutes of limitation with respect to any tax returns have been given by or requested from the Company or any Subsidiary. All material deficiencies asserted or assessments made as a result of any examinations with respect to Taxes of the Company or any Subsidiary have been fully paid or are being contested and an adequate reserve therefor has been established and is fully reflected in the latest audited financial statements included within the SEC Reports. There are no liens for Taxes (other than for current Taxes not yet due and payable) on any of the assets of the Company or any Subsidiary. None of the Company or any Subsidiary is a party to or bound by any tax-indemnity, tax-sharing or tax-allocation agreement. As of the date of the latest audited financial statements included within the SEC Reports, the unpaid Taxes of the Company and its Subsidiaries did not exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and tax income) set forth or included in such financial statements. Since the date of the latest audited financial statements included within the SEC Reports, the Company and its Subsidiaries have not incurred any liability for Taxes outside the ordinary course of business consistent with past practice. None of the Company or any Subsidiary will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (a) change in method of accounting for a taxable period (or portion thereof) ending on or prior to the Closing Date, (b) disposition made on or prior to the Closing Date, (c) prepaid amount received on or prior to the Closing Date or (d) intercompany transaction, excess loss account described in Treasury Regulations under Code Section 1502 (or any corresponding or similar provision of state, local or foreign Tax Law) or the recapture of a dual consolidated loss described in Code Section 1503 and the Treasury Regulations promulgated thereunder. The Company will not be required to include in taxable income under Section 951 of the Code for any taxable period (or portion thereof) ending after the Closing Date a material amount of income arising from transactions or events occurring in a taxable period (or portion thereof) ending on or prior to the Closing Date. None of the Company, any of its domestic Subsidiaries, its affiliates or predecessors by merger or consolidation has within the past two (2) years been a party to a transaction intended to qualify under Section 355 of the Code or under so much of Section 356 of the Code as relates to Section 355 of the Code. No Subsidiaries is a “passive foreign investment company” within the meaning of Code Section 1297. None of the Company or any Subsidiaries is participating or has participated in a listed transaction, as defined in TreasuryRegulation Section 1.6011-4(b)(2). Schedule 3.1(aa) of the Disclosure Schedules sets forth the tax basis that the Company has in each of its non-domestic Subsidiaries for US federal income tax purposes.

(dd) No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Shares or New Warrants by any form of general solicitation or general advertising. The Company has offered the Shares and New Warrants for sale only to Elixir within the meaning of Rule 501 under the Securities Act.

(ee) Acknowledgment Regarding Elixir’s Purchase of Shares and Warrants. The Company acknowledges and agrees that Elixir is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that Elixir is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by Elixir or any of its respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to Elixir’s purchase of the Shares and Warrants. The Company further represents to Elixir that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

(ff) Fairness Opinion. The Company’s board of directors has received the written opinion of Capstone Valuation Services, LLC, financial advisor to the Company (the “Financial Advisor”), dated the

A-19

date of this Agreement, to the effect that the consideration received by the Company in exchange for its issuance and repricing of its equity securities pursuant to Section 2.1 of this Agreement is fair, from a financial point of view, to the stockholders of the Company, and such opinion has not been withdrawn or modified. The Company has furnished an accurate and complete copy of said written opinion to Elixir. All information provided by or on behalf of the Company and the Company Board to the Financial Advisor and considered by the Financial Advisor in preparing its fairness opinion is accurate and complete.

(gg) Material Contracts. Schedule 3.1(gg) sets forth a list of all Material Contracts. The Company has, or will prior to Closing, make available to Elixir true, complete and correct copies of all Material Contracts. Each of the Material Contracts is in full force and effect. There is no material default under any Material Contract by the Company or, to the Company’s knowledge, by any other party thereto, and no event has occurred that with the lapse of time or the giving of notice or both would constitute a material default thereunder by the Company or, to the Company’s knowledge, any other party.

(hh) Certain Registration Matters. The Company will be eligible to register the Shares for resale by Elixir underForm S-3 promulgated under the Securities Act no later than the Closing Date. Except as set forth onSchedule 3.1(hh), no Person has any mandatory right (including “piggy back” registration rights) to cause the Company to effect the registration under the Securities Act of any securities of the Company.

(ii) Disclosure. All information and disclosures furnished by or on behalf of the Company to Elixir regarding the Company, its Subsidiaries, its business and the transactions contemplated hereby, (including the Company’s representations and warranties set forth in this Agreement and the Disclosure Schedules to this Agreement, as well as all information furnished by or on behalf of the Company in connection with Elixir’s due diligence), are true and correct and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

The Company has not taken and will not take any action designed to or that might reasonably be expected to cause or result in an unlawful manipulation of the price of the Common Stock to facilitate the sale or resale of the Securities.

3.2 Representations and Warranties of Elixir. Elixir hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows:

(a) Organization; Authority. Elixir is an entity duly organized, validly existing and in good standing under the laws of Hong Kong with all requisite corporate power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution, delivery and performance of this Agreement and each of the other Transaction Documents by Elixir and the consummation by it of the transactions contemplated by this Agreement and each other Transaction Document have been or upon delivery will have been duly authorized by all necessary corporate action on the part of Elixir. Each Transaction Document to which it is a party has been duly executed by Elixir, and when delivered by Elixir in accordance with the terms hereof, will constitute the legal, valid and binding obligation of Elixir, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b) Own Account. Elixir understands that the Securities are “restricted securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof without prejudice, however, to Elixir’s right, subject to the provisions of this Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant to

A-20

an exemption from registration under the Securities Act and in compliance with applicable federal and state securities laws. Subject to the immediately preceding sentence, nothing contained herein shall be deemed a representation or warranty by Elixir to hold the Securities for any period of time. Elixir does not have any agreement, plan or understanding, directly or indirectly, with any Person to distribute any of the Securities.

(c) Purchaser Status. At the time Elixir was offered the Securities, it was, and at the date hereof it is, an “accredited investor” as defined in Rule 501(a) under the Securities Act. Elixir is not required to be registered as a broker-dealer under Section 15 of the Exchange Act.

(d) Experience of Elixir. Elixir, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares and New Warrants, and has so evaluated the merits and risks of such investment. Elixir is able to bear the economic risk of an investment in the Shares and New Warrants and, at the present time, is able to afford a complete loss of such investment.

(e) General Solicitation. Elixir is not acquiring the Shares and New Warrants as a result of any advertisement, article, notice or other communication regarding the Shares and the New Warrants published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

(f) Access to Information. Elixir acknowledges that it has received and had the opportunity to review copies of the SEC Reports. Elixir further acknowledges that it or its representatives have been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the New Warrants, and the merits and risks of investing in the Shares and the New Warrants; (ii) access to information about the Company and the Company’s financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment in the Shares and the New Warrants; and (iii) the opportunity to obtain such additional information which the Company possesses or can acquire without unreasonable effort or expense that is necessary to verify the accuracy and completeness of the information contained in the SEC Reports. Neither such inquiries nor any other investigation conducted by or on behalf of Elixir or its representatives or counsel shall modify, amend or affect Elixir’s right to rely on the truth, accuracy and completeness of the SEC Reports and the Company’s representations and warranties contained in this Agreement and the other Transaction Documents.

(g) Restrictions on Shares and Warrants. Elixir understands that the Securities have not been registered under the Securities Act and may not be offered, resold, pledged or otherwise transferred except (a) pursuant to an exemption from registration under the Securities Act or pursuant to an effective registration statement in compliance with Section 5 under the Securities Act and (b) in accordance with all applicable securities laws of the states of the United States and other jurisdictions.

(h) Compliance. Neither Elixir or any of its subsidiaries (i) is in violation of any order of any court, arbitrator or governmental body, or (ii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, the environment, occupational health and safety and gaming regulatory matters, except in each case in (i) and (ii) as could not have or reasonably be expected to result in a material adverse effect.

(i) Regulatory Permits. Elixir and its subsidiaries possess all applicable certificates, authorizations and permits issued by the appropriate federal, state, local or gaming and other regulatory authorities necessary to conduct their respective current businesses as currently conducted, except where the failure to possess such permits could not have or reasonably be expected to result in a material adverse effect (“Material Elixir Permits”), and Elixir has not received any notice of proceedings relating to the revocation or modification of any Material Elixir Permit.

A-21

(j) Certain Fees. The Company shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons (save and except for Elixir’s own financial advisor) for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents as a result of any action taken by Elixir or any of its Affiliates.

(k) Disclosure. None of the information supplied or to be supplied by Elixir or Melco for inclusion or incorporation by reference in the Proxy Statement will, at the time the Proxy Statement is mailed to shareholders, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.

ARTICLE IV

OTHER AGREEMENTS OF THE PARTIES

4.1 Transfer Restrictions.

(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Securities other than (i) pursuant to an effective registration statement, (ii) pursuant to Rule 144; (iii) to the Company or (iv) to an Affiliate of Elixir, the Company may request the transferor thereof to provide to the Company an opinion of counsel selected by the transferor to the effect that such transfer does not require registration of such transferred Shares under the Securities Act.

(b) Elixir agrees to the imprinting, so long as is required by this Section 4.1(b),of a legend on any of the Securities in the following form:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE “RESTRICTED SECURITIES” AS THAT TERM IS DEFINED IN RULE 144 UNDER THE SECURITIES ACT. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND THE APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREUNDER.

4.2 Furnishing of Information. As long as Elixir owns any Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. As long as Elixir owns any Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to Elixir and make publicly available in accordance with Rule 144(c) such information as is required for Elixir to sell the Securities under Rule 144. The Company further covenants that it will take such further action as any holder of Securities may reasonably request, to the extent required from time to time to enable such Person to sell such Securities without registration under the Securities Act within the requirements of the exemption provided by Rule 144.

4.3 Integration. The Company shall not, and shall use its best efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to Elixir or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

4.4 Securities Laws Disclosure; Publicity. The Company shall, promptly after the execution of this Agreement, issue a press release disclosing the material terms of the transactions contemplated hereby, and shall file a Current Report onForm 8-K which shall attach the Transaction Documents thereto by the fourth Business Day following the execution date. The press release andForm 8-K shall be acceptable to Elixir in its

A-22

reasonable discretion. Neither Elixir nor its Affiliates shall issue any such press release or otherwise make a public announcement, statement or other disclosure concerning this Agreement or the transactions contemplated hereby without the prior consent of the Company unless such public announcement, statement or disclosure is required by the laws, rules or regulations applicable to Elixir or Melco (including, without limitation, those stipulated by any applicable stock exchange), in which case Elixir shall use reasonable efforts to provide the Company with prior notice of its requirement to do so.

4.5 Listing of Common Stock. The Company hereby agrees to use best efforts to maintain the listing of the Common Stock on each Trading Market in which it is traded, and as soon as reasonably practicable but in no event later than 45 days following the Closing, to list all of the Shares and not later than 15 days following issuance thereof to list any Warrant Shares, on each such Trading Market). The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will include in such application all of the Shares and the Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed on such other Trading Market as promptly as possible. The Company will take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Trading Market.

4.6 Short Sales and Confidentiality After The Date Hereof. Elixir covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will engage in any transactions, including any Short Sales, in the securities of the Company during the period commencing on the date of this Agreement and ending at the time that the transactions contemplated by this Agreement are first publicly announced as described in Section 4.4. Elixir covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in Section 4.4, Elixir will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).

4.7 Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to Elixir. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to Elixir at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of Elixir.

4.8 Proxy Statement. As promptly as practicable after the date of this Agreement, the Company shall prepare and cause to be filed with the SEC the Proxy Statement. The Company shall use reasonable best efforts to cause the Proxy Statement to comply with all applicable Legal Requirements, including the rules and regulations promulgated by the SEC and to respond promptly to any comments of the Commission or its staff. The Company shall use reasonable best efforts to cause the Proxy Statement to be mailed to the Company’s stockholders as promptly as practicable. Elixir shall promptly furnish to the Company all information concerning Elixir or Melco that may be required or reasonably requested in connection with any action contemplated by this Section 4.8. If any event relating to Elixir or Melco occurs, or if Elixir becomes aware of any information, that is required to be disclosed in an amendment or supplement to the Proxy Statement, then Elixir shall promptly inform the Company thereof and shall cooperate with the Company in filing such amendment or supplement with the Commission and, if appropriate, in mailing such amendment or supplement to the stockholders of the Company. If any event relating to the Company occurs, or if the Company becomes aware of any information, that is required to be disclosed in an amendment or supplement to the Proxy Statement, then the Company shall promptly inform Elixir.

4.9 Shareholder Approval. The Company Board shall take all lawful action to (i) cause a special meeting of its shareholders (the “Company Shareholder Meeting”) to be duly called and held as soon as practicable after the date hereof for the purpose of voting on the approval and adoption of this Agreement, the other Transaction Documents and the Amendment and the election to the Company Board, effective as of the Closing Date, of the initial Elixir Nominees and (ii) solicit proxies from its shareholders to obtain the required vote for the approval and adoption of this Agreement, the other Transaction Documents and the Amendment, the issuance of the Shares and New Warrants and the election to the Company Board, effective as of the

A-23

Closing Date, of the initial Elixir Nominees and any action necessary or desirable to effectuate the transactions contemplated herein. The Proxy Statement shall include a statement that the Company Board recommends that the shareholders of the Company adopt this Agreement and the other Transaction Documents and thereby approve the issuance of the Shares and the New Warrants and the transactions contemplated hereby and that the shareholders of the Company approve the Amendment and the election to the Company Board, effective as of the Closing Date, of the initial Elixir Nominees and the Company Board shall take all lawful action (including the solicitation of proxies) to solicit such adoption and approval; provided, however, that the Company Board may, at any time prior to the time of the Company Shareholder Meeting, withdraw, modify or change any such recommendation to the extent that the Company Board determines in good faith, after receiving written advice from outside legal counsel, that such recommendation would not be consistent with its fiduciary duties to the Company’s shareholders under applicable Legal Requirements (a “Fiduciary Exception”). At any such Company Shareholder Meeting, each of Jim Crabbe and Mark Newburg shall vote all shares over which they have voting control (including, with respect to Mr. Newburg, any shares over which Mr. Newburg exercises sole voting control pursuant to that certain voting trust agreement dated August 28, 2006, by and among Mr. Newburg, Triage Offshore Fund, Ltd., Triage Capital Management B LP, Triage Capital Management LP and Periscope Partners LP) in favor of the approval and adoption of this Agreement and the other Transaction Documents, the Amendment, the issuance of the Shares and the New Warrants and the election to the Company Board, effective as of the Closing Date, of the initial Elixir Nominees and any action necessary or desirable to effectuate the transactions contemplated herein and therein. Mr. Crabbe and Mr. Newburg further agree to (i) execute an irrevocable voting agreement, in form and substance reasonably satisfactory to Elixir, with respect to the foregoing and (ii) not to sell, transfer, assign, pledge or dispose of any shares of Common Stock or Common Stock Equivalents, prior to the Closing except that (y) Mr. Newburg may sell up to 375,000 shares of Common Stock resulting from the exercise of stock options currently held by Mr. Newburg, for personal financial reasons, after the date hereof and prior to the Closing and (z) Mr. Crabbe may sell up to 150,000 shares of Common Stock of the Phileo Foundation, of which Mr. Crabbe is trustee and up to 500,000 shares of Common Stock for his own account after the date hereof and prior to Closing.

4.10 Regulatory Approvals. Each party shall use all reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all notices, applications, reports and other documents required to be filed by such party with or otherwise submitted by such party to any Governmental Authority with respect to the Transaction, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Company and Elixir shall, promptly after the date of this Agreement, prepare and file (a) any notification or report forms required to be filed under the HSR Act and (b) any notification or other document required to be filed in connection with the transactions contemplated hereunder any applicable foreign Legal Requirement relating to antitrust or competition matters. Without limiting the generality of the foregoing, the Company and Elixir shall (i) take all reasonable action necessary to ensure that no state takeover statute or similar statute or regulation is or becomes applicable to the transactions contemplated hereunder or the Transaction Documents and (ii) if any state takeover statute or similar statute or regulation becomes applicable to the transactions contemplated hereunder or the Transaction Documents, take all reasonable action necessary to ensure that the transactions contemplated hereunder may be consummated as promptly as practicable on the terms contemplated by the Transaction Documents and otherwise to minimize the effect of such statute or regulation thereon. The Company and Elixir shall use commercially reasonable efforts to respond as promptly as practicable to: (A) any inquiries or requests received from the Federal Trade Commission or the Department of Justice for additional information or documentation; and (B) any inquiries or requests received from any state attorney general, foreign antitrust or competition authority or other governmental body in connection with antitrust or competition matters. .

4.11 Board Representation.

(a) From and after the Closing until the second anniversary of the Closing, the pre-Closing shareholders of the Company will be entitled to the benefit of the continued representation on the Company Board of two of the existing directors (the “Company Nominees”). In the event of the resignation, termination or death of any Company Nominee (a “Retiring Nominee”), the remaining Company Nominee shall be entitled to

name a

A-24

replacement (“Replacement Nominee”) to the Retiring Nominee by written notice to the Company signed by the remaining Company Nominee. Upon appointment of the Replacement Nominee to the Company’s Board of Directors, the Replacement Nominee shall be considered within the meaning of the term Company Nominee as such term is used in this Section 4.11. At least one Company Nominee shall qualify as an independent director under American Stock Exchange Rule 121A(2) or any successor rule and meet the criteria for independence as set forth inRule 10A-3(b)(1) under the Exchange Act or any successor rule (“Independence Requirements”). At least one Company Nominee shall be entitled to serve on each committee of the Board of Directors of the Company, provided, in the case of the audit committee, such Company Nominee satisfies the Independence Requirements.

(b) At the Closing the authorized number of members of the Company Board shall be no more than eight (8) and Elixir will be entitled to appoint to the Company Board no less than three (3) directors (as such number may be adjusted after the Closing, the “Elixir Nominees”) as of the Closing Date. At least one of the Elixir Nominees shall satisfy the Independence Requirements. From and after the Closing Date Elixir will at all times be entitled to appoint to the Company Board a number of additional directors (who shall also be “Elixir Nominees”) equal to the Pro Rata Share. The Company and the Company Board will use their best efforts to (i) cause any additional Elixir Nominees to be elected to the Company Board and (ii) ensure that the quotient of (x) the Elixir Nominees and (y) the authorized number of members of the Company Board, is at all times equal to the Pro Rata Share, including, without limitation: promptly calling a special meeting of the shareholders of the Company at the request of Elixir and recommending to the shareholders of the Company that they vote for the election of any additional Elixir Nominees to the Company Board. In the event of the resignation, termination or death of any Elixir Nominee (a “Retiring Elixir Nominee”), Elixir shall be entitled to name a replacement (“Replacement Elixir Nominee”) to the Retiring Elixir Nominee by written notice to the Company. Upon appointment of the Replacement Elixir Nominee to the Company Board, the Replacement Elixir Nominee shall be considered within the meaning of the term Elixir Nominee as such term is used in this Section 4.11. At least one Elixir Nominee shall be entitled to serve on each committee of the Company Board, provided, in the case of the audit committee, such Elixir Nominee satisfies the Independence Requirements.

(c) While serving on the Company Board, each Company Nominee who is not a member of management of the Company shall receive compensation (both cash and equity) and other benefits provided to the independent members of the Company Board generally. Notwithstanding the foregoing, the Company shall maintain in effect, for the benefit of the Company Nominees with respect to their acts and omissions as directors and officers of the Company either (i) the existing policies (primary and excess) of directors’ and officers’ liability insurance maintained by the Company as of the date of this Agreement and listed onSchedule 4.11(c) (“Existing D&O Policies”);provided, however that the Company may substitute for the Existing D&O Policies a policy or policies of comparable coverage.

(d) From and after the Closing, the Company Board shall create and maintain a committee of the Company Board (“Conflicts Committee”) made up exclusively of at least three (3) members of the Board of Directors of the Company who satisfy the Independence Requirements and who are not then, and during two years prior to their appointment or election have not been, an officer, director, employee of or consultant or advisor to Elixir and or any Affiliate of Elixir. Elixir may appoint at least one representative to the Conflicts Committee if that person satisfies the foregoing criteria. The Conflicts Committee shall operate under a charter in the form of the Conflicts Committee Charter attached hereto asExhibit C. The Conflicts Committee Charter shall not be amended or modified unless (i) such amendment or modification has been approved and recommended by a majority of the members of the Conflicts Committee and (ii) at least five (5) Business Days preceding the effective date of such amendment or modification the Company has filed with the Commission a current report onForm 8-K that accurately and fully discloses the proposed amendment or modification and the basis for the Conflicts Committee’s recommendation.

(e) The Company, Elixir (in its capacity as stockholder of the Company), and the Company Board will do and will cause to be done all things necessary or desirable (including amending the organizational documents of the Company) as expeditiously as possible to give effect to this Section 4.11. Elixir agrees, on behalf of itself and its assignees, to vote all voting shares of the Company owned by Elixir or under its control

A-25

for purposes of approving the election to the Company Board each of the Company Nominees, the Replacement Nominee and eligible members of the Conflicts Committee, as the case may be.

4.12 Indemnification of Officers and Directors.

(a) All rights to indemnification by the Company existing in favor of each individual who is an officer or director of the Company as of the date of this Agreement (each such individual, an “Indemnified Member of Management”) for his acts and omissions as a director or officer of the Company occurring prior to the Closing, as provided in the Company’s bylaws (as in effect as of the date of this Agreement) and as provided in any indemnification agreement between the Company and such Indemnified Person (as in effect as of the date of this Agreement), shall survive the Closing and shall continue in full force and effect pursuant to the term thereof. A true, correct and complete copy of each such agreement has been provided to Elixir prior to the date hereof.

(b) From the Closing until the fourth anniversary thereof and subject to Section 4.11(c), the Company shall maintain in effect the Existing D&O Policies for the benefit of each Indemnified Member of Management with respect to their acts and omissions as directors and officers of the Company occurring prior to the Closing;provided, however, that the Company may substitute for the Existing D&O Policies a policy or policies of comparable coverage.

4.13 Access to Information.

(a) Between the date hereof and the Closing Date, the Company will give Elixir and its authorized representatives (including counsel, financial advisors and auditors) reasonable access during normal business hours to all employees, offices and other facilities and to all books and records of the Company and its Subsidiaries, will permit Elixir to make such inspections as Elixir may reasonably require and will cause the Company’s officers and those of its Subsidiaries to furnish Elixir with such financial and operating data and other information with respect to the business, properties and personnel of the Company and its Subsidiaries as Elixir may from time to time reasonably request, provided that no investigation pursuant to this Section 4.13(a) shall affect or be deemed to modify any of the representations or warranties made by the Company.

(b) Between the date hereof and the Closing Date, the Company shall furnish to Elixir within two (2) days after the delivery thereof to management, such monthly financial statements and data as are regularly prepared for distribution to Company management.

4.14 Manufacturing Agreement; Technology Cross-License Agreement. The parties will continue to negotiate in good faith the terms and conditions of (i) an agreement (the “Manufacturing Agreement”) to be entered into between the Company and Elixir pursuant to which Elixir shall grant the Company exclusive rights to manufacture certain agreed gaming products manufactured by or on behalf of Elixir, and the Company shall agree to serve as the exclusive manufacturer of such gaming products manufactured by or on behalf of Elixir and (ii) an agreement (the “Technology Cross-License Agreement”) to be entered into between the Company, on the one hand, and Elixir and Melco, on the other, pursuant to which the parties thereto shall agree (x) to jointly develop certain intellectual property and proprietary rights (“Developed Property”) relating to development, design and manufacture of gaming devices, (y) that Elixir and Melco shall have a perpetual, royalty-free and exclusive license to the use and commercialization of the Developed Property in the Exclusive Territory, and (z) that the Company shall have a perpetual, royalty-free and exclusive license to the use and commercialization of the Developed Property in outside of the Exclusive Territory. The parties shall use commercially reasonable efforts to finalize and execute the Manufacturing Agreement and the Technology Cross-License Agreement as soon as practicable after the date hereof.

4.15 U.S. Gaming Licenses. The Company agrees that promptly after Closing the Company shall the commence the process of surrendering its gaming licenses in the United States and shall use its best efforts to surrender all such gaming licenses, and in doing so modify its business operations to eliminate the requirement for such licenses under the Gaming Laws of the U.S., so as to no longer be subject to any Gaming Laws or the jurisdiction of any Gaming Authority in the U.S.

A-26

4.16 Conduct of Business by the Company. Until the Closing, except (1) as contemplated by this Agreement or (2) as consented to by Elixir, the Company shall, and shall cause each of its Subsidiaries to, (i) carry on its business in the ordinary course consistent with past practice, (ii) use commercially reasonable efforts to preserve intact its business organization, to keep available the services of its current officers and employees and to preserve the goodwill of and maintain satisfactory relationships with those Persons and entities having significant business relationships with the Company and its Subsidiaries, (iii) promptly advise Elixir in writing of any material change in the business, condition (financial or otherwise), properties, customer or supplier relationships, assets, liabilities, prospects or results of operations of the Company and its Subsidiaries and (iv) otherwise report periodically to Elixir concerning the status of the business, operations, and finances of the Company and its Subsidiaries. Without limiting the generality of the foregoing, until the Closing, except as contemplated by this Agreement or as required by applicable Legal Requirements, neither the Company nor any of the Subsidiaries shall, without the prior written consent of Elixir:

(a) amend or propose any amendments to its certificate of incorporation, bylaws or other comparable organizational documents;

(b) acquire or agree to acquire by merging or consolidating with, or by purchasing a substantial portion of the assets of, or by any other manner, any business or any corporation, limited liability company, partnership, joint venture, association or other business organization or division thereof;

(c) sell, lease, license, mortgage or otherwise subject to any Lien or dispose of any of its properties or assets that are material to the Company and its Subsidiaries, taken as a whole;

(d) except for intercompany indebtedness between the Company and any Subsidiary or between any of the Subsidiaries of the Company, (i) incur any indebtedness (except for borrowings under any existing credit facility incurred in the ordinary course of business consistent with past practice) or (ii) enter into any financing arrangements or modify the terms of any existing indebtedness or financing arrangements or (iii) prepay any interest on any indebtedness;

(e) except as, individually or in the aggregate, does not have and is not reasonably expected to have, a Material Adverse Effect, enter into, modify, amend or terminate any Material Contract or waive, release or assign any rights or claims thereunder;

(f) make any change to its accounting methods, principles or practices, except as may be required by applicable generally accepted accounting principles;

(g) fail to use commercially reasonable efforts to maintain the material assets of the Company and the Subsidiaries in their current physical condition, except for ordinary wear and tear and damage;

(h) merge or consolidate with or into any other legal entity or dissolve or liquidate;

(i) except as required by the terms and provisions of written contracts between the Company or any Subsidiary of the Company, on the one hand, and an employee, on the other hand, as in existence on the date of this Agreement, (i) adopt, amend or terminate any employee benefit plan, (ii) enter into any new, or amend any existing, employment, severance, consulting or salary continuation agreements with any shareholders, officers, directors or employees or (iii) materially increase in any manner the aggregate compensation or benefits (including, without limitation, commissions) or severance or termination pay payable to any shareholder, officer, director, employee or independent contractor of any Company or any Subsidiary of any Company;

(j) issue, sell, grant options or rights to purchase, pledge, or authorize the issuance, sale, grant of options or rights to purchase or pledge any of the shares of the Company or any Subsidiary, other than (A) shares of Common Stock issued upon the exercise of options or warrants outstanding as of the date hereof, or (B) shares of Common Stock or Common Stock Equivalents sold at a price of $2.65 per share or greater;provided, howeverthat in the event of any sale pursuant to clause (B) hereof, a corresponding increase shall be deemed to be made to the number of shares of Common Stock issuable pursuant to the warrants set forth in clause (i) of the definition of “New Warrants” such that, immediately following such

A-27

increase, Elixir’s percentage ownership of voting securities of the Company, on an as-converted, fully-diluted basis (and assuming no sales of voting securities by Elixir), is not less than 75%;

(k) acquire or redeem, directly or indirectly, or amend the terms of any shares of Common Stock;

(l) split, combine or reclassify its capital stock or declare, set aside, make or pay any dividend or distribution (whether in cash, stock or property) on any shares of its capital stock;

(m) make any Tax election;

(n) settle or agree to settle any suit, action, claim, proceeding or investigation (including any suit, action, claim, proceeding or investigation relating to this Agreement or the transactions contemplated hereby); or

(o) authorize, or commit or agree to take, any of the foregoing actions or take any action which would make any representation or warranty in this Agreement untrue or incorrect as of the date when made or as of a future date or which would result in any of the conditions set forth in Section 2.4 not being satisfied.

4.17 Commercially Reasonable Efforts. Subject to the terms and conditions of this Agreement, each party will use its commercially reasonable efforts to take, or cause to be taken, all actions necessary, proper or advisable to consummate the transactions contemplated by this Agreement and the other Transaction Documents.

ARTICLE V

PLACEMENT OF EGMS

5.1 Placement of EGMs. The Company hereby grants Elixirand/or its Subsidiaries the exclusive right to source and identify on behalf of the Company, Qualified Lessees in the Exclusive Territory. During the term of this Agreement the Company shall not, directly or indirectly, enter into any Participation Agreement with any Qualified Lessee in the Exclusive Territory unless the relevant Qualified Lessee is identified, referred or introduced by Elixirand/or its Subsidiaries. Elixir shall use its reasonable best efforts to source and identify on behalf of the Company, Qualified Lessees in the Exclusive Territory in accordance with the terms of this Agreement and with the goal of achieving the milestones for execution of Participation Agreements and Placement of EGMs set forth in Section 2.1. During the term of this Agreement, Elixir and its Subsidiaries shall not, directly or indirectly, except as otherwise provided in this Agreement, enter into EGM leases on a revenue sharing basis with any Qualified Lessee in the Exclusive Territory or source, introduce or refer any Qualified Lessee in the Exclusive Territory to other third parties with a view for those third parties to enter into any EGM leases on a revenue sharing basis with such Qualified Lessee.

5.2 Purchase of EGMs.

(a) The Company shall buy from Elixir, and Elixir shall sell to the Company, EGMs contemplated for Placement pursuant to this Agreement. Elixir agrees to sell to the Company EGMs at Elixir’s cost. In the event of Elixir’s purchase of the EGM for resale to the Company from a party not Affiliated with Elixir, Elixir’s cost shall be the purchase price paid by Elixir plus 15%. In the event of the manufacture of the EGM by Elixir or Elixir’s purchase of the EGM for resale to the Company from an Affiliate of Elixir, Elixir will sell such EGMs to the Company at the same price as it would sell such EGMs in an arm’s length transaction with an unrelated third party.

(b) Elixir shall retain title to all EGMs sold to the Company pursuant to Section 5.2(a), until it has received full payment therefor from the Company.

(c) Payment for EGMs sold to the Company pursuant to Section 5.2(a) shall be made as follows: 50% upon placement of an order and the balance within 45 days thereafter.

(d) The Company shall use its commercially reasonable best efforts to raise additional capital (the “Capital Raising”) as soon as practicable after the date hereof and in any event prior to December 31, 2007, in

A-28

order to repay all amounts owing to Elixir for EGMs purchased pursuant to Section 5.2(a) (the “Elixir Payables”) as well as any amounts owing pursuant to the 8% Notes. Elixir shall use reasonable commercial efforts to assist the Company in the Capital Raising. In the event the Capital Raising does not occur or is not sufficient to repay the Elixir Payables or purchase EGMs hereunder, Elixir shall continue to provide trade credit to the Company for its purchase of EGMs hereunder. Elixir Payables shall bear interest at an annual rate of 8%, compounded annually, commencing January 1, 2008.

5.3 Participation Agreements. Elixir shall submit to the Company proposed Participation Agreements from time to time and, in connection therewith, Elixir shall have the authority to enter into negotiations for the terms of proposed Participation Agreements for and on behalf of the Company. However, Elixir shall have no authority to enter into any agreements on behalf of the Company with respect to the Placement of EGMs or otherwise. The parties acknowledge that Elixir may assign to the Company certain agreements previously entered into by Elixir relating to the placement of EGMs in the Exclusive Territory and, subject to and upon the Company’s acceptance and assumption of such agreements, those agreements will constitute Participation Agreements hereunder.

5.4 Expenses. Unless otherwise agreed to in writing, each party shall bear its own costs and expenses and provide all staff and labor for performing its obligation under this Section 5; provided, however, the Company shall reimburse Elixir for all direct costs incurred in setting up at the location where the EGMs will be installed including, without limitation, costs associated with casino management systems, computers, and signage.

ARTICLE VI

MISCELLANEOUS

6.1 Term and Termination. Unless terminated earlier pursuant to the terms hereof, this Agreement shall continue and remain in force for a period of six years from the Closing Date. This Agreement may be terminated:

(a) by written agreement of the Company and Elixir;

(b) by the Company or Elixir upon written notice to the other, if the Closing shall not have taken place by 4:30 p.m., Las Vegas time on October 31, 2007 or such later date as may be agreed by the parties in writing (“Outside Date”);provided, that the right to terminate this Agreement under this Section 6.1 shall not be available to any Person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time;

(c) by either party if any Legal Requirements permanently restraining, enjoining or otherwise prohibiting consummation of the transactions contemplated by the Transaction Documents shall become final and non-appealable (whether before or after the Shareholder Approval has been obtained).

(d) by Elixir if the Company Board (i) fails to include in the Proxy Statement its recommendation without modification or qualification that shareholders approve and adopt this Agreement, the other Transaction Documents, the Amendment and the election to the Company Board of the initial Elixir Nominees, (ii) withdraws or modifies in an adverse manner its approval or recommendation of this Agreement, the Amendment and the election to the Company Board of the initial Elixir Nominees, or (iii) fails to reaffirm such approval or recommendation upon Elixir’s request within five (5) Business Days of such request.

(e) by either party if: (y) the Company Shareholder Meeting (including any adjournment or postponement thereof) shall have been held and completed and this Agreement, the Amendment and the election of the initial Elixir Nominees shall not have been adopted and approved at the Company Shareholder Meeting or (z) if applicable, Melco fails to obtain the approval of its shareholders of this Agreement and the transactions contemplated thereunder;

(f) by Elixir in the event of a Triggering Event; or

A-29

(g) by either party: (i) if any of the other party’s (“Breaching Party”) representations and warranties contained in this Agreement shall be inaccurate as of the date of this Agreement, or shall have become inaccurate as of a date subsequent to the date of this Agreement (as if made on and as of such subsequent date), such that the condition set forth in Section 2.4(a)(i) or 2.4(b)(i),as the case may be, would not be satisfied; or (ii) any of the Breaching Party’s covenants or obligations contained in this Agreement shall have been breached such that the condition set forth in Section 2.4(a)(ii)or 2.4(b)(ii),as the case may be, would not be satisfied; provided, however, that if an inaccuracy in any of the Breaching Party’s representations and warranties as of a date subsequent to the date of this Agreement or a breach of a covenant or obligation by the Breaching Party is curable by the Breaching Party prior to the Outside Date and the Breaching Party is continuing to exercise reasonable efforts to cure such inaccuracy or breach, then non-Breaching Party may not terminate this Agreement under this Section 6.1(g) on account of such inaccuracy or breach until: (A) the Outside Date; or (B) such time as such inaccuracy or breach is not capable of being fully cured prior to the Outside Date in a manner that does not result in a breach of any covenant or obligation of the Company.

In the event of the termination of this Agreement as provided in Section 6.1, this Agreement shall be of no further force or effect; provided, however, that this Section 6 shall survive the termination of this Agreement and shall remain in full force and effect, and (ii) the termination of this Agreement shall not relieve any party from any liability for any inaccuracy in or breach of any representation or warranty contained in this Agreement, or any willful breach of any covenant, obligation or other provision contained in this Agreement.

6.2 Termination Fees. If this Agreement is terminated by Elixir pursuant to Section 6.1(d) then the Company shall make a nonrefundable cash payment to Elixir in an amount equal to $500,000, unless the relevant act or omission set forth in Section 6.1(d) was done or omitted to be done pursuant to a Fiduciary Exception, in which case no payment shall be made. If this Agreement is terminated by Elixir pursuant to Section 6.1(f),then the Company shall make a nonrefundable cash payment to Elixir in an amount equal to $500,000, unless a Fiduciary Exception exists and is continuing at the time of the Triggering Event, in which case no payment shall be made. If this Agreement is terminated by Elixir pursuant to Section 6.1(e)(y) and a Triggering Event has occurred, then the Company shall make a nonrefundable cash payment to Elixir in an amount equal to $500,000, unless a Fiduciary Exception exists and is continuing at the time of the Triggering Event, in which case no payment shall be made.

6.3 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to Elixir and the sale of such Securities.

6.4 Entire Agreement. The October 2006 Agreements and the Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede and replace in their entirety all prior and contemporaneous agreements, discussions, negotiations and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

6.5 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth in this Section 6.5 prior to 3:00 p.m. (Las Vegas time) on a Business Day, (b) the next Business Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Business Day or later than 3:00 p.m. (Las Vegas time) on any Business Day, (c) the 2nd Business Day following the date of mailing, if sent by

A-30

U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:

If to the Company:

VendingData Corporation
1120 Town Center Drive, Suite 260
Las Vegas, NV 89144
Facsimile:(702) 733-7197
Attn: Mark R. Newburg

With a copy to:

Greenberg Traurig, LLP
650 Town Center Drive, Suite 1700
Costa Mesa, CA 92626
Facsimile:(714) 708-6501
Attn.: Daniel K. Donahue

If to Elixir:

Elixir Group Limited
38/F., The Centrium,
60 Wyndham Street
Central, Hong Kong
Facsimile: (852) 3162 2579
Attn.: Gordon Yuen

With a copy to:

Latham & Watkins
41^st Floor, One Exchange Square
8 Connaught Place, Central
Hong Kong
Facsimile:(852) 2912-2501
Attn.: John A. Otoshi

or such other address as may be designated in writing hereafter, in the same manner, by such Person.

6.6 Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and Elixir or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

6.7 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

6.8 Successors and Assigns. Elixir may assign any of its rights and obligations to one or more Affiliates of Elixir, which shall agree in writing to be bound by the terms hereof. Any such assignment shall not relieve Elixir of its obligations hereunder. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.

6.9 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

A-31

6.10 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of New York. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

6.11 Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Shares and the Warrants and continue in full force and effect until the second anniversary of the Closing. The representations, warranties, covenants and indemnity obligations contained herein shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of Elixir or the Company. The Company expressly agrees that it may not invoke knowledge of Elixir (actual, constructive or imputed) of a fact or circumstance that might make a statement untrue, inaccurate, incomplete or misleading as a defense to a claim for breach of the Company’s representations and warranties.

6.12 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or bye-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

6.13 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.

6.14 Replacement of Shares. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall promptly issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.

6.15 Construction. The parties agree that each of themand/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.

(Signature Pages Follow)

A-32

IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase and Product Participation Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

VENDINGDATA CORPORATION


	By:	/s/ Mark R. Newburg

Mark R. Newburg,

President and Chief Executive Officer

ELIXIR GROUP LIMITED


	By:	/s/ Gordon Yuen

Gordon Yuen,

Chief Executive Officer

As to Section 4.9 and Section 4.11 only

/s/ Mark Newburg

MARK NEWBURG, an individual

/s/ James Crabbe

JAMES CRABBE, an individual

A-33

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE “RESTRICTED SECURITIES” AS THAT TERM IS DEFINED IN RULE 144 UNDER THE SECURITIES ACT. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND THE APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREUNDER.

COMMON STOCK PURCHASE WARRANT

To Purchase 22,000,000 Shares of Common Stock of

VENDINGDATA CORPORATION

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Elixir Group Limited (together with its successors or assigns the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as defined below) and on or prior to the close of business on December 31, 2012 (the “Termination Date”) but not thereafter, to subscribe for and purchase from VendingData Corporation, a Nevada corporation (the “Company”), up to 22,000,000 shares (the ‘‘Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”), subject to adjustment as set forth herein. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 3(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase and Product Participation Agreement (the “Purchase Agreement”) dated June , 2007 between the Company, the Holder and the other parties thereto.

Section 2. Vesting

a) This Warrant shall vest and first become exercisable subject to, and upon, both (a) the Company having entered into Participation Agreements on or before December 31, 20 for the Placement of a Cumulative Total EGMs, and (b) the Placement of a Cumulative Total EGMs on or before December 31, 20 (the “Initial Exercise Date”).

c) If Elixir or Holder breach (unless such breach is due to fault on the part of the Company or its Affiliates) any of their material obligations under this Warrant or the Purchase Agreement, and the breaching party does not remedy such breach within ninety (90) days of receiving written notice of the same from the Company, the Company may, at its option, cancel any portion or all of this Warrant that remains unexercised at the end of such 90 day period. Any such cancellation of this Warrant shall not affect the agreements of the parties under the Transaction Documents with respect to other Warrants, any exercised Warrants or the Warrant Shares.

Section 3. Exercise.

a) Exercise of Warrant. Subject to Section 2, exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed Notice of Exercise Form annexed hereto (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of such Holder appearing on the books of the Company) along with payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within 3 Trading Days of the date the final Notice of Exercise is delivered to

A-34

the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased or reduced, as the case may be. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase or reduction of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $2.65, subject to adjustment herein (the “Exercise Price”).

c) Mechanics of Exercise.

i. Authorization of Warrant Shares. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free and clear of all Liens caused by the Company (except as resulting from the restrictions on transfer set forth in the Transaction Documents) but not including the restrictions on resale of restricted securities set forth in the Securities Act or any Lien imposed under any other U.S. law, rule or regulation.

ii. Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be promptly transmitted by the transfer agent of the Company to the Holder subject to the Holder’s delivery to the Company of the Notice of Exercise Form, surrender of this Warrant (if required) and payment of the aggregate Exercise Price as set forth above.

iii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iv. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the VWAP of one Warrant Share or round up to the next whole share.

v. Charges, Taxes and Expenses. Issuance and delivery of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fees or other incidental tax or expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;provided,however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum equal to the transfer tax incurred by it as a result of such assignment.

vi. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

For purposes of this Agreement, “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market other than the OTC Bulletin Board, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted for trading as reported by Bloomberg Financial L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time); (b) if the OTC Bulletin Board is the Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC

A-35

Bulletin Board; (c) if the Common Stock is not then quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported; or (d) in all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Company in good faith.

Section 4. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (B) subdivides or reclassifies outstanding shares of Common Stock into a larger number of shares, (C) combines or reclassifies (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, (D) makes a distribution on its Common Stock in shares of its capital stock other than Common Stock, or (E) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted so that the Holder of any Warrant thereafter exercised shall be entitled to receive the number of shares of capital stock of the Company which such Holder would have owned immediately following such action had such Warrant been exercised immediately prior thereto. If, after an adjustment, a Holder of a Warrant upon exercise of it may receive shares of two or more classes of capital stock of the Company, the Company shall determine the allocation of the adjusted Exercise Price between the classes of capital stock. The adjustment referenced herein shall be made successively whenever any event listed above shall occur. Any adjustment made pursuant to clause (A) of this Section 4(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and any adjustment pursuant to clause (B), (C), (D) or (E) shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b) Subsequent Rights Offerings. If the Company, at any time while the Warrant is outstanding, shall issue rights, options or warrants to all holders of Common Stock entitling them to subscribe for or purchase shares of Common Stock at a price per share less than the VWAP at the record date mentioned below, then the Exercise Price shall be multiplied by a fraction, of which the denominator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights or warrants plus the number of additional shares of Common Stock offered for subscription or purchase, and of which the numerator shall be (A) the number of shares of the Common Stock outstanding on the date of issuance of such rights or warrants plus (B) the number of shares which the aggregate offering price of the total number of shares so offered (assuming receipt by the Company in full of all consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP. Such adjustment shall be made successively whenever such rights or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such rights, options or warrants.

c) Pro Rata Distributions. If the Company, at any time prior to the Termination Date, shall distribute to all holders of Common Stock (i) evidences of indebtedness of the Company or any of its Subsidiaries, (ii) assets of the Company or any of its Subsidiaries (including cash and cash dividends) or (iii) rights, options or warrants to subscribe for or purchase any of the foregoing or any other security of the Company, then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences

A-36

of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made successively whenever any such distribution is made and shall become effective immediately after the record date mentioned above.

d) Adjustment for Common Stock Issue. If the Company issues shares of Common Stock or on or after the date hereof for a consideration per share less than the VWAP on the date the Company fixes the offering price of such additional shares, the Warrant Shares shall be adjusted in accordance with the formula:


W		=		W		×		A O + P M

where:


W’ =		the adjusted Warrant Shares
W =		the Warrant Shares immediately prior to any such issuance.
O =		the number of shares of Common Stock outstanding, on a Fully Diluted Basis, immediately prior to the issuance of such additional shares of Common Stock.
P =		the aggregate consideration received for the issuance of such additional shares of Common Stock.
M =		the VWAP per share of Common Stock on the date of issuance of such additional shares.
A =		the number of shares of Common Stock outstanding, on a fully diluted basis, immediately after the issuance of such additional shares of Common Stock.

The adjustment shall be made successively whenever any such issuance is made, and shall become effective immediately after such issuance.

This subsection (d) does not apply to any of the transactions described in subsection (a) of this Section 4.

e) Adjustment for Convertible Securities Issue. If the Company issues any options, warrants or other securities convertible into or exchangeable or exercisable for Common Stock (other than securities issued in transactions described in subsection (b) or (c) of this Section 4 and other than the Warrant) on or after the date hereof for a consideration per share of Common Stock initially deliverable upon conversion, exchange or exercise of such securities less than the VWAP on the date of issuance of such securities, the Warrant Shares shall be adjusted in accordance with this formula:


W’		=		W		×		O + D O + P M

where:


W’ =		the adjusted Warrant Shares.
W =		the Warrant Shares immediately prior to any such issuance.
O =		the number of outstanding immediately, on a fully diluted basis, prior to the issuance of such securities.
P =		the aggregate consideration received for the issuance of such securities.
M =		the VWAP per share of Common Stock on the date of issuance of such securities.
D =		the maximum number of shares of Common Stock deliverable upon conversion or in exchange for or upon exercise of such securities at the initial conversion, exchange or exercise rate.

The adjustment shall be made successively whenever any such issuance is made, and shall become effective immediately after such issuance.

A-37

f) Fundamental Transaction. If, at any time while this Warrant is outstanding, (A) the Company effects any merger or consolidation or other business combination with and into another Person, (B) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions (C) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (D) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a “Fundamental Transaction”), and such Fundamental Transaction constitutes a Change of Control then, upon consummation of such transaction the Warrant shall automatically become exercisable for the kind and amount of securities, cash or other assets which the Holder of a Warrant would have owned immediately after the Fundamental Transaction if the Holder had exercised the Warrant immediately before the effective date of such transaction, without further action required on the part of any party (the “Alternate Consideration”). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to expressly assume, by a supplemental warrant agreement or other acknowledgement executed and delivered to the Holder, the obligation to deliver to such Holder the Alternate Consideration as, in accordance with the foregoing provisions, such Holder may be entitled to purchase, and all other obligations and liabilities of the Company under this Agreement.

g) Calculations. All calculations under this Section 4 shall be made to the nearest cent or thenearest 1/100th of a share, as the case may be. For purposes of this Section 4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

h) Voluntary Adjustment by Company. The Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. A reduction of the Exercise Price shall not change or adjust the Exercise Price otherwise in effect for purposes of subsections (a), (b), (c), (d) or (e).

i) Notice to Holders.

i. Adjustment to Exercise Price. Upon any adjustment pursuant to Section 4 hereof, the Company shall promptly thereafter cause to be mailed to the Holder a notice setting forth the number of underlying shares of Common Stock with respect to the Warrant and the Exercise Price after such adjustment, and setting forth in reasonable detail the method of calculation and the facts upon which such calculations are based.

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock; (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation, merger or other business combination to which the Company is a party or any sale or transfer of all or substantially all of the assets of the Company, whereby the Common Stock is converted into other securities, cash or property; (E) a tender offer or exchange offer will be commenced (whether by the Company or another person) pursuant to which holders of the Common Stock will be permitted to tender or exchange their shares for other securities, cash or property; (F) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; or (G) the Company proposes to take any other action that would require an adjustment of Exercise Price pursuant to Section 4; then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 30

A-38

calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distribution, redemption, rights or warrants are to be determined, (y) the date on which such reclassification, consolidation, merger, other business combination, sale, transfer dissolution, liquidation or winding up is expected to become effective or close or (z) the initial expiration date set forth in any tender offer or exchange offer for Common Stock, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, other business combination, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

j) The Holder will not be entitled to any adjustments pursuant to this Section 4 in the event of the issuance of Common Stock (i) upon the exercise of any employee stock options outstanding on the date hereof or upon the exercise of any employee stock options issued after the date hereof pursuant to any plan adopted by the Company Board, (ii) upon the exercise of any common stock purchase warrants outstanding on the date hereof or (iii) upon the issuance of Common Stock pursuant to the Purchase Agreement.

Section 5. Transfer of Warrant.

a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 5(d) hereof, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new Holder for the purchase of Warrant Shares without having a new Warrant issued.

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice.

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d) Transfer Restrictions. The Company may request, in connection with a transfer of this Warrant (i) the opinion of counsel to the Holder that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws and (ii) that the holder or transferee execute and deliver to the Company an investment letter in form and substance acceptable to the Company and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.

e) Legend Removal. The Warrant Shares shall bear a restrictive legend substantially in the form of the legend appearing on the first page of this Warrant until such time as the Warrant Shares (A) have been sold pursuant to an effective Registration Statement, (B) have been sold pursuant to Rule 144 (or any similar rule

A-39

or regulation), or (C) may be sold pursuant to Rule 144(k) in the opinion of counsel to Holder reasonably satisfactory in the form and substance to the Company.

Section 6. Miscellaneous.

a) No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder of the Company prior to the exercise hereof as set forth herein.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

d) Authorized Shares.

The Company covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant at the Exercise Price as so adjusted, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement. Where used in this Agreement, the singular includes the plural and vice versa.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date.

A-40

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to compliance with applicable securities laws, this Warrant and all rights hereunder are freely transferable or assignable in whole or in part, by the Holder to any person or entity upon written notice to the Company. The transfer shall be recorded in the Warrant Register upon the surrender of this Warrant, properly endorsed, to the Company at its principal offices, and the payment to the Company of any transfer taxes imposed on such transfer. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by any such Holder or holder of Warrant Shares and, without limiting the generality of the foregoing it is acknowledged and agreed that the term “Holder” shall include the successors and permitted assigns of the initial Holder.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Registration Rights. This Warrant and the Warrant Shares are entitled to the benefits of that certain Registration Rights Agreement dated as of even date herewith between the Company, Holder and the other signatories thereto (the “Registration Rights Agreement”). The Company shall keep a copy of the Registration Rights Agreement, and any amendments thereto, at its principal office, and shall furnish copies thereof to the Holder upon request. The parties hereto acknowledge and agree that a holder of Warrant Shares issued upon the exercise of this Warrant, in whole or in part, shall continue to be entitled with respect to such shares to all rights to which it would have been entitled as a “Holder” under the Registration Rights Agreement.

o) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

A-41

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized.

VENDINGDATA CORPORATION


	By:

Mark R. Newburg,

President and Chief Executive Officer

Dated: , 2007

A-42

NOTICE OF EXERCISE

TO: VENDINGDATA CORPORATION

(1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full[transfer taxes for account of Company per Section 3(d)(v), if applicable.]

(2) Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

(3) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

A-43

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute
this form and supply required information.
Do not use this form to exercise the Warrant.)

FOR VALUE RECEIVED, [ ] all of or [ ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to whose address is .

Dated: ,

Holder’s Signature:

Holder’s Address:

Signature Guaranteed:

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

A-44

EXHIBIT B

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of , 2007 between VendingData Corporation, a Nevada corporation (the “Company”), and Elixir Group Limited, a Hong Kong company (the “Selling Shareholder”).

RECITALS

WHEREAS, the Company will sell up to 55,000,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and warrants to purchase up to 88,000,000 shares of Common Stock (“Warrants”) to the Selling Shareholder pursuant to that certain Securities Purchase and Product Participation Agreement (“Purchase Agreement”) dated as of June , 2007 by and among the Company, the Selling Shareholder and the other parties thereto.

AGREEMENT

1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Adverse Disclosure” means public disclosure of material non-public information, which disclosure in the good faith judgment of a majority of the Board of Directors of the Company after consultation with counsel to the Company would have a material adverse effect on the ability of the Company to consummate a material acquisition, disposition or other comparable extraordinary transaction.

“Advice” shall have the meaning set forth in Section 6(d).

“Effectiveness Date” means, with respect to the initial Registration Statement required to be filed hereunder, the 60^h calendar day following the Closing (the 75^h calendar day in the case of a “full review” by the Commission.

“Effectiveness Period”shall have the meaning set forth in Section 2.

“Filing Date” means, with respect to the initial “Shelf” Registration Statement required hereunder, the 30^th calendar day following the Closing.

“Holder” or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

“Indemnified Party”shall have the meaning set forth in Section 5(c).

“Indemnifying Party”shall have the meaning set forth in Section 5(c).

“Losses”shall have the meaning set forth in Section 5(a).

“Prospectus” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

A-45

“Registrable Securities” means all of (i) the Warrant Shares, (ii) the shares of Common Stock issued pursuant to the Purchase Agreement, (iii) the 1,000,000 shares of Common Stock purchased by the Selling Shareholder pursuant to that certain Securities Purchase Agreement (“2006 Purchase Agreement”) entered into with Company and the other parties thereto, (iv) 2006 Warrant Shares (v) any additional shares of Common Stock acquired on any Trading Market by the Selling Shareholder or its successors or assigns and (vi) any shares of Common Stock issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar transaction with respect to the foregoing; provided, however, a security shall no longer be a Registrable Security once it has been sold, or may be sold, without volume restrictions pursuant to Rule 144 or pursuant to a Registration Statement that has been declared effective under the Securities Act.

“Registration Statement” means the registration statements required to be filed hereunder, including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.

“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“Selling Shareholder Questionnaire”shall have the meaning set forth in Section 3(a).

2. Shelf and Demand Registration.

(a) Demand Registration. If, on or at any time after the Effectiveness Date there is no currently effective “Shelf” Registration Statement, then at any time thereafter, upon written notice (a “Demand”) from a Holder or Holders holding at least 50% of the Registrable Securities requesting that the Company effect the registration under the Securities Act of any or all of the Registrable Securities held by such Holder or Holders, which notice shall specify the intended method or methods of disposition of such Registrable Securities, the Company shall, within five (5) days after receiving the Holder’s or Holders’ Demand, give written notice (the “Request Notice”) of such registration request to all other Holders, except if all the Registrable Securities are held by a single Holder, no Request Notice shall be required. The Request Notice shall offer to each such Holder the opportunity to include in such Registration Statement such number of Registrable Securities as such Holder may request within ten (10) days after the date of the Request Notice, subject to the limitations of this Section 2(a) and to compliance with the other provisions of this Agreement. As promptly as possible after such ten (10) day period, but no later than the 30^th day following receipt of the Demand, the Company shall file a Registration Statement with the Commission for purposes of effecting, in the manner set forth in this Section 2 and Section 3 hereof, the registration under the Securities Act of all such Registrable Securities for disposition in accordance with the intended method or methods of disposition stated in the Holder’s or Holders’ request and shall use its best efforts to cause such Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, provided that:

(i) if the filing of a Registration Statement in respect of a Demand would require the Company (A) to make an Adverse Disclosure or (B) if the Company has already commenced a bona fide financing plan through a formal “all hands” meeting or comparable action, and, in the good faith business judgment of a majority of the Board of Directors, a Demand registration at the time and on the terms requested would have a material adverse effect on the ability of the Company to obtain such financing, the Company may, upon giving prompt written notice of such action to the Holders, delay the filing of such Registration Statement for the shortest period of time determined in good faith by the Company to be necessary for such purpose; provided, however that the Company shall not be permitted to do so (A) more than three times during any twenty-four month period, (B) for a period not exceeding 40 days on any one occasion or (C) for a period exceeding 60 days in any 12 month period. The Company shall immediately

A-46

notify the Holders of the expiration of any period during which it exercised its rights under this Section 2(a)(i);

(ii) the Company shall not be obligated to file a Registration Statement relating to a registration request pursuant to this Section 2(a): (A) on more than three occasions (it being understood and agreed that the Company shall only be responsible for Registration Expenses for the first two occasions), (B) within a period of one (1) month after the effective date of any other Registration Statement of the Company demanded pursuant to this Section 2(a); or (C) if such registration request is for a number of Registrable Securities that represent in the aggregate (on an as converted basis) less than one third of the number of Shares originally acquired by the Holders;

(iii) the Company shall be deemed to have effected a Demand registration if (i) the applicable Registration Statement is withdrawn at the request of the Purchasers after having been filed with the Commission or (ii) the applicable Registration Statement is declared effective by the Commission and remains effective for not less than 180 days, or, if such Registration Statement relates to an underwritten offering, such longer period as, in the opinion of counsel for the underwriter or underwriters is required by law for the delivery of a Prospectus in connection with the sale of Registrable Securities by an underwriter or dealer;

(iv) a Holder may elect to withdraw its Registrable Securities from a Demand Registration at any time. If all such Holders do so, the Company shall cease its efforts to secure registration; and

(v) Registrations pursuant to this Section 2(a) shall be onForm S-3 (except if the Company is not then eligible to register for resale the Registrable Securities onForm S-3, in which case such registration shall be on another appropriate form, reasonably acceptable to the Holders of a majority of the Registrable Securities, and as shall permit the disposition of the Registrable Securities in accordance with the intended method of distribution or methods of distribution specified in the applicable Holder’s or Holders’ requests for such registration.

(b) Shelf Registration. On or prior to the Filing Date, the Company shall prepare and file with the Commission a “Shelf” Registration Statement covering the resale of the Registrable Securities by the Holders thereof from time to time in accordance with the methods of distribution elected by such Holders, to be made on a continuous basis pursuant to Rule 415. The Shelf Registration Statement shall be onForm S-3 (except if the Company is not then eligible to register for resale the Registrable Securities onForm S-3, in which case such registration shall be on another appropriate form in accordance herewith, reasonably acceptable to Holders of a majority of the Registrable Securities), as modified by the Company as necessary to conform to comments from the Commission. Subject to the terms of this Agreement, the Company shall use its best efforts to cause the Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event prior to the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act until all Registrable Securities covered by such Registration Statement have been sold, or may be sold without volume restrictions pursuant to Rule 144(k), as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent and the affected Holders (the “Effectiveness Period”). Within two Trading Days after the Registration Statement is declared effective, the Company shall (i) file a final Prospectus with the Commission pursuant to Rule 424 and (ii) notify the Holders via facsimile of effectiveness of the Registration Statement.

(c) If, in connection with a registration statement pursuant to either Section 2(a) or 2(b), the Holders intend to distribute the Registrable Securities by means of an underwriting, they shall so advise the Company (and the Company shall, if necessary amend or supplement the Shelf Registration Statement for such purpose). The underwriter will be selected by a majority in interest (as determined by the number of Registrable Securities held) of the Holders after consultation with the Company.

A-47

(d) Incidental Registrations.

(i) Participation. (A) If the Company at any time proposes to file a Registration Statement with respect to any offering of its securities for its own account or for the account of any holders of its securities (other than (1) a registration under Section 2(a) or 2(b) hereof, (2) a registration onForm S-4 orS-8 or any successor form to such forms, (3) a registration of securities solely relating to an offering and sale to employees or directors of the Company pursuant to any employee stock plan or other employee benefit plan arrangement, (4) a registration of securities for the benefit of the holders pursuant to Section 6(b) of that certain registration rights agreement (the “Bric Registration Rights Agreement”) dated as of May 1, 2006 among the Company, Bricoleur Partners, L.P., Bricoleur Enhanced, L.P., BRIC 6, L.P. and Bricoleur Offshore Ltd. (the “Bricoleur Parties”) but only for so long as there is not an effective registration statement covering the registrable securities of the Bricoleur Parties or (5) except in the case where the Holders desire to exercise their incidental registration rights hereunder with respect to any of the 1,000,000 shares of Common Stock purchased by Elixir pursuant to the 2006 Purchase Agreement or any 2006 of the Warrant Shares (in which case this clause 5 shall not apply), a registration of securities for the benefit of the holders pursuant to Section 7(b) of that certain registration rights agreement dated as of March 27, 2007 between the Company and GLG North American Opportunity Fund but only for so long as there is not an effective registration statement covering the registrable securities thereunder, then, as soon as practicable (but in no event less than 20 days prior to the proposed date of filing such Registration Statement), the Company shall give written notice of such proposed filing to all Holders of Registrable Securities and (unless all such Registrable Securities are then registered pursuant to Section 2(a) or a Shelf Registration Statement under Section 2(b) is in effect) such notice shall offer the Holders of such Registrable Securities the opportunity to register such number of Registrable Securities as each such Holder may request in writing (an “Incidental Registration”). Subject to Section 2(d)(ii), the Company shall include in such Registration Statement all such Registrable Securities which are requested to be included therein within 10 days after the receipt by such Holder of any such notice. If at any time after giving written notice of its intention to register any securities and prior to the effective date of the Registration Statement filed in connection with such registration, the Company shall determine for any reason not to register or to delay registration of such securities, the Company may, at its election, give written notice of such determination to each Holder of Registrable Securities and, (x) in the case of a determination not to register, shall be relieved of its obligation to register any Registrable Securities in connection with such registration, and (y) in the case of a determination to delay registering, shall be permitted to delay registering any Registrable Securities for the same period as the delay in registering such other securities.

(B) If the offering pursuant to an Incidental Registration is to be an underwritten offering, then each Holder making a request for its Registrable Securities to be included therein must, and the Company shall make such arrangements with the underwriters so that each such Holder may, participate in such underwritten offering on the same terms as the Company and other Persons selling securities in such underwritten offering. If the offering pursuant to such registration is to be on any other basis, then each Holder making a request for an Incidental Registration pursuant to this Section 2(d) must participate in such offering on such basis.

(C) Each Holder shall be permitted to withdraw all or part of such Holder’s Registrable Securities from an Incidental Registration at any time prior to effectiveness of the Registration Statement.

(ii) Priority of Incidental Registration. If the managing underwriter or underwriters of any proposed underwritten offering of a class of securities included in an Incidental Registration (or in the case of an Incidental Registration not being underwritten, the Company) informs the Holders of Registrable Securities sought to be included in such registration in writing that, in its or their opinion, the total amount or kind of securities which such Holders and any other Persons intend to include in such offering exceeds the number which can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the class or classes of the securities offered or the market for the class or classes of securities offered, then the securities of each class to be included in such registration shall be allocated as follows:

(A) first, 100% of the securities that the Company or the Bricoleur Parties (with respect to the Bricoleur Parties, subject to the conditions in Section 2(d)(i)(4));

A-48

(B) second, and only if all the securities referenced in clause (i) have been included, the number of Registrable Securities of such class that, in the opinion of such underwriter or underwriters (or in the case of an Incidental Registration not being underwritten, the Company), can be sold without having such adverse effect shall be included therein, with such number to be allocated pro rata among the Holders which have requested participation in the Incidental Registration (based, for each such Holder, on the percentage derived by dividing (x) the number of Registrable Securities of such class which such Holder has requested to include in such Incidental Registration by (y) the aggregate number of Registrable Securities of such class which all such Holders have requested to include); and

(C) third, and only if all of the Registrable Securities referenced in clauses (i) and (ii) have been included, any other securities eligible for inclusion in such registration shall be included therein.

3. Registration Procedures

In connection with the Company’s registration obligations under Sections 2(a), 2(b) and 2(d), the Company shall:

(a) Not less than five Trading Days prior to the filing of each Registration Statement and not less than two Trading Days prior to the filing of any related amendment or supplement thereto, the Company shall, (i) furnish to each Holder copies of all documents to be filed, and (ii) cause its officers, directors and counsel to respond to all reasonable inquiries from the Holders. Each Holder agrees to furnish to the Company a completed Questionnaire in the form attached to this Agreement as Annex B (a “Selling Shareholder Questionnaire”) by the end of the fourth Trading Day following the date on which such Holder receives the Selling Shareholder Questionnaire and draft materials in accordance with this Section.

(b) (i) Prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible, and in any event within ten Business Days, to any comments received from the Commission with respect to the Registration Statement or any amendment thereto and, as promptly as reasonably possible provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the Holders as selling shareholders but not any comments that would result in the disclosure to the Holders of material and non-public information concerning the Company; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to a Registration Statement and the disposition of all Registrable Securities covered by each Registration Statement.

(c) Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (ii) through (iv) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (i) with respect to a Registration Statement or any post-effective amendment, when the same has become effective; (ii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities; (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction; or (iv) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. Any and all of such information contemplated by subparagraphs (i) through

A-49

(iv) shall remain confidential to each Holder until such information otherwise becomes public, unless disclosure by a Holder is required by law.

(d) Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

(e) Furnish to each Holder, without charge, such number of each such final Prospectus and each final amendment or supplement thereto as each such Holder may reasonably request, promptly after the filing of such documents with the Commission, for Holder’s delivery in connection with a sale of the Registrable Securities.

(f) Subject to the terms of this Agreement, the Company hereby consents to the use of each Prospectus and each amendment or supplement thereto, provided by the Company pursuant to subpart (e) above, by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).

(g) If NASDR Rule 2710 requires any broker-dealer to make a filing prior to executing a sale by a Holder, the Company shall (i) make an Issuer Filing with the NASDR, Inc. Corporate Financing Department pursuant to proposed NASDR Rule 2710(b)(10)(A)(i), (ii) respond within five Trading Days to any comments received from NASDR in connection therewith, and (iii) pay the filing fee required in connection therewith.

(h) promptly incorporate in a Prospectus supplement or post-effective amendment to the applicable Registration Statement such information as the Holders of a majority of the Registrable Securities agree should be included therein relating to the plan of distribution with respect to such Registrable Securities.

(i) cooperate with each seller of Registrable Securities and their respective counsel in connection with any filings required to be made with the NASD.

(j) provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration Statement from and after a date not later than the effective date of such Registration Statement.

(k) cause all Registrable Securities of a class covered by the applicable Registration Statement to be listed on each securities exchange on which any of the Company’s securities of such class are then listed or quoted and on each inter-dealer quotation system on which any of the Company’s securities of such class are then quoted.

(l) The Company covenants that it will file, on a timely basis, the reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the SEC thereunder (or, if the Company is not required to file such reports, it will upon the request of any Holder of Registrable Securities after the Closing, make publicly available other information so long as necessary to permit sales pursuant to Rule 144 or 144A under the Securities Act, and it will take such further action as any Holder of Registrable Securities may reasonably request, all to the extent required from time to time to enable such Holder to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 or 144A or Regulation S under the Securities Act, as such Rules may be amended from time to time, or (ii) any similar rule or regulation hereafter adopted by the Commission.

(m) Prior to any resale of Registrable Securities by a Holder, use its reasonable best efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary

A-50

or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.

(n) If requested by the Holders, cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Securities Act, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may request.

(o) Upon the occurrence of any event contemplated by clauses (ii) through (iv) of Section 3(c) hereof, as promptly as reasonably possible under the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (ii) through (iv) of Section 3(c) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.

(p) Use its best efforts to comply with all applicable rules and regulations of the Commission.

(q) The Company may require each selling Holder to furnish to the Company a certified statement as to (i) the number of shares of Common Stock beneficially owned by such Holder, (ii) the natural persons thereof that have voting and dispositive control over the shares of Common Stock, and (iii) any affiliation between the Holder and either the Company’s independent accountants or any member of the NASD.

(r) The Company may require each Holder of Registrable Securities as to which any registration is being effected to furnish to the Company such information regarding the distribution of such Registrable Securities and such other information as the Company may from time to time reasonably request. Each Holder agrees to furnish such information to the Company and to cooperate with the Company as necessary to enable the Company to comply with the provisions of this Agreement. The Company shall have the right to exclude any Holder that does not comply with the preceding sentence from the applicable registration.

4. Registration Expenses. All fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings or listings or quotations required to be made with any Trading Market on which the Common Stock is then listed for trading, (B) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities) and (C) if not previously paid by the Company in connection with an Issuer Filing, with respect to any filing that may be required to be made by any broker through which a Holder intends to make sales of Registrable Securities with NASD Regulation, Inc. pursuant to the NASD Rule 2710, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale, (ii) printing expenses incurred by the Company (including, without limitation, expenses of printing certificates for Registrable Securities, (iii) messenger, telephone and delivery expenses incurred by the Company, (iv) fees and disbursements of counsel for

A-51

the Company and of all independent certified public accountants of the Company, (v) Securities Act liability insurance incurred by the Company, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders.

5. Indemnification

(a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, advisors, agents and employees of each of them, each Person who controls any such Person (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, shareholders, partners, advisors, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities or actions or proceedings thereof, whether or not such indemnified party is a party thereto, costs (including, without limitation, reasonable costs of investigation and reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in a Registration Statement under which such Registrable Securities were registered under the Securities Act (including any final, preliminary or summary Prospectus contained therein) or any amendment or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or preliminary Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent that any such Loss is based solely upon an untrue statement or alleged untrue statement or omission or alleged omission made in any such Registration Statement in reliance upon and in conformity with written information furnished to the Company by such Holder expressly for use in the preparation thereof. This indemnity shall be in addition to any liability the Company may otherwise have. This indemnity shall remain in full force and effect regardless of any investigations made by or on behalf of such Holder or any indemnified party and shall survive the transfer of such securities by such Holder.

(b) Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents, attorneys and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents, attorneys or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances in which they were made to the extent, but only to the extent, that such Loss is based solely upon an untrue statement or omission made in such Registration Statement in reliance upon and in conformity with written information furnished to the Company by such Holder to the Company expressly for use in the preparation thereof and was not corrected in a subsequent writing prior to or concurrently with the sale of the Registrable Securities to the Person asserting the Loss. This indemnity shall be in addition to any liability such Holder may otherwise have. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

(c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party

A-52

shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that such failure shall have materially prejudiced the Indemnifying Party.

An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed to assume the defense of such Proceeding within a reasonable time after having received notice of such claim from the person entitled to indemnification hereunder and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; (3) in the reasonable judgment of the Indemnified Party, based upon advice of its counsel, a conflict of interest may exist between such Person and the Indemnifying Party with respect to such claims or (4) the Indemnified Party has reasonably concluded, based on the advice of counsel, that there are legal defenses available to it that are different from or in addition to those available to the Indemnifying Party, in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party. If such defense is not assumed by the Indemnifying Party, the Indemnifying Party will not be subject to any liability for any settlement made without its consent, but such consent may not be unreasonably withheld; provided, however, that an Indemnifying Party shall not be required to consent to any settlement involving the imposition of equitable remedies or involving the imposition of any material obligations on such Indemnifying Party other than financial obligations for which such Indemnified Party will be indemnified hereunder. If the Indemnifying Party assumes the defense, the Indemnifying Party shall have the right to settle such action without the consent of the Indemnified Party, provided, however, that the Indemnifying Party shall be required to obtain such consent (which consent shall not be unreasonably withheld) if the settlement includes any admission of wrongdoing on the part of the Indemnified Party or any restriction on the Indemnified Party or its officers or directors. No Indemnifying Party shall consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to each Indemnified party of an unconditional release from all liability in respect of such claim or litigation.

Subject to and without limiting the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party under this Section 5 (including reasonable fees and expenses incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party as incurred by such Indemnified Party.

(d) Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.

A-53

The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to

contribution from any Person who was not guilty of such fraudulent misrepresentation.

The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.

6. Miscellaneous

(a) Remedies. It is hereby agreed and acknowledged that it will be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure an aggrieved Person will be irreparably damaged and will not have an adequate remedy at law. Any such person shall therefore be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including, without limitation, specific performance, to enforce such obligations, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

(b) No Piggyback on Registrations. Except for the Bricoleur Parties exercising registration rights previously granted to them under the Bric Registration Rights Agreement (and only for so long as there is not an effective registration statement covering the registrable securities of the Bricoleur Parties) neither the Company nor any of its present or future security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in the initial “Shelf” Registration Statement other than the Registrable Securities.

(c) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to a Registration Statement.

(d) Discontinued Disposition. Each Holder agrees by its acquisition of Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(c)(ii) through (iv), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as it practicable.

(e) Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of at least a majority the then outstanding Registrable Securities. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that does not directly or indirectly affect the rights of other Holders may be given by Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the immediately preceding sentence. The parties acknowledge and agree that effective as of the date of this Agreement, that certain Registration Rights Agreement dated January 17, 2007 between the Company and the Selling Shareholder shall terminate and be superseded by this Agreement.

(f) Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.

A-54

(g) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign its rights (except by merger) or obligations hereunder without the prior written consent of at least a majority of the Holders of the then-outstanding Registrable Securities. The registration rights of any Holder under this Agreement with respect to any Registrable Securities may be transferred and assigned only to a transferee of the Registrable Securities, the 2006 Warrants or the New Warrants who agrees in writing to be bound by the provisions of this Agreement and where notice of such assignment shall have been provided to the Company.

(h) No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would be inconsistent with the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof.

(i) Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or bye-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

(j) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of New York. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

(k) Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.

(l) Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.

(m) Headings. The headings in this Agreement are for convenience only, do not constitute a part of this Agreement, and shall not be deemed to limit or affect any of the provisions hereof.

A-55

(n) Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holders are in any way acting in concert with respect to such obligations or the transactions contemplated by this Agreement. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE PAGES FOLLOW]

A-56

IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

VENDINGDATA CORPORATION


	By:

Mark Newburg,

President and Chief Executive Officer

ELIXIR GROUP LIMITED


	By:

A-57

Annex B
VendingData Corporation

Selling Securityholder Notice and Questionnaire

The undersigned beneficial owner of common stock, par value $0.001 per share (the “Common Stock”), of VendingData Corporation, a Nevada corporation (the “Company”), (the “Registrable Securities”) understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement onForm S-3 (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement, dated as of , 2007 (the “Registration Rights Agreement”), among the Company and the Holders named therein. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

Certain legal consequences arise from being named as a selling securityholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and the related prospectus.

NOTICE

The undersigned beneficial owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the Registrable Securities owned by it and listed below in Item 3 (unless otherwise specified under such Item 3) in the Registration Statement.

The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

QUESTIONNAIRE

1. Name.


	(a)	Full Legal Name of Selling Securityholder


	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities Listed in Item 3 below are held:


	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by the questionnaire):

2. Address for Notices to Selling Securityholder:

Telephone:
Fax:
Contact Person:

A-58

3. Beneficial Ownership of Registrable Securities:


	(a)	Type and Number of Registrable Securities beneficially owned:

4. Broker-Dealer Status:

(a) Are you a broker-dealer?

Yes o Noo


	(b)	If “yes” to Section 4(a), did you receive your Registrable Securities as compensation for investment banking services to the Company.

Yes o Noo

Note: If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

Yes o Noo


	(d)	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

Yes o Noo

Note: If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

5. Beneficial Ownership of Other Securities of the Company Owned by the Selling Securityholder.

Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than the Registrable Securities listed above in Item 3.


	(a)	Type and Amount of Other Securities beneficially owned by the Selling Securityholder:

6. Relationships with the Company:

Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.

State any exceptions here:

A-59

7. Relationships with the Company’s Independent Accountant:

Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company’s independent accountants, Piercy Bowler Taylor & Kern, of Las Vegas , Nevada (or its predecessors or affiliates) during the past three years.

State any exceptions here:

The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective.

By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 7 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus.

A-60

IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.

Beneficial Owner:


	By:

Name:

Title:

Dated:

PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:

A-61

SCHEDULE 6(B)

PIGGYBACK REGISTRATIONS

The Company intends to include on the initial Registration Statement:

A-62

EXHIBIT C

VENDINGDATA CORPORATION

CHARTER FOR THE

CONFLICTS COMMITTEE

OF THE BOARD OF DIRECTORS

Adopted 2007

1. PURPOSE

The Conflicts Committee (the “Committee”) shall have the power to veto any agreement or transaction between VendingData Corporation (the “Company”) and its subsidiaries, on the one hand (each a “VendingData Company” and collectively, the “VendingData Companies”), and Elixir Group Limited (“Elixir”) and its affiliates other than the VendingData Companies (each an “Elixir Company” and collectively the “Elixir Companies”) involving an aggregate amount in excess of US$[200,000] (a “Material Transaction”) and that has been approved by the Board of Directors of any VendingData Company (“Board”). The Committee shall exercise its veto power with a view to ensuring that any Material Transaction approved by the Board is fair to all stockholders of the Company. In any case where the Committee exercises its veto power with respect to a Material Transaction, it may suggest modifications to such Material Transaction.

2. COMPOSITION OF THE COMMITTEE

The Committee shall be comprised of not less than three directors each of whom (i) shall be an “independent director” under American Stock Exchange Rule 121A(2) or any successor rule and meet the criteria for independence as set forth inRule 10A-3(b)(1) under the Exchange Act or any successor, (ii) shall not be, and shall not have been during the previous two years, an officer, director or employee of, or consultant or advisor to, an Elixir Company, and (iii) shall otherwise not have a relationship that would interfere with the exercise of independent judgment in carrying out the purpose of this Charter and the responsibilities of a member of the Conflicts Committee. Until , 2009, at least one member of the Committee shall be a “Company Nominee”, as that term is defined in that certain Securities Purchase and Product Participation Agreement dated June , 2007 between the Company and Elixir (the “Participation Agreement”), subject to the presence on the Board of at least one Company Nominee that meets the above qualifications. At least one member of the Committee shall be an “Elixir Nominee”, as that term is defined in the Participation Agreement, provided such person meets the above qualifications.

Each Committee member shall be subject to annual reconfirmation and may be removed by the Board of Directors of the Company.

3. RESPONSIBILITIES AND DUTIES

A. The Committee shall have the power to veto any Material Transaction that has been approved by the Board of Directors of any VendingData Company; it being understood and agreed that the agreements and transactions set forth in the Participation Agreement, the other Transaction Documents and the October 2006 Agreements (as such terms are defined in the Participation Agreement) have already been approved by the Board of Directors of the Company.

B. The Committee shall exercise its veto power with a view to ensuring that all Material Transactions approved by a Board are fair to all stockholders of the Company. In discharging its responsibilities, the Committee shall be entitled to all rights and presumptions afforded directors under the General Corporation Law of Nevada (the “Law”), including Section 78.138 of the Law or any successor rule.

C. In discharging its responsibilities, the Committee shall have full access to any relevant records of the Company and may also request that any officer or other employee of the Company, the Company’s outside counsel or any other person, meet with any members of, or consultants to, the Committee. The Committee shall also have the authority to, as it deems appropriate in its reasonable discretion, to select, retainand/or replace outside advisors to the Committee to provide independent advice to the Committee.

A-63

4. COMMITTEE MEETINGS

The Committee will meet periodically as necessary to act upon any matter within its jurisdiction. At all Committee meetings a majority of the total number of members shall constitute a quorum. All meetings shall be held subject to and in accordance with applicable sections of the Law (including without limitation notice, quorum and votes/actions of the committee) and the bylaws of the Company. Minutes shall be kept of each meeting of the Committee.

A-64

ANNEX B — OPINION OF CAPSTONE VALUATION SERVICES, LLC

11 June 2007

Board of Directors of
VendingData Corporation
c/o Arnaldo F. Gallasi, CFO
VendingData Corporation
1120 N. Town Centre Drive
Las Vegas, NV 89144

To the Board of Directors:

You have requested our opinion as to the fairness from a financial point of view to the shareholders of VendingData Corporation (“the Company”) of the consideration to be received by the Company in a proposed change in control transaction (the “Transaction”) between the Company and Elixir Group Limited (“Elixir”), a wholly-owned subsidiary of Melco International Development Limited (“Melco”). The Securities Purchase and Product Participation Agreement (“the Agreement”) sets forth the principal terms of the Transaction which is presently expected to include the Company’s issuance of a control block of its common stock and common stock purchase warrants to Elixir and the Company’s repricing of certain warrants presently held by Elixir in exchange for Elixir’s placement of certain electronic gaming machines on a revenue sharing basis pursuant to gaming machine lease agreements to be entered into between the Company and the gaming operator.

In connection with our opinion, we have:

(a) considered the execution version of the Agreement distributed 11 June 2007;

(b) considered certain financial and other information relating to the Company, Elixir and Melco that was publicly available or furnished to us by the Company, including financial forecasts;

(c) met with or interviewed members of the Company’s and Elixir’s managements to discuss the business, operations, historical financial results and future prospects of the Company assuming the Transaction is completed;

(d) considered certain financial and securities information of the Company and Elixir and compared that information with similar data for otherpublicly-held companies that are in businesses similar to those of the Company and Elixir;

(e) considered the financial terms of certain recent acquisitions of companies in businesses similar to those of the Company;

B-1

Board of Directors of

VendingData Corporation

11 June 2007

(f) performed discounted cash flow analyses and a guideline company method analysis;

(g) considered such other information, financial studies, analysis and investigations and financial, economic and market criteria as we deemed relevant and appropriate for purposes of this opinion, and

(h) when opining “as to the fairness from a financial point of view to the shareholders of the company,” considered the term “shareholders of the Company to include the shareholders of the Company other than Elixir as of the date hereof.

Our opinion is based on prevailing market conditions, interest rates and other circumstances and conditions existing as of the date hereof, and our opinion does not represent our view as to what the value of the Company’s Common Stock actually will be following consummation of the Transaction. Such actual value of the Company’s Common Stock could be higher or lower depending upon changes in such interest rates, dividend rates, market conditions, general economic conditions and other factors, which generally influence the price of securities. Because of the large aggregate amount of Company Common Stock being issued to Elixir and other factors, such securities may trade initially at prices below those at which they would trade on a fully distributed basis. Furthermore, any valuation of securities is only an approximation, subject to uncertainties and contingencies, all of which are difficult to predict and beyond the control of our firm.

The opinions that are expressed herein are subject to these additional qualifications and limitations:

(a) In arriving at our opinion, we have relied upon and assumed, without independent verification, the accuracy and completeness of all financial and other information that was publicly available or furnished to us by the Company and Elixir. With respect to the financial forecasts analyzed by us, we have assumed that they have been reasonably prepared on bases reflecting the best currently available information and judgments of the Company’s and Elixir’s management as to the future financial performance of the Company upon completion of the Transaction. We also considered such other information, financial studies, analyses and investigations and financial, economic and market criteria which we deemed relevant.

(b) Based on your declaration, we have assumed that the Transaction will be consummated in accordance with the terms described in the Agreement, without waiver, modification or amendment of any material term, condition or agreement and that, in the course of obtaining the necessary regulatory or third party approvals, consents and releases for the Transactions, no delay, limitation, restriction or condition will be imposed that would have an adverse effect on the Company or the Transaction. Representatives or the Company have advised us, and we further have assumed, that the final terms of the Agreement will not vary materially from those set forth in the draft reviewed by us.

(c) Our opinion does not consider, and should not be interpreted to consider, either the underlying business decision to complete the Transaction or whether the consideration to be received by the stockholders in the Transaction represents the highest possible price attainable. We are not making any comment on the federal, state or local tax consequences of the Transaction.

(d) Our opinion does not represent any analysis regarding the solvency of the Company or Elixir prior to or subsequent to the Transaction. Capstone has not undertaken any procedures to determine the solvency of the Company or Elixir, and therefore, this Opinion does not constitute a solvency opinion, and should not be relied upon for such purposes.

(e) We have not made an independent evaluation or appraisal of the individual assets of the Company such as the Company’s technology, software and other proprietary information, nor have we been furnished with any such valuations. We have not been requested to, and did not, solicit third party indications of interest in acquiring all or any part of the Company.

B-2

Board of Directors of

VendingData Corporation

11 June 2007

(f) Our opinion is based on business, economic, market and other conditions as they exist as of the date hereof or as of the date of the information provided to us.

(g) This opinion is effective as of the date hereof. We have no obligation to update the opinion unless requested by you in writing to do so and expressly disclaim any responsibility to do so in the absence of any such request.

We will receive a fee as compensation for our services in rendering this opinion which fee is not contingent upon consummation of the Transaction. In addition, the Company has agreed to indemnify us against certain liabilities arising out of our engagement.

Based upon and subject to the foregoing, it is our opinion that, as of the date hereof, the consideration to be received by the Company in the Transaction pursuant to the terms of the Agreement is fair from a financial point of view to the shareholders of the Company.

This letter is intended only for the information of the Board of Directors in connection with the Transaction described herein and does not constitute a recommendation to any stockholder as to how such stockholder should vote on the proposed Transaction. This opinion is not to be quoted or referred to, in whole or in part, filed with, or furnished or disclosed to any other party, or used for any other purpose, without our prior written consent; except that this opinion may be included in its entirety in any proxy statement/ prospectus filed with the U.S. Securities and Exchange Commission and to be distributed to the stockholders of the Company in connection with the Transaction, provided that such inclusion and any discussion thereof is in form and substance reasonably acceptable to us and our counsel.

Sincerely yours,

B-3

ANNEX C — CERTIFICATE OF AMENDMENT
TO ARTICLES OF INCORPORATION
OF
VENDINGDATA CORPORATION

1. Name of corporation:

VendingData Corporation

2. The articles have been amended as follows (provide article numbers, if available):

“ARTICLE IV

Section 4.1 CAPITAL STOCK

This Corporation shall have the authority to issue an aggregate of Three Hundred Million (300,000,000) shares of common stock, par value $0.001 (hereinafter “Common Stock”), and Ten Million (10,000,000) shares of preferred stock, par value $0.001 (hereinafter, “Preferred Stock”). Common Stock and Preferred Stock may be issued from time to time without action by the stockholders. Common Stock and Preferred Stock may be issued for such consideration as may be fixed from time to time by the Board of Directors.”

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation have voted in favor of the amendment is: .

4. Effective date of filing (optional): Upon filing

5. Officer Signature (Required):

Mark R. Newburg, President

C-1

YOUR VOTE IS IMPORTANT
PLEASE COMPLETE, DATE, SIGN AND MAIL YOUR
PROXY CARD IN THE ENVELOPE PROVIDED AS SOON
AS POSSIBLE.

TO VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE

PROXY FOR SPECIAL MEETING OF STOCKHOLDERS, SEPTEMBER 10, 2007
SOLICITED BY THE BOARD OF DIRECTORS OF VENDINGDATA CORPORATION

The undersigned stockholder of VendingData Corporation hereby acknowledges receipt of the Notice of Special Meeting of Stockholders and Proxy Statement in connection with our special meeting of stockholders to be held at our principal offices at 1120 Town Center Drive, Suite 260, Las Vegas, Nevada, on Monday, September 10, 2007 at 10:00 o’clock in the morning, Pacific Time, and hereby appoints Mark R. Newburg and James E. Crabbe, as proxy, with power of substitution, to attend and to vote all shares the undersigned would be entitled to vote if personally present at said special meeting and at any adjournment thereof.

(The proxy is instructed to vote as specified on the reverse)


P R O X Y		THIS PROXY SHALL BE VOTED AS DIRECTED, OR IF NO DIRECTION IS INDICATED, WILL BE VOTED “FOR” THE PROPOSALS. THIS PROPOSAL IS SOLICITED ON BEHALF OF THE BOARD OR DIRECTORS

(The proxy is instructed to vote as specified on the reverse)

VENDINGDATA CORPORATION OFFERS STOCKHOLDERS OF RECORD
THREE WAYS TO VOTE YOUR PROXY

Your telephone or Internet vote authorizes the named proxies to vote your shares in the same manner as if you had returned your proxy card. We encourage you to use these cost effective and convenient ways of voting, 24 hours a day, 7 days a week.


TELEPHONE VOTING	INTERNET VOTING	VOTING BY MAIL
This method of voting is available for residents of the U.S. and Canada. On a touch tone telephone, callTOLL FREE 1-877-381-4019,24 hours a day, 7 days a week. Have this proxy card ready, then follow the prerecorded instructions. Your vote will be confirmed and cast as you have directed. Available 24 hours a day, 7 days a week until 11:59 p.m. Eastern Daylight Time on September 9, 2007.	Visit the Internet voting Web site at http://proxy.georgeson.com. Have this proxy card ready and follow the instructions on your screen. You will incur only your usual Internet charges. Available 24 hours a day, 7 days a week until 11:59 p.m. Eastern Daylight Time on September 9, 2007.	Simply sign and date your proxy card and return it in the postage-paid envelope to Georgeson Inc., Wall Street Station, P.O. Box 0000, New York, NY 10269-0646. If you are voting by telephone or the Internet, please do not mail your proxy card.

‚FOLD AND DETACH HERE AND READ THE REVERSE SIDE.‚

PROXY

Please make your votes like thisx

APPROVE THE SECURITIES PURCHASE AND PRODUCT PARTICIPATION AGREEMENT WITH ELIXIR GROUP LIMITED AND THE ISSUANCE OF OUR COMMON STOCK AND WARRANTS PURSUANT THERETO.

FOR
o

AGAINST
o

ABSTAIN
o

APPROVE THE GRANT OF OPTIONS TO ACQUIRE 5,000,000 SHARES OF OUR COMMON STOCK TO THE ELIXIR PARTIES.

FOR
o

AGAINST
o

ABSTAIN
o

APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 1999 STOCK OPTION PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED UNDER THE PLAN TO 15 MILLION.

FOR
o

AGAINST
o

ABSTAIN
o

APPROVE AN AMENDMENT TO OUR ARTICLES OF INCORPORATION INCREASING OUR AUTHORIZED COMMON STOCK TO 300 MILLION SHARES.

FOR
o

AGAINST
o

ABSTAIN
o

ELECTION OF DIRECTORS

(To withhold authority to vote for any individual nominee, strike a line through that nominee’s name in the list below)

FOR
o

WITHHOLD
AUTHORITY
o

James E. Crabbe

Mark R. Newburg

Vincent L. DiVito

Gordon Yuen

Robert L. Miodunski

Joe Pisano

Paul Harvey

Lorna Patajo-Kapunan

VOTE ON THE ADJOURNMENT OR POSTPONEMENT OF THE SPECIAL MEETING TO ANOTHER TIME AND DATE IF SUCH ACTION IS NECESSARY FOR THE BOARD OF DIRECTORS TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF PROPOSALS 1, 2, 3, 4 or 5.

FOR
o

AGAINST
o

ABSTAIN
o

IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING.

FOR
o

AGAINST
o

ABSTAIN
o

Dated: , 2007

Signature

NOTE: Please sign exactly as name appears hereon. When shares are held by joint owners, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give title as such. If a corporation, please sign in full corporate name by President or other authorized officer. If a partnership, please sign in partnership name by authorized person.

286169923v2

Entertainment Gaming Asia (EGT) Inactive DEF 14ADefinitive proxy